

Law Offices
FOLEY & LARDNER
3000 K Street, N.W., Suite 500
P.O. Box 25696
Washington, D.C. 20007-8696
(202) 672-5300

1c511 U.S. PTO
09/114285
07/13/98

TO: Assistant Commissioner for Patents
Box Patent Applications
Washington D.C. 20231

Attorney Docket No.53466/234

(must include alphanumeric codes if no inventors named)

UTILITY PATENT APPLICATION TRANSMITTAL
(new nonprovisional applications under 37 CFR 1.53(b))

Transmitted herewith for filing is the patent application of:

INVENTOR(S): Masayuki TSUCHIYA, Koh SATO and Mary BENDIG

TITLE: RESHAPED HUMAN ANTIBODY TO HUMAN INTERLEUKIN-6 RECEPTOR

In connection with this application, the following are enclosed:

APPLICATION ELEMENTS:

XX Specification - 149 TOTAL PAGES

(preferred arrangement:)

- Descriptive Title of the Invention
- Cross Reference to Related Applications
- Statement Regard Fed sponsored R&D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

XX Drawings - Total Sheets 24

XX Declaration and Power of Attorney - Total Sheets 2

 Newly executed (original or copy)

XX Copy from a prior application (37 CFR 1.63(d))

(relates to continuation/divisional boxes completed) - NOTE: Box below

 DELETION OF INVENTOR(S) - Signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

XX Incorporation By Reference (useable if copy of prior application
Declaration being submitted)

The entire disclosure of the prior application, from which a COPY of the
oath or declaration is supplied as noted above, is considered as being
part of the disclosure of the accompanying application and is hereby
incorporated by reference therein.

 Microfiche Computer Program (Appendix)

 Nucleotide and/or Amino Acid Sequence Submission (if applicable,
all necessary)

 Computer Readable Copy

 Paper Copy (identical to computer copy)

 Statement verifying identify of above copies

ACCOMPANYING APPLICATION PARTS

 Assignment Papers (cover sheet & document(s))

 37 CFR 3.73(b) Statement (when there is an assignee)

XX Proposed Drawing Change

XX Information Disclosure Statement(IDS) with PTO-1449.

XX Preliminary Amendment

XX Return Receipt Postcard (MPEP 503)

____ Small Entity Statement(s)
____ Statement file in prior application, status still proper and desired.
____ Certified Copy of Priority Document(s) with Claim of Priority
(if foreign priority is claimed).
XX OTHER: Check for \$954.00

If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:

____ Continuation XX Divisional ____ Continuation-in-part (CIP)
of prior application Serial No. 08/436,717.

XX Amend the specification by inserting before the first line the following sentence: --This application is a ____ continuation, XX divisional or ____ continuation-in-part of application Serial No. 08/436,717, filed May 8, 1995 which is a divisional of 08/137,117, filed December 20, 1993 which is a national stage of PCT/JP92/00544 filed April 24, 1992.--

CORRESPONDENCE ADDRESS:

Foley & Lardner Address noted above.
Telephone: (202) 672-5300
Fax Number: (202) 672-5399

FEE CALCULATIONS: (Small entity fees indicated in parentheses.)

(1) For	(2) Number Filed	(3) Number Extra	(4) Rate	(5) Basic Fee \$790 (\$395)
Total Claims	10 - 20 =	0	x \$22 (x \$11)	0.00
Independent Claims	6 - 3 =	2	x \$82 (x \$41)	164.00
Multiple Dependent Claims			\$270 (\$135)	0.00
Assignment Recording Fee per property			\$40	0.00
Surcharge Under 37 C.F.R. 1.16(e)			\$130 (\$65)	0.00
TOTAL FEE:				\$954.00

METHOD OF PAYMENT:

A check in the amount of the above TOTAL FEE is attached. If payment is enclosed, this amount is believed to be correct; however, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 19-0741.

Respectfully submitted,



Stephen B. Maebius
Reg. No. 35,264

Date: July 13, 1998
Docket No.: 53466/234

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of
Masayuki Tsuchiya et al.

Serial No. Unassigned

Group Art Unit:

Filed: July 13, 1998

Examiner:

For: RESHAPED HUMAN ANTIBODY TO
HUMAN INTERLEUKIN-6
RECEPTOR

PROPOSED CHANGES TO THE DRAWINGS


The Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

Applicants propose to amend the drawing as shown in
red on the attached copy. With the Examiner's approval, the
changes will be made to the formal drawings in due course.

Respectfully submitted,

July 13, 1998



Stephen B. Maebius
Reg. No.

FOLEY & LARDNER
3000 K Street, N.W.
Suite 500
Washington, D.C. 20007-5109
Tel: (202) 672-5300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 53466/234

In re patent application of

Masayuki Tsuchiya et al.

Serial No.: Unassigned

Filed: July 13, 1998

For: RESHAPED HUMAN ANTIBODY TO HUMAN INTERLEUKIN-6 RECEPTOR

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Page 83, at the end of the specification, before the claims, delete the Sequence Listing (pages 84-140) and insert the printed Sequence Listing submitted concurrently herewith, and renumber pages 1-57 of the Sequence Listing submitted concurrently herewith as pages 84-140 of the specification.

IN THE FIGURES:

A proposed drawing correction to Fig. 13 is submitted herewith to correct a typographical error (deletion of "o PV_{LA} + RV_{HE}"). The proposed deletion in Fig. 13 is indicated in the attached drawing in red ink by a red line drawn through the phrase to be deleted.

Serial No. Unassigned

IN THE CLAIMS:

Please cancel claims 1-66 without prejudice or disclaimer.

Please add the following new claims:

--67. A chimeric antibody to human interleukin-6 receptor (IL-6R), comprising:

(1) light chains (L chains) each comprising a human L chain constant region (C region) and an L chain variable region (V region) of a mouse monoclonal antibody to human IL-6R; and

(2) heavy chains (H chains) each comprising a human H chain C region, and H chain V region of a mouse monoclonal antibody to human IL-6R;

wherein the mouse L chain V region includes an amino acid sequence shown in SEQ ID Nos: 24 or 26 and the mouse H chain V region includes an amino acid sequence shown in SEQ ID Nos: 25 or 27.

68. The chimeric antibody according to claim 67, wherein the human L chain C region is a human Kc region.

69. The chimeric antibody according to claim 67, wherein the H chain C region is a human γ -1C region.

70. The chimeric antibody according to claim 68, wherein the H chain C region is a human γ -1C region.

71. An isolated DNA encoding an L chain comprising a human L chain C region and an L chain V region of a mouse monoclonal antibody to human IL-6R wherein the human L chain C region is a human Kc region and the L chain V region includes the amino acid sequence set forth in SEQ ID NOS: 24 or 26.

Serial No. Unassigned

72. An isolated DNA encoding an H chain comprising a human H chain C region and an H chain V region of a mouse monoclonal antibody to IL-6R, wherein the human H chain C region is a human γ -1C region and the H chain V region includes the amino acid sequence set forth in SEQ ID NOS: 25 or 27.

73. An expression vector comprising a DNA coding for an L chain comprising a human L chain C region and L chain V region of a mouse monoclonal antibody to human IL-6R, wherein the human L chain C region is a human Kc region, and the L chain V region includes an amino acid sequence shown in SEQ ID NOS: 24 or 26.

74. An expression vector comprising a DNA coding for an H chain comprising a human H chain C region and H chain V region of a mouse monoclonal antibody to human IL-6R, wherein the human L chain C region is a human Kc region, and the L chain V region includes an amino acid sequence shown in SEQ ID NOS: 25 or 27.

75. A host cell co-transformed with:

- (1) an expression vector comprising a DNA coding for an L chain comprising a human L chain C region and an L chain V region of a mouse monoclonal antibody to human IL-6R, and with
- (2) an expression vector comprising a DNA coding for an H chain comprising a human H chain C region and an H chain V region of a mouse monoclonal antibody to IL-6R, wherein the human L chain C region is a human Kc region; the L chain V region includes an amino acid sequence shown in SEQ ID NOS: 24 or 26, the human L chain C region is a human γ -1C region and the H chain V region includes an amino acid sequence shown in SEQ ID NOS: 25 or 27.

76. A method of producing the chimeric antibody to human IL-6R according to claim 67, said method at least comprising the steps of:

Serial No. Unassigned

(a) culturing host cells co-transformed with a first expression vector and a second expression vector, for a time and under conditions sufficient for expression to occur, wherein the first expression vector comprises DNA encoding a human L chain C region and a mouse L chain V region including the sequence set forth in SEQ ID NOS: 24 or 26 and the second expression vector comprises DNA encoding a human H chain C region and a mouse H chain V region including a sequence set forth in SEQ ID NOS: 25 or 27; and

(b) recovering the chimeric antibody from the culture.--

SEQUENCE LISTING

The Sequence Listing from the parent application has been added to the present specification by the above amendments. Applicant requests that the computer readable form of the Sequence Listing submitted in the parent application be used to satisfy the sequence listing requirement for the present application as well. The sequence information in the paper copy of the Sequence Listing submitted herewith is the same as the sequence information in the computer readable form submitted in the parent application. Therefore, applicants request that the computer readable form of the parent application be used to satisfy the sequence listing requirements for the instant application. No new matter has been introduced by the paper copy of the sequence listing, which is identical to that submitted in the parent application and which contains the same sequence information as the computer readable form in the parent application.

Serial No. Unassigned


REMARKS

The above amendment adds claims covering additional embodiments described in the present specification, as well as the sequence listing from the parent application. No new matter has been introduced.

In accordance with the foregoing, a favorable early action is requested.

Respectfully submitted,

July 13, 1998
Date


Stephen B. Maebius
Registration No. 35,264

FOLEY & LARDNER
3000 K Street, N.W., Suite 500
Washington, DC 20007-5109
Telephone: (202) 672-5569

(i) APPLICANT: TSUCHIYA, Masayuki
SATO, Koh
BENDIG, Mary
JONES, Steven
SALDANHA, Jose

(ii) TITLE OF INVENTION: RESHAPED HUMAN ANTIBODY TO HUMAN INTERLEUKIN-6 RECEPTOR

(iii) NUMBER OF SEQUENCES: 158

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Foley & Lardner
(B) STREET: 3000 K Street, N.W., Suite 500
(C) CITY: Washington
(D) STATE: D.C.
(E) COUNTRY: USA
(F) ZIP: 20007-5109

(v) COMPUTER READABLE FORM:
 (A) MEDIUM TYPE: Floppy disk
 (B) COMPUTER: IBM PC compatible
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:
 (A) APPLICATION NUMBER: US 08/137,117
 (B) FILING DATE: 20-DEC-1993
 (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: WO PCT/JP92/00544
(B) FILING DATE: 24-APR-1992

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: JP 4-32084
(B) FILING DATE: 19-FEB-1992

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: JP 3-95476
(B) FILING DATE: 25-APR-1991

(viii) ATTORNEY/AGENT INFORMATION:
 (A) NAME: WEGNER, Harold C.
 (B) REGISTRATION NUMBER: 25,258
 (C) REFERENCE/DOCKET NUMBER: 53466/126/AAOK

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (202) 672-5300
(B) TELEFAX: (202) 672-5399
(C) TELEX: 904136

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ACTAGTCGAC ATGAAGTTGC CTGTTAGGCT GTTGGTGCTG

40

(2) INFORMATION FOR SEQ ID NO:2:

- (1) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ACTAGTCGAC ATGGAGWCAG ACACACTCCT GYTATGGGT

39

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 40 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ACTAGTCGAC ATGAGTGTGC TCACTCAGGT CCTGGSGTTG

40

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 43 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ACTAGTCGAC ATGAGGRCCC CTGCTCAGWT TYTTGGMWTC TTG

43

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 40 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

40

40

(1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

37

37

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

41

41

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

41

41

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

35

35

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

ACTAGTCGAC ATGTATATAT GTTTGTTGTC TATTTCT

37

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

ACTAGTCGAC ATGGAAGCCC CAGCTCAGCT TCTCTTCC

38

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

GGATCCCGGG TGGATGGTGG GAAGATG

27

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

ACTAGTCGAC ATGAAATGCA GCTGGGTCAT STTCTTC

37

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

ACTAGTCGAC ATGGGATGGA GCTRTATCAT SYTCTT

36

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 37 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ACTAGTCGAC ATGAAGWTGT GGTAAACTG GGTTTTT

37

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 35 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ACTAGTCGAC ATGRACCTTG GGYTCAGCTT GRTTT

35

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 40 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

ACTAGTCGAC ATGGACTCCA GGCTCAATTT AGTTTTTCCTT

40

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 37 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

ACTAGTCGAC ATGGCTGTCY TRGSGCTRCT CTTCTGC

37

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ACTAGTCGAC ATGGRATGGA GCKGGRTCTT TMTCTT

36

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

ACTAGTCGAC ATGAGAGTGC TGATTCTTTT GTG

33

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 40 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ACTAGTCGAC ATGGMTTGGG TGTGGAMCTT GCTATTCCTG

40

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 37 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

0914265-071398
060720-5524150

37

(1) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

28

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 393 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(A) NAME/KEY: CDS
(B) LOCATION: 1..393

```

FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 1..393

```

ATG Met 1	GAG Glu	TCA Ser	GAC Asp	ACA Thr 5	CTC Leu	CTG Leu	CTA Leu	TGG Trp	GTA Val 10	CTG Leu	CTC Leu	TGG Trp	GTT Val 15	CCA Pro	48	
GGT Gly	TCC Ser	ACT Thr 20	GGT Gly 20	GAC Asp	ATT Ile	GTG Val	CTG Leu	ACA Thr 25	CAG Gln	TCT Ser	CCT Pro	GCT Ala	TCC Ser 30	TTA Leu	GGT Gly	96
GTA Val	TCT Ser	CTG Leu 35	GGG Gly	CAG Gln	AGG Arg	GCC Ala	ACC Thr 40	TCA Ile	TGC Ser	AGG Cys	GCC Ala 45	AGC Ser	AAA Lys	AGT Ser	144	
GTC Val 50	AGT Ser	ACA Thr	TCT Ser	GGC Gly	TAT Tyr	AGT Ser 55	TAT Tyr	ATG Met	CAC His	TGG Trp 60	TAC Tyr	CAA Gln	CAG Gln	AAA Lys	CCA Pro	192
GGA Gly 65	CAG Gln	ACA Thr	CCC Pro	AAA Lys	CTC Leu 70	CTC Leu	ATC Ile	TAT Tyr	CTT Leu 75	GCA Ala	TCC Ser	AAC Asn	CTA Leu	GAA Glu 80	TCT Ser	240
GGG Gly	GTC Val	CCT Pro	GCC Ala	AGG Arg 85	TTC Phe	AGT Ser	GGC Gly	AGT Ser	GGG Gly 90	TCT Ser	GGG Gly	ACA Thr	GAC Asp	TTC Phe 95	ACC Thr	288

CTC AAC ATC CAT CCT GTG GAG GAG GAG GAT GCT GCA ACC TAT TAC TGT	336
Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys	
100 105 110	
CAG CAC AGT AGG GAG AAT CCG TAC ACG TTC GGA GGG GGG ACC AAG CTG	384
Gln His Ser Arg Glu Asn Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu	
115 120 125	
GAA ATA AAA	393
Glu Ile Lys	
130	

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 131 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Met	Glu	Ser	Asp	Thr	Leu	Leu	Leu	Trp	Val	Leu	Leu	Leu	Trp	Val	Pro
1				5					10					15	
Gly	Ser	Thr	Gly	Asp	Ile	Val	Leu	Thr	Gln	Ser	Pro	Ala	Ser	Leu	Gly
			20					25					30		
Val	Ser	Leu	Gly	Gln	Arg	Ala	Thr	Ile	Ser	Cys	Arg	Ala	Ser	Lys	Ser
		35					40					45			
Val	Ser	Thr	Ser	Gly	Tyr	Ser	Tyr	Met	His	Trp	Tyr	Gln	Gln	Lys	Pro
	50					55					60				
Gly	Gln	Thr	Pro	Lys	Leu	Leu	Ile	Tyr	Leu	Ala	Ser	Asn	Leu	Glu	Ser
	65				70					75				80	
Gly	Val	Pro	Ala	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr
				85				90						95	
Leu	Asn	Ile	His	Pro	Val	Glu	Glu	Glu	Asp	Ala	Ala	Thr	Tyr	Tyr	Cys
			100					105					110		
Gln	His	Ser	Arg	Glu	Asn	Pro	Tyr	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu
		115				120						125			
Glu	Ile	Lys													
	130														

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 405 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..405

00114285.071390

(A) NAME/KEY: mat_peptide
(B) LOCATION: 1..405

[illegible]

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 135 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Met	Gly	Trp	Ser	Gly	Ile	Phe	Leu	Phe	Leu	Leu	Ser	Gly	Thr	Ala	Gly
1				5					10					15	
Val	His	Ser	Glu	Ile	Gln	Leu	Gln	Gln	Ser	Gly	Pro	Glu	Leu	Met	Lys
			20					25					30		
Pro	Gly	Ala	Ser	Val	Lys	Ile	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Ser	Phe
		35					40					45			
Thr	Ser	Tyr	Tyr	Ile	His	Trp	Val	Lys	Gln	Ser	His	Gly	Lys	Ser	Leu
	50					55					60				

Glu Trp Ile Gly Tyr Ile Asp Pro Phe Asn Gly Gly Thr Ser Tyr Asn
65 70 75 80
Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser
85 90 95
Thr Ala Tyr Met His Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val
100 105 110
Tyr Tyr Cys Ala Arg Gly Gly Asn Arg Phe Ala Tyr Trp Gly Gln Gly
115 120 125
Thr Leu Val Thr Val Ser Ala
130 135

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 381 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- (ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..381

- (ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 1..381

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

ATG GTG TCC TCA GCT CAG TTC CTT GGT CTC CTG TTG CTC TGT TTT CAA	48
Met Val Ser Ser Ala Gln Phe Leu Gly Leu Leu Leu Leu Cys Phe Gln	
1 5 10 15	
GGT ACC AGA TGT GAT ATC CAG ATG ACA CAG ACT ACA TCC TCC CTG TCT	96
Gly Thr Arg Cys Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser	
20 25 30	
GCC TCT CTG GGA GAC AGA GTC ACC ATC AGT TGC AGG GCA AGT CAG GAC	144
Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp	
35 40 45	
ATT AGC AGT TAT TTA AAC TGG TAT CAG CAG AAA CCA GAT GGA ACT ATT	192
Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Ile	
50 55 60	
AAA CTC CTG ATC TAC TAC ACA TCA AGA TTA CAC TCA GGA GTC CCA TCA	240
Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser	
65 70 75 80	
AGG TTC AGT GGC AGT GGG TCT GGA ACA GAT TAT TCT CTC ACC ATT AAC	288
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Asn	
85 90 95	
AAC CTG GAG CAA GAA GAC ATT GCC ACT TAC TTT TGC CAA CAG GGT AAC	336
Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn	
100 105 110	
ACG CTT CCG TAC ACG TTC GGA GGG GGG ACC AAG CTG GAA ATA AAT	381
Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Asn	
115 120 125	

0914285 071398

96

TCT CAG TCT CTG TCC CTC ACC TGC ACT GTC ACT GGC TAC TCA ATC ACC	144
Ser Gln Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr	
35 40 45	
AGT GAT CAT GCC TGG AGC TGG ATC CGG CAG TTT CCA GGA AAC AAA CTG	192
Ser Asp His Ala Trp Ser Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu	
50 55 60	
GAG TGG ATG GGC TAC ATA AGT TAC AGT GGT ATC ACT ACC TAC AAC CCA	240
Glu Trp Met Gly Tyr Ile Ser Tyr Ser Gly Ile Thr Thr Tyr Asn Pro	
65 70 75 80	
TCT CTC AAA AGT CGA ATC TCT ATC ACT CGA GAC ACA TCC AAG AAC CAG	288
Ser Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln	
85 90 95	
TTC TTC CTA CAG TTG AAT TCT GTG ACT ACT GGG GAC ACG TCC ACA TAT	336
Phe Phe Leu Gln Leu Asn Ser Val Thr Thr Gly Asp Thr Ser Thr Tyr	
100 105 110	
TAC TGT GCA AGA TCC CTA GCT CGG ACT ACG GCT ATG GAC TAC TGG GGT	384
Tyr Cys Ala Arg Ser Leu Ala Arg Thr Thr Ala Met Asp Tyr Trp Gly	
115 120 125	
CAA GGA ACC TCA GTC ACC GTC TCC TCA	411
Gln Gly Thr Ser Val Thr Val Ser Ser	
130 135	

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 137 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Met Arg Val Leu Ile Leu Leu Trp Leu Phe Thr Ala Phe Pro Gly Ile	
1 5 10 15	
Leu Ser Asp Val Gln Leu Gln Glu Ser Gly Pro Val Leu Val Lys Pro	
20 25 30	
Ser Gln Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr	
35 40 45	
Ser Asp His Ala Trp Ser Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu	
50 55 60	
Glu Trp Met Gly Tyr Ile Ser Tyr Ser Gly Ile Thr Thr Tyr Asn Pro	
65 70 75 80	
Ser Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln	
85 90 95	
Phe Phe Leu Gln Leu Asn Ser Val Thr Thr Gly Asp Thr Ser Thr Tyr	
100 105 110	
Tyr Cys Ala Arg Ser Leu Ala Arg Thr Thr Ala Met Asp Tyr Trp Gly	
115 120 125	
Gln Gly Thr Ser Val Thr Val Ser Ser	
130 135	

0014305-071330

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 131 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- ```
(A) NAME/KEY: mat_peptide
(B) LOCATION: 1..393
```

[illegible]

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 131 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Met Glu Ser Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro  
 1 5 10 15  
 Gly Ser Thr Gly Asp Ile Val Leu Ile Gln Ser Pro Ala Ser Leu Ala  
 20 25 30  
 Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser  
 35 40 45  
 Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro  
 50 55 60  
 Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser  
 65 70 75 80  
 Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr  
 85 90 95  
 Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys  
 100 105 110  
 Gln Gln Ser Asn Glu Asp Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu  
 115 120 125  
 Glu Leu Lys  
 130

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 417 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 1..417

- (ix) FEATURE:  
 (A) NAME/KEY: mat\_peptide  
 (B) LOCATION: 1..417

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

ATG GGA TGG AGC GGG GTC TTT ATC TTC CTC CTG TCA GTA ACT GCA GGT 48  
 Met Gly Trp Ser Gly Val Phe Ile Phe Leu Leu Ser Val Thr Ala Gly  
 1 5 10 15  
 GTC CAC TCC CAG GTT CAA TTG CAG CAG TCT GGA GCT GAG TTG ATG AAG 96  
 Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys  
 20 25 30  
 CCT GGG GCC TCA GTC AAG ATC TCC TGC AAG GCT ACT GGC TAC ACA TTC 144  
 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe  
 35 40 45  
 AGT AGT TAT TGG ATA GTG TGG ATA AAG CAG AGG CCT GGA CAT GGC CTT 192  
 Ser Ser Tyr Trp Ile Val Trp Ile Lys Gln Arg Pro Gly His Gly Leu  
 50 55 60

09114285-071300

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| GAG TGG ATT GGA GAG ATT TTA CCT GGA ACC GGT AGT ACT AAC TAC AAT | 240 |
| Glu Trp Ile Gly Glu Ile Leu Pro Gly Thr Gly Ser Thr Asn Tyr Asn |     |
| 65 70 75 80                                                     |     |
| GAG AAA TTC AAG GGC AAG GCC ACA TTC ACT GCA GAT ACA TCT TCC AAC | 288 |
| Glu Lys Phe Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn |     |
| 85 90 95                                                        |     |
| ACA GCC TAC ATG CAA CTC AGC AGC CTG ACA TCT GAG GAC TCT GCC GTC | 336 |
| Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val |     |
| 100 105 110                                                     |     |
| TAT TAC TGT GCA AGT CTA GAC AGC TCG GGC TAC TAT GCT ATG GAC TAT | 384 |
| Tyr Tyr Cys Ala Ser Leu Asp Ser Ser Gly Tyr Tyr Ala Met Asp Tyr |     |
| 115 120 125                                                     |     |
| TGG GGT CAA GGA ACC TCA GTC ACC GTC TCC TCA                     | 417 |
| Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser                     |     |
| 130 135                                                         |     |

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 139 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

|                                                                 |  |
|-----------------------------------------------------------------|--|
| Met Gly Trp Ser Gly Val Phe Ile Phe Leu Leu Ser Val Thr Ala Gly |  |
| 1 5 10 15                                                       |  |
| Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys |  |
| 20 25 30                                                        |  |
| Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe |  |
| 35 40 45                                                        |  |
| Ser Ser Tyr Trp Ile Val Trp Ile Lys Gln Arg Pro Gly His Gly Leu |  |
| 50 55 60                                                        |  |
| Glu Trp Ile Gly Glu Ile Leu Pro Gly Thr Gly Ser Thr Asn Tyr Asn |  |
| 65 70 75 80                                                     |  |
| Glu Lys Phe Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn |  |
| 85 90 95                                                        |  |
| Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val |  |
| 100 105 110                                                     |  |
| Tyr Tyr Cys Ala Ser Leu Asp Ser Ser Gly Tyr Tyr Ala Met Asp Tyr |  |
| 115 120 125                                                     |  |
| Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser                     |  |
| 130 135                                                         |  |

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 381 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

052220 3824160

(ix) FEATURE:

(A) NAME/KEY: CDS  
(B) LOCATION: 1..381

(ix) FEATURE:

(A) NAME/KEY: mat\_peptide  
(B) LOCATION: 1..381

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| ATG GTG TCC ACA CCT CAG TTC CTT GGT CTC CTG TTG ATC TGT TTT CAA | 48  |
| Met Val Ser Thr Pro Gln Phe Leu Gly Leu Leu Ile Cys Phe Gln     |     |
| 1 5 10 15                                                       |     |
| GGT ACC AGA TGT GAT ATC CAG ATG ACA CAG ACT ACA TCC TCC CTG TCT | 96  |
| Gly Thr Arg Cys Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser |     |
| 20 25 30                                                        |     |
| GCC TCT CTG GGA GAC AGA GTC ACC ATC AGT TGC AGG GCA AGT CAG GAC | 144 |
| Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp |     |
| 35 40 45                                                        |     |
| ATT AGT AAT TAT TTA AAC TGG TAT CAA CAG AAA CCA GAT GGA ACT GTT | 192 |
| Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val |     |
| 50 55 60                                                        |     |
| AAA CTC CTG ATC TAC TAT ACA TCA AGA TTA CAC TCA GGA GTC CCA TCA | 240 |
| Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser |     |
| 65 70 75 80                                                     |     |
| AGG TTC AGT GGC AGT GGG TCT GGA ACA GAT TAT TCT CTC ACC ATT AGC | 288 |
| Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser |     |
| 85 90 95                                                        |     |
| AAC CTG GAG CAA GAA GAT ATT GCC AGT TAC TTT TGC CAA CAG GGT TAT | 336 |
| Asn Leu Glu Gln Glu Asp Ile Ala Ser Tyr Phe Cys Gln Gln Gly Tyr |     |
| 100 105 110                                                     |     |
| ACG CCT CCG TGG ACG TTC GGT GGA GGC ACC AAG TTG GAA ATC AAA     | 381 |
| Thr Pro Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys         |     |
| 115 120 125                                                     |     |

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 127 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

|                                                                 |  |
|-----------------------------------------------------------------|--|
| Met Val Ser Thr Pro Gln Phe Leu Gly Leu Leu Leu Ile Cys Phe Gln |  |
| 1 5 10 15                                                       |  |
| Gly Thr Arg Cys Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser |  |
| 20 25 30                                                        |  |
| Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp |  |
| 35 40 45                                                        |  |
| Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val |  |
| 50 55 60                                                        |  |



Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser  
65 70 75 80  
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser  
85 90 95  
Asn Leu Glu Gln Glu Asp Ile Ala Ser Tyr Phe Cys Gln Gln Gly Tyr  
100 105 110  
Thr Pro Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys  
115 120 125

(2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 402 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- (ix) FEATURE:  
(A) NAME/KEY: CDS  
(B) LOCATION: 1..402

- (ix) FEATURE:  
(A) NAME/KEY: mat\_peptide  
(B) LOCATION: 1..402

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| ATG GAG CTG GAT CTT TAT CTT ATT CTG TCA GTA ACT TCA GGT GTC TAC | 48  |
| Met Glu Leu Asp Leu Tyr Leu Ile Leu Ser Val Thr Ser Gly Val Tyr |     |
| 1 5 10 15                                                       |     |
| TCA CAG GTT CAG CTC CAG CAG TCT GGG GCT GAG CTG GCA AGA CCT GGG | 96  |
| Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly |     |
| 20 25 30                                                        |     |
| GCT TCA GTG AAG TTG TCC TGC AAG GCT TCT GGC TAC ACC TTT ACT AAC | 144 |
| Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn |     |
| 35 40 45                                                        |     |
| TAC TGG GTG CAG TGG GTA AAA CAG AGG CCT GGA CAG GGT CTG GAA TGG | 192 |
| Tyr Trp Val Gln Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp |     |
| 50 55 60                                                        |     |
| ATT GGG TCT ATT TAT CCT GGA GAT GGT GAT ACT AGG AAC ACT CAG AAG | 240 |
| Ile Gly Ser Ile Tyr Pro Gly Asp Gly Asp Thr Arg Asn Thr Gln Lys |     |
| 65 70 75 80                                                     |     |
| TTC AAG GGC AAG GCC ACA TTG ACT GCA GAT AAA TCC TCC ATC ACA GCC | 288 |
| Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ile Thr Ala |     |
| 85 90 95                                                        |     |
| TAC ATG CAA CTC ACC AGC TTG GCA TCT GAG GAC TCT GCG GTC TAT TAC | 336 |
| Tyr Met Gln Leu Thr Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr |     |
| 100 105 110                                                     |     |
| TGT GCA AGA TCG ACT GGT AAC CAC TTT GAC TAC TGG GGC CAA GGC ACC | 384 |
| Cys Ala Arg Ser Thr Gly Asn His Phe Asp Tyr Trp Gly Gln Gly Thr |     |
| 115 120 125                                                     |     |

00142005 071300

ACT CTC ACA GTC TCC TCA  
Thr Leu Thr Val Ser Ser  
130

402

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 134 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Met Glu Leu Asp Leu Tyr Leu Ile Leu Ser Val Thr Ser Gly Val Tyr  
1 5 10 15  
Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly  
20 25 30  
Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn  
35 40 45  
Tyr Trp Val Gln Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp  
50 55 60  
Ile Gly Ser Ile Tyr Pro Gly Asp Gly Asp Thr Arg Asn Thr Gln Lys  
65 70 75 80  
Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ile Thr Ala  
85 90 95  
Tyr Met Gln Leu Thr Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr  
100 105 110  
Cys Ala Arg Ser Thr Gly Asn His Phe Asp Tyr Trp Gly Gln Gly Thr  
115 120 125  
Thr Leu Thr Val Ser Ser  
130

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 35 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

ACAAAGCTTC CACCATGGAG TCAGACACAC TCCTG

35

(2) INFORMATION FOR SEQ ID NO:41:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 36 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

0011420101439

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

GGCTAAGCTT CCACCATGGG ATGGAGCGGG ATCTTT

36

(2) INFORMATION FOR SEQ ID NO:42:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 35 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

CTTGGATCCA CTCACGTTTT ATTCCAGCT TGGTC

35

(2) INFORMATION FOR SEQ ID NO:43:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 36 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

GTTGGATCCA CTCACCTGCA GAGACAGTTA CCAGAG

36

(2) INFORMATION FOR SEQ ID NO:44:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 35 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

CTTGGATCCA CTCACGATTT ATTTCCAGCT TGGTC

35

(2) INFORMATION FOR SEQ ID NO:45:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 35 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

0914285-071396

35

35

(1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 36 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

36

36

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

39

39

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

36

36

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

17

17

(2) INFORMATION FOR SEQ ID NO:50:

- (1) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 18 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

GAGTGCACCA TATGCGGT

18

(2) INFORMATION FOR SEQ ID NO:51:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 55 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

ACCGTGTCTG GCTACACCTT CACCAGCGAT CATGCCTGGA GCTGGGTGAG ACAGC

55

(2) INFORMATION FOR SEQ ID NO:52:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 63 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

TGAGTGGATT GGATACATTA GTTATAGTGG AATCACAACC TATAATCCAT CTCTCAAATC  
CAG

60

63

(2) INFORMATION FOR SEQ ID NO:53:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 54 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

TATTATTGTG CAAGATCCCT AGCTCGGACT ACGGCTATGG ACTACTGGGG TCAA

54

0914265 07 398  
06ET 20 58247160

(2) INFORMATION FOR SEQ ID NO:54:

- (1) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

GTGACAATGC TGAGAGACAC CAGCAAG

27

(2) INFORMATION FOR SEQ ID NO:55:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

GGTGTCCACT CCGATGTCCA ACTG

24

(2) INFORMATION FOR SEQ ID NO:56:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

GGTCTTGAGT GGATGGGATA CATTAGT

27

(2) INFORMATION FOR SEQ ID NO:57:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

GTGTCTGGCT ACTCAATTAC CAGCATCAT

29

09114285-0733

(2) INFORMATION FOR SEQ ID NO:58:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 48 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

TGTAGAGCCA GCCAGGACAT CAGCAGTTAC CTGAACTGGT ACCAGCAG

48

(2) INFORMATION FOR SEQ ID NO:59:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 42 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

ATCTACTACA CCTCCAGACT GCACTCTGGT GTGCCAAGCA GA

42

(2) INFORMATION FOR SEQ ID NO:60:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 50 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

ACCTACTACT GCCAACAGGG TAACACGCTT CCATACACGT TCGGCCAAGG

50

(2) INFORMATION FOR SEQ ID NO:61:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

AGCGGTACCG ACTACACCTT CACCATC

27

001125 071398  
060720 05241600

|            |            |            |            |            |            |     |     |     |     |     |     |     |     |     |     |     |
|------------|------------|------------|------------|------------|------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| AAGCTTC    | ATG        | GGA        | TGG        | AGC        | TGT        | ATC | ATC | CTC | TTC | TTG | GTA | GCA | ACA | GCT | 49  |     |
|            | Met        | Gly        | Trp        | Ser        | Cys        | Ile | Ile | Leu | Phe | Leu | Val | Ala | Thr | Ala |     |     |
|            | 1          |            |            |            | 5          |     |     |     |     | 10  |     |     |     |     |     |     |
| ACA        | GGTAAGGGGC | TCACAGTAGC | AGGCTTGAGG | TCTGGACATA | TATATGGGTG | 102 |     |     |     |     |     |     |     |     |     |     |
| Thr        |            |            |            |            |            |     |     |     |     |     |     |     |     |     |     |     |
| 15         |            |            |            |            |            |     |     |     |     |     |     |     |     |     |     |     |
| ACAATGACAT | CCACTTTGCC | TTTCTCTCCA | CA         | GGT        | GTC        | CAC | TCC | CAG | GTC | CAA | 155 |     |     |     |     |     |
|            |            |            |            | Gly        | Val        | His | Ser | Gln | Val | Gln |     |     |     |     |     |     |
|            |            |            |            | 1          |            |     |     | 5   |     |     |     |     |     |     |     |     |
| CTG        | CAG        | GAG        | AGC        | GGT        | CCA        | GGT | CTT | GTG | AGA | CCT | AGC | CAG | ACC | CTG | AGC | 203 |
| Leu        | Gln        | Glu        | Ser        | Gly        | Pro        | Gly | Leu | Val | Arg | Pro | Ser | Gln | Thr | Leu | Ser |     |
|            | 10         |            |            |            |            |     | 15  |     |     |     |     | 20  |     |     |     |     |
| CTG        | ACC        | TGC        | ACC        | GTG        | TCT        | GGC | TAC | TCA | ATT | ACC | AGC | GAT | CAT | GCC | TGG | 251 |
| Leu        | Thr        | Cys        | Thr        | Val        | Ser        | Gly | Tyr | Ser | Ile | Thr | Ser | Asp | His | Ala | Trp |     |
|            | 25         |            |            |            |            | 30  |     |     |     |     | 35  |     |     |     |     |     |
| AGC        | TGG        | GTG        | AGA        | CAG        | CCA        | CCT | GGA | CGA | GGT | CTT | GAG | TGG | ATT | GGA | TAC | 299 |
| Ser        | Trp        | Val        | Arg        | Gln        | Pro        | Pro | Gly | Arg | Gly | Leu | Glu | Trp | Ile | Gly | Tyr |     |
|            | 40         |            |            |            | 45         |     |     |     |     | 50  |     |     |     |     | 55  |     |
| ATT        | AGT        | TAT        | AGT        | GGA        | ATC        | ACA | ACC | TAT | AAT | CCA | TCT | CTC | AAA | TCC | AGA | 347 |
| Ile        | Ser        | Tyr        | Ser        | Gly        | Ile        | Thr | Thr | Tyr | Asn | Pro | Ser | Leu | Lys | Ser | Arg |     |
|            |            |            |            | 60         |            |     |     |     | 65  |     |     |     |     | 70  |     |     |
| GTG        | ACA        | ATG        | CTG        | AGA        | GAC        | ACC | AGC | AAG | AAC | CAG | TTC | AGC | CTG | AGA | CTC | 395 |
| Val        | Thr        | Met        | Leu        | Arg        | Asp        | Thr | Ser | Lys | Asn | Gln | Phe | Ser | Leu | Arg | Leu |     |
|            |            |            | 75         |            |            |     |     | 80  |     |     |     |     | 85  |     |     |     |
| AGC        | AGC        | GTG        | ACA        | GCC        | GCC        | GAC | ACC | GCG | GTT | TAT | TAT | TGT | GCA | AGA | TCC | 443 |
| Ser        | Ser        | Val        | Thr        | Ala        | Ala        | Asp | Thr | Ala | Val | Tyr | Tyr | Cys | Ala | Arg | Ser |     |
|            |            | 90         |            |            |            |     | 95  |     |     |     |     | 100 |     |     |     |     |



ACA GTC TCC TCA GGTGAGTCCT TACAACCTCT CTCTTCTATT CAGCTTAAAT 543  
Thr Val Ser Ser  
120

(2) INFORMATION FOR SEQ ID NO:63:

(ii) MOLECULE TYPE: protein

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr  
1 5 10 15

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 123 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser  
115 120

(1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 506 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

```
(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 8..52
```

```
(ix) FEATURE:
 (A) NAME/KEY: mat_peptide
 (B) LOCATION: 8..52
```

(ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 135..467

```
(ix) FEATURE:
 (A) NAME/KEY: mat_peptide
 (B) LOCATION: 135..467
```

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

AAGCTTC ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA GCA ACA GCT 49  
Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala  
1 5 10

ACA GGTAAGGGGC TCACAGTAGC AGGCTTGAGG TCTGGACATA TATATGGGTG 102  
Thr  
15

ACAATGACAT CCACTTTGCC TTTCTCTCCA CA GGT GTC CAC TCC GAC ATC CAG 155  
Gly Val His Ser Asp Ile Gln  
1 5

ATG ACC CAG AGC CCA AGC AGC CTG AGC GCC AGC GTG GGT GAC AGA GTG 203  
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val  
10 15 20

ACC ATC ACC TGT AGA GCC AGC CAG GAC ATC AGC AGT TAC CTG AAT TGG 251  
Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Tyr Leu Asn Trp  
25 30 35

TAC CAG CAG AAG CCA GGT AAG GCT CCA AAG CTG CTG ATC TAC TAC ACC 299  
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Tyr Thr  
40 45 50 55

TCC AGA CTG CAC TCT GGT GTG CCA AGC AGA TTC AGC GGT AGC GGT AGC 347  
Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser  
60 65 70

GGT ACC GAC TTC ACC TTC ACC ATC AGC AGC CTC CAG CCA GAG GAC ATC 395  
Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile  
75 80 85

GCT ACC TAC TAC TGC CAA CAG GGT AAC ACG CTT CCA TAC ACG TTC GGC 443  
Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly  
90 95 100

CAA GGG ACC AAG GTG GAA ATC AAA CGTGAGTAGA ATTTAACTT TGCTTCCTCA 497  
 Gln Gly Thr Lys Val Glu Ile Lys  
     105                    110  
 GTTGGATCC 506

(2) INFORMATION FOR SEQ ID NO:66:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr  
     1                    5                    10                    15

(2) INFORMATION FOR SEQ ID NO:67:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 111 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

Gly Val His Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser  
     1                    5                    10                    15  
 Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp  
                     20                    25                    30  
 Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro  
                     35                    40                    45  
 Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser  
                     50                    55                    60  
 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser  
                     65                    70                    75                    80  
 Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Gly Asn  
                     85                    90                    95  
 Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
                     100                    105                    110

(2) INFORMATION FOR SEQ ID NO:68:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 438 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 12..425

0011265 071396

(1x) FEATURE:

(A) NAME/KEY: mat\_peptide  
(B) LOCATION: 12..425

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

|                                                                  |     |
|------------------------------------------------------------------|-----|
| AAGCTTCCAC C ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA GCA ACA | 50  |
| Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr              |     |
| 1 5 10                                                           |     |
| GCT ACA GGT GTC CAC TCC CAG GTC CAA CTG CAG GAG AGC GGT CCA GGT  | 98  |
| Ala Thr Gly Val His Ser Gln Val Gln Leu Gln Glu Ser Gly Pro Gly  |     |
| 15 20 25                                                         |     |
| CTT GTG AGA CCT AGC CAG ACC CTG AGC CTG ACC TGC ACC GTG TCT GGC  | 146 |
| Leu Val Arg Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly  |     |
| 30 35 40 45                                                      |     |
| TAC TCA ATT ACC AGC GAT CAT GCC TGG AGC TGG GTT CGC CAG CCA CCT  | 194 |
| Tyr Ser Ile Thr Ser Asp His Ala Trp Ser Trp Val Arg Gln Pro Pro  |     |
| 50 55 60                                                         |     |
| GGA CGA GGT CTT GAG TGG ATT GGA TAC ATT AGT TAT AGT GGA ATC ACA  | 242 |
| Gly Arg Gly Leu Glu Trp Ile Gly Tyr Ile Ser Tyr Ser Gly Ile Thr  |     |
| 65 70 75                                                         |     |
| ACC TAT AAT CCA TCT CTC AAA TCC AGA GTG ACA ATG CTG AGA GAC ACC  | 290 |
| Thr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Met Leu Arg Asp Thr  |     |
| 80 85 90                                                         |     |
| AGC AAG AAC CAG TTC AGC CTG AGA CTC AGC AGC GTG ACA GCC GCC GAC  | 338 |
| Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp  |     |
| 95 100 105                                                       |     |
| ACC GCG GTT TAT TAT TGT GCA AGA TCC CTA GCT CGG ACT ACG GCT ATG  | 386 |
| Thr Ala Val Tyr Tyr Cys Ala Arg Ser Leu Ala Arg Thr Thr Ala Met  |     |
| 110 115 120 125                                                  |     |
| GAC TAC TGG GGT CAA GGC AGC CTC GTC ACA GTC TCC TCA GGTGAGTGGGA  | 435 |
| Asp Tyr Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser              |     |
| 130 135                                                          |     |
| TCC                                                              | 438 |

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 138 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

|                                                                 |  |
|-----------------------------------------------------------------|--|
| Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly |  |
| 1 5 10 15                                                       |  |
| Val His Ser Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg |  |
| 20 25 30                                                        |  |
| Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile |  |
| 35 40 45                                                        |  |

Thr Ser Asp His Ala Trp Ser Trp Val Arg Gln Pro Pro Gly Arg Gly  
 50 55 60

Leu Glu Trp Ile Gly Tyr Ile Ser Tyr Ser Gly Ile Thr Thr Tyr Asn  
 65 70 75 80

Pro Ser Leu Lys Ser Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn  
 85 90 95

Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val  
 100 105 110

Tyr Tyr Cys Ala Arg Ser Leu Ala Arg Thr Thr Ala Met Asp Tyr Trp  
 115 120 125

Gly Gln Gly Ser Leu Val Thr Val Ser Ser  
 130 135

(2) INFORMATION FOR SEQ ID NO:70:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 402 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 12..389

- (ix) FEATURE:  
 (A) NAME/KEY: mat\_peptide  
 (B) LOCATION: 12..389

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

|                                                                  |     |
|------------------------------------------------------------------|-----|
| AAGCTTCCAC C ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA GCA ACA | 50  |
| Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr              |     |
| 1 5 10                                                           |     |
| GCT ACA GGT GTC CAC TCC GAC ATC CAG ATG ACC CAG AGC CCA AGC AGC  | 98  |
| Ala Thr Gly Val His Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser  |     |
| 15 20 25                                                         |     |
| CTG AGC GCC AGC GTG GGT GAC AGA GTG ACC ATC ACC TGT AGA GCC AGC  | 146 |
| Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser  |     |
| 30 35 40 45                                                      |     |
| CAG GAC ATC AGC AGT TAC CTG AAT TGG TAC CAG CAG AAG CCA GGA AAG  | 194 |
| Gln Asp Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys  |     |
| 50 55 60                                                         |     |
| GCT CCA AAG CTG CTG ATC TAC TAC ACC TCC AGA CTG CAC TCT GGT GTG  | 242 |
| Ala Pro Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val  |     |
| 65 70 75                                                         |     |
| CCA AGC AGA TTC AGC GGT AGC GGT AGC GGT ACC GAC TTC ACC TTC ACC  | 290 |
| Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr  |     |
| 80 85 90                                                         |     |
| ATC AGC AGC CTC CAG CCA GAG GAC ATC GCT ACC TAC TAC TGC CAA CAG  | 338 |
| Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln  |     |
| 95 100 105                                                       |     |

0014065 071396

GGT AAC ACG CTT CCA TAC ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC 386  
Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile  
110 115 120 125

AAA CGTGAGTGGA TCC 402  
Lys

(2) INFORMATION FOR SEQ ID NO:71:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 126 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly  
1 5 10 15  
Val His Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala  
20 25 30  
Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile  
35 40 45  
Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys  
50 55 60  
Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg  
65 70 75 80  
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser  
85 90 95  
Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Thr  
100 105 110  
Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
115 120 125

(2) INFORMATION FOR SEQ ID NO:72:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 36 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

TAAGGATCCA CTCACCTGAG GAGACTGTGA CGAGGC

36

(2) INFORMATION FOR SEQ ID NO:73:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 32 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

SECRET 20140416

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

ATCAAGCTTC CACCATGGGA TGGAGCTGTA TC

32

(2) INFORMATION FOR SEQ ID NO:74:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

AATGGATCCA CTCACGTTTG ATTTCCACCT

30

(2) INFORMATION FOR SEQ ID NO:75:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 33 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

CATGCCTGGA GCTGGGTTTCG CCAGCCACCT GGA

33

(2) INFORMATION FOR SEQ ID NO:76:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 33 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

TCCAGGTGGC TGGCGAACCC AGCTCCAGGC ATG

33

(2) INFORMATION FOR SEQ ID NO:77:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

001425 0130

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

CAGCAGAAGC CAGGAAAGGC TCCAAAGCTG

30

(2) INFORMATION FOR SEQ ID NO:78:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

CAGCTTTGGA GCCTTTCCTG GCTTCTGCTG

30

(2) INFORMATION FOR SEQ ID NO:79:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 66 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

ACCTGTAGAG CCAGCAAGAG TGTTAGTACA TCTGGCTATA GTTATATGCA CTGGTACCAG  
CAGAAG

60

66

(2) INFORMATION FOR SEQ ID NO:80:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

GCTGGCTCTA CAGGT

15

(2) INFORMATION FOR SEQ ID NO:81:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 48 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

0014285 071398



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

AAGCTGCTGA TCTACCTTCC ATCCACCCTG GAATCTGGTG TGCCAAGC

48

(2) INFORMATION FOR SEQ ID NO:82:

- (1) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

GTAGATCAGC AGCTT

15

(2) INFORMATION FOR SEQ ID NO:83:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 48 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

GCTACCTACT ACTGCCAGCA CAGTAGGGAG ACCCCATACA CGTTCGGC

48

(2) INFORMATION FOR SEQ ID NO:84:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

CTGGCAGTAG GTAGC

15

(2) INFORMATION FOR SEQ ID NO:85:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 414 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 12..401

004425-07350  
05 OCT 2008 08:24:50

(ix) FEATURE:

(A) NAME/KEY: mat\_peptide  
(B) LOCATION: 12..401

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:85:

|                                                                 |                                                     |     |
|-----------------------------------------------------------------|-----------------------------------------------------|-----|
| AAGCTTCCAC C                                                    | ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA GCA ACA | 50  |
|                                                                 | Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr |     |
|                                                                 | 1 5 10                                              |     |
| GCT ACA GGT GTC CAC TCC GAC ATC CAG ATG ACC CAG AGC CCA AGC AGC |                                                     | 98  |
| Ala Thr Gly Val His Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser |                                                     |     |
|                                                                 | 15 20 25                                            |     |
| CTG AGC GCC AGC GTG GGT GAC AGA GTG ACC ATC ACC TGT AGA GCC AGC |                                                     | 146 |
| Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser |                                                     |     |
|                                                                 | 30 35 40 45                                         |     |
| AAG AGT GTT AGT ACA TCT GGC TAT AGT TAT ATG CAC TGG TAC CAG CAG |                                                     | 194 |
| Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln |                                                     |     |
|                                                                 | 50 55 60                                            |     |
| AAG CCA GGA AAG GCT CCA AAG CTG CTG ATC TAC CTT GCA TCC AAC CTG |                                                     | 242 |
| Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu |                                                     |     |
|                                                                 | 65 70 75                                            |     |
| GAA TCT GGT GTG CCA AGC AGA TTC AGC GGT AGC GGT AGC GGT ACC GAC |                                                     | 290 |
| Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp |                                                     |     |
|                                                                 | 80 85 90                                            |     |
| TTC ACC TTC ACC ATC AGC AGC CTC CAG CCA GAG GAC ATC GCT ACC TAC |                                                     | 338 |
| Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr |                                                     |     |
|                                                                 | 95 100 105                                          |     |
| TAC TGC CAG CAC AGT AGG GAG AAC CCA TAC ACG TTC GGC CAA GGG ACC |                                                     | 386 |
| Tyr Cys Gln His Ser Arg Glu Asn Pro Tyr Thr Phe Gly Gln Gly Thr |                                                     |     |
|                                                                 | 110 115 120 125                                     |     |
| AAG GTG GAA ATC AAA CGTGAGTGGGA TCC                             |                                                     | 414 |
| Lys Val Glu Ile Lys                                             |                                                     |     |
|                                                                 | 130                                                 |     |

(2) INFORMATION FOR SEQ ID NO:86:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 130 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

|                                                                 |  |
|-----------------------------------------------------------------|--|
| Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly |  |
| 1 5 10 15                                                       |  |
| Val His Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala |  |
| 20 25 30                                                        |  |
| Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Lys Ser Val |  |
| 35 40 45                                                        |  |
| Ser Thr Ser Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly |  |
| 50 55 60                                                        |  |

Lys Ala Pro Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly  
65 70 75 80  
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe  
85 90 95  
Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln  
100 105 110  
His Ser Arg Glu Asn Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu  
115 120 125  
Ile Lys  
130

(2) INFORMATION FOR SEQ ID NO:87:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 45 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

GGTTATTCAT TCACTAGTTA TTACATACAC TGGGTTAGAC AGGCC

45

(2) INFORMATION FOR SEQ ID NO:88:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

AGTGAATGAA TAACCGCTAG CTTTACA

27

(2) INFORMATION FOR SEQ ID NO:89:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 69 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

GAGTGGGTGG GCTATATTGA TCCTTTCAAT GGTGGTACTA GCTATAATCA GAAGTTCAAG  
GGCAGGGTT

60

69

0014205 17430

(2) INFORMATION FOR SEQ ID NO:90:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

ATAGCCCACC CACTC

15

(2) INFORMATION FOR SEQ ID NO:91:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 36 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

GGGGGTAACC GCTTTGCTTA CTGGGGACAG GGTACC

36

(2) INFORMATION FOR SEQ ID NO:92:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 36 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

AGCAAAGCGG TTACCCCCTC TGGCGCAGTA GTAGAC

36

(2) INFORMATION FOR SEQ ID NO:93:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

CAAGGTTACC ATGACCGTGG ACACCTCTAC

30

0044285 071298  
052720 6824160



(2) INFORMATION FOR SEQ ID NO:98:

- (1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 17 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

AACAGCTATG ACCATGA

17

(2) INFORMATION FOR SEQ ID NO:99:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 433 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 16..420

(ix) FEATURE:

- (A) NAME/KEY: mat\_peptide  
 (B) LOCATION: 16..420

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

|                                                                  |     |
|------------------------------------------------------------------|-----|
| AAGCTTGCCG CCACC ATG GAC TGG ACC TGG CGC GTG TTT TGC CTG CTC GCC | 51  |
| Met Asp Trp Thr Trp Arg Val Phe Cys Leu Leu Ala                  |     |
| 1 5 10                                                           |     |
| GTG GCT CCT GGG GCC CAC AGC CAG GTG CAA CTA GTG CAG TCC GGC GCC  | 99  |
| Val Ala Pro Gly Ala His Ser Gln Val Gln Leu Val Gln Ser Gly Ala  |     |
| 15 20 25                                                         |     |
| GAA GTG AAG AAA CCC GGT GCT TCC GTG AAA GTC AGC TGT AAA GCT AGC  | 147 |
| Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser  |     |
| 30 35 40                                                         |     |
| GGT TAT TCA TTC ACT AGT TAT TAC ATA CAC TGG GTT AGA CAG GCC CCA  | 195 |
| Gly Tyr Ser Phe Thr Ser Tyr Tyr Ile His Trp Val Arg Gln Ala Pro  |     |
| 45 50 55 60                                                      |     |
| GGC CAA GGG CTC GAG TGG GTG GGC TAT ATT GAT CCT TTC AAT GGT GGT  | 243 |
| Gly Gln Gly Leu Glu Trp Val Gly Tyr Ile Asp Pro Phe Asn Gly Gly  |     |
| 65 70 75                                                         |     |
| ACT AGC TAT AAT CAG AAG TTC AAG GGC AAG GTT ACC ATG ACC GTG GAC  | 291 |
| Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Val Thr Met Thr Val Asp  |     |
| 80 85 90                                                         |     |
| ACC TCT ACA AAC ACC GCC TAC ATG GAA CTG TCC AGC CTG CGC TCC GAG  | 339 |
| Thr Ser Thr Asn Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu  |     |
| 95 100 105                                                       |     |

GAC ACT GCA TGC TAC TAC TGC GCC AGA GGG GGT AAC CGC TTT GCT TAC 387  
 Asp Thr Ala Cys Tyr Tyr Cys Ala Arg Gly Gly Asn Arg Phe Ala Tyr  
 110 115 120

TGG GGA CAG GGT ACC CTT GTC ACC GTC AGT TCA GGTGAGTGGGA TCC 433  
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 125 130 135

(2) INFORMATION FOR SEQ ID NO:100:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 135 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

Met Asp Trp Thr Trp Arg Val Phe Cys Leu Leu Ala Val Ala Pro Gly  
 1 5 10 15

Ala His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys  
 20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe  
 35 40 45

Thr Ser Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu  
 50 55 60

Glu Trp Val Gly Tyr Ile Asp Pro Phe Asn Gly Gly Thr Ser Tyr Asn  
 65 70 75 80

Gln Lys Phe Lys Gly Lys Val Thr Met Thr Val Asp Thr Ser Thr Asn  
 85 90 95

Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Cys  
 100 105 110

Tyr Tyr Cys Ala Arg Gly Gly Asn Arg Phe Ala Tyr Trp Gly Gln Gly  
 115 120 125

Thr Leu Val Thr Val Ser Ser  
 130 135

(2) INFORMATION FOR SEQ ID NO:101:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 433 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 16..420

(ix) FEATURE:  
 (A) NAME/KEY: mat\_peptide  
 (B) LOCATION: 16..420

00142005 07 1300

|                                                                   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
|-------------------------------------------------------------------|-----|--|--|--|--|--|--|--|--|--|--|--|--|--|--|----|
| AAGCTTGGCCG CCACC ATG GAC TGG ACC TGG CGC GTG TTT TGC CTG CTC GCC |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 51 |
| Met Asp Trp Thr Trp Arg Val Phe Cys Leu Leu Ala                   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| 1 5 10                                                            |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| GTG GCT CCT GGG GCC CAC AGC CAG GTG CAA CTA GTG CAG TCC GGC GCC   | 99  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| Val Ala Pro Gly Ala His Ser Gln Val Gln Leu Val Gln Ser Gly Ala   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| 15 20 25                                                          |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| GAA GTG AAG AAA CCC GGT GCT TCC GTG AAA GTC AGC TGT AAA GCT AGC   | 147 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| 30 35 40                                                          |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| GGT TAT TCA TTC ACT AGT TAT TAC ATA CAC TGG GTT AGA CAG GCC CCA   | 195 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| Gly Tyr Ser Phe Thr Ser Tyr Tyr Ile His Trp Val Arg Gln Ala Pro   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| 45 50 55 60                                                       |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| GGC CAA GGG CTC GAA TGG ATT GGC TAT ATT GAT CCT TTC AAT GGT GGT   | 243 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asp Pro Phe Asn Gly Gly   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| 65 70 75                                                          |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| ACT AGC TAT AAT CAG AAG TTC AAG GGC AAG GTT ACC ATG ACC GTG GAC   | 291 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Val Thr Met Thr Val Asp   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| 80 85 90                                                          |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| ACC TCT ACA AAC ACC GCC TAC ATG GAA CTG TCC AGC CTG CGC TCC GAG   | 339 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| Thr Ser Thr Asn Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| 95 100 105                                                        |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| GAC ACT GCA GTC TAC TAC TGC GCC AGA GGG GGT AAC CGC TTT GCT TAC   | 387 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Asn Arg Phe Ala Tyr   |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| 110 115 120                                                       |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| TGG GGA CAG GGT ACC CTT GTC ACC GTC AGT TCA GGTGAGTGGGA TCC       | 433 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser                       |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |
| 125 130 135                                                       |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |    |

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 135 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asp | Trp | Thr | Trp | Arg | Val | Phe | Cys | Leu | Leu | Ala | Val | Ala | Pro | Gly |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Ala | His | Ser | Gln | Val | Gln | Leu | Val | Gln | Ser | Gly | Ala | Glu | Val | Lys | Lys |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Pro | Gly | Ala | Ser | Val | Lys | Val | Ser | Cys | Lys | Ala | Ser | Gly | Tyr | Ser | Phe |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Thr | Ser | Tyr | Tyr | Ile | His | Trp | Val | Arg | Gln | Ala | Pro | Gly | Gln | Gly | Leu |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Glu | Trp | Ile | Gly | Tyr | Ile | Asp | Pro | Phe | Asn | Gly | Gly | Thr | Ser | Tyr | Asn |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| Gln | Lys | Phe | Lys | Gly | Lys | Val | Thr | Met | Thr | Val | Asp | Thr | Ser | Thr | Asn |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |



|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Ala | Tyr | Met | Glu | Leu | Ser | Ser | Leu | Arg | Ser | Glu | Asp | Thr | Ala | Val |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Tyr | Tyr | Cys | Ala | Arg | Gly | Gly | Asn | Arg | Phe | Ala | Tyr | Trp | Gly | Gln | Gly |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Thr | Leu | Val | Thr | Val | Ser | Ser |     |     |     |     |     |     |     |     |     |
|     | 130 |     |     |     | 135 |     |     |     |     |     |     |     |     |     |     |

(2) INFORMATION FOR SEQ ID NO:103:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 90 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

|                                                                   |    |
|-------------------------------------------------------------------|----|
| GATAAGCTTG CCGCCACCAT GGACTGGACC TGGAGGGTCT TCTTCTTGCT GGCTGTAGCT | 60 |
| CCAGGTGCTC ACTCCCAGGT GCAGCTTGTG                                  | 90 |

(2) INFORMATION FOR SEQ ID NO:104:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 90 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

|                                                                   |    |
|-------------------------------------------------------------------|----|
| CACTCCCAGG TGCAGCTTGT GCAGTCTGGA GCTGAGGTGA AGAAGCCTGG GGCCTCAGTG | 60 |
| AAGGTTTCCT GCAAGGCTTC TGGATACTCA                                  | 90 |

(2) INFORMATION FOR SEQ ID NO:105:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 90 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

|                                                                    |    |
|--------------------------------------------------------------------|----|
| TGCAAGGCTT CTGGATACTC ATTCAGTAGT TATTACATAC ACTGGGTGCG CCAGGCCCCCC | 60 |
| GGACAAAGGC TTGAGTGGAT GGGATATATT                                   | 90 |

(2) INFORMATION FOR SEQ ID NO:106:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 90 base pairs

0014466 01398

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

CTTGAGTGGA TGGGATATAT TGACCCTTTC AATGGTGGTA CTAGCTATAA TCAGAAGTTC 60  
AAGGGCAGAG TCACCATTAC CGTAGACACA 90

(2) INFORMATION FOR SEQ ID NO:107:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 90 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

GTCACCATTA CCGTAGACAC ATCCGCGAGC ACAGCCTACA TGGAGCTGAG CAGCCTGAGA 60  
TCTGAAGACA CGGCTGTGTA TTACTGTGCG 90

(2) INFORMATION FOR SEQ ID NO:108:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 94 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

ACGGCTGTGT ATTACTGTGC GAGAGGGGGT AACCGCTTTG CTTACTGGGG CCAGGGAACC 60  
CTGGTCACCG TCTCCTCAGG TGAGTGGATC CGAC 94

(2) INFORMATION FOR SEQ ID NO:109:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

GATAAGCTTG CCGCC 15

0014285 071358

(2) INFORMATION FOR SEQ ID NO:110:

- (1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 15 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

GTCGGATCCA CTCAC

15

(2) INFORMATION FOR SEQ ID NO:111:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 433 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 16..420

(ix) FEATURE:

- (A) NAME/KEY: mat\_peptide  
 (B) LOCATION: 16..420

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

|                                                                  |     |
|------------------------------------------------------------------|-----|
| AAGCTTGCCG CCACC ATG GAC TGG ACC TGG AGG GTC TTC TTC TTG CTG GCT | 51  |
| Met Asp Trp Thr Trp Arg Val Phe Phe Leu Leu Ala                  |     |
| 1 5 10                                                           |     |
| GTA GCT CCA GGT GCT CAC TCC CAG GTG CAG CTT GTG CAG TCT GGA GCT  | 99  |
| Val Ala Pro Gly Ala His Ser Gln Val Gln Leu Val Gln Ser Gly Ala  |     |
| 15 20 25                                                         |     |
| GAG GTG AAG AAG CCT GGG GCC TCA GTG AAG GTT TCC TGC AAG GCT TCT  | 147 |
| Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser  |     |
| 30 35 40                                                         |     |
| GGA TAC TCA TTC ACT AGT TAT TAC ATA CAC TGG GTG CGC CAG GCC CCC  | 195 |
| Gly Tyr Ser Phe Thr Ser Tyr Tyr Ile His Trp Val Arg Gln Ala Pro  |     |
| 45 50 55 60                                                      |     |
| GGA CAA AGG CTT GAG TGG ATG GGA TAT ATT GAC CCT TTC AAT GGT GGT  | 243 |
| Gly Gln Arg Leu Glu Trp Met Gly Tyr Ile Asp Pro Phe Asn Gly Gly  |     |
| 65 70 75                                                         |     |
| ACT AGC TAT AAT CAG AAG TTC AAG GGC AGA GTC ACC ATT ACC GTA GAC  | 291 |
| Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Val Thr Ile Thr Val Asp  |     |
| 80 85 90                                                         |     |
| ACA TCC GCG AGC ACA GCC TAC ATG GAG CTG AGC AGT CTG AGA TCT GAA  | 339 |
| Thr Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu  |     |
| 95 100 105                                                       |     |

001422-07330

387

433

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 135 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asp | Trp | Thr | Trp | Arg | Val | Phe | Phe | Leu | Ala | Val | Ala | Pro | Gly |     |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     | 15  |     |     |
| Ala | His | Ser | Gln | Val | Gln | Leu | Val | Gln | Ser | Gly | Ala | Glu | Val | Lys | Lys |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Pro | Gly | Ala | Ser | Val | Lys | Val | Ser | Cys | Lys | Ala | Ser | Gly | Tyr | Ser | Phe |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Thr | Ser | Tyr | Tyr | Ile | His | Trp | Val | Arg | Gln | Ala | Pro | Gly | Gln | Arg | Leu |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Glu | Trp | Met | Gly | Tyr | Ile | Asp | Pro | Phe | Asn | Gly | Gly | Thr | Ser | Tyr | Asn |
| 65  |     |     |     |     | 70  |     |     |     | 75  |     |     |     |     |     | 80  |
| Gln | Lys | Phe | Lys | Gly | Arg | Val | Thr | Ile | Thr | Val | Asp | Thr | Ser | Ala | Ser |
|     |     |     |     | 85  |     |     |     | 90  |     |     |     |     |     | 95  |     |
| Thr | Ala | Tyr | Met | Glu | Leu | Ser | Ser | Leu | Arg | Ser | Glu | Asp | Thr | Ala | Val |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| Tyr | Tyr | Cys | Ala | Arg | Gly | Gly | Asn | Arg | Phe | Ala | Tyr | Trp | Gly | Gln | Gly |
|     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |
| Thr | Leu | Val | Thr | Val | Ser | Ser |     |     |     |     |     |     |     |     |     |
|     | 130 |     |     |     |     | 135 |     |     |     |     |     |     |     |     |     |

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## 27

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 27 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

AAGTTCAAGG GCAAGGTCAC CATTACC

27

(2) INFORMATION FOR SEQ ID NO:115:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

GGTGCTTCCG TGAAAGTCAG CTGTAAAGCT

30

(2) INFORMATION FOR SEQ ID NO:116:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

AGCTTTACAG CTGACTTTCA CGGAAGCACC

30

(2) INFORMATION FOR SEQ ID NO:117:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 11 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

Arg Ala Ser Gln Asp Ile Ser Ser Tyr Leu Asn  
1 5 10

(2) INFORMATION FOR SEQ ID NO:118:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 7 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

Tyr Thr Ser Arg Leu His Ser  
1 5

(2) INFORMATION FOR SEQ ID NO:119:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 9 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

Gln Gln Gly Asn Thr Leu Pro Tyr Thr  
1 5

(2) INFORMATION FOR SEQ ID NO:120:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15  
Asp Arg Val Thr Ile Thr Cys  
20

(2) INFORMATION FOR SEQ ID NO:121:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:122:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 32 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr  
1 5 10 15  
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys  
20 25 30

(2) INFORMATION FOR SEQ ID NO:123:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 10 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
1 5 10

(2) INFORMATION FOR SEQ ID NO:124:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 32 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr  
1 5 10 15  
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys  
20 25 30

(2) INFORMATION FOR SEQ ID NO:125:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 6 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

0914235 071390

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

Ser Asp His Ala Trp Ser  
1 5

(2) INFORMATION FOR SEQ ID NO:126:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 16 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

Tyr Ile Ser Tyr Ser Gly Ile Thr Thr Tyr Asn Pro Ser Leu Lys Ser  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:127:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 10 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

Ser Leu Ala Arg Thr Thr Ala Met Asp Tyr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:128:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Gln  
1 5 10 15  
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Thr Phe Thr  
20 25 30

004400-22-000000



(2) INFORMATION FOR SEQ ID NO:129:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile Gly  
1 5 10

(2) INFORMATION FOR SEQ ID NO:130:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

Arg Val Thr Met Leu Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg  
1 5 10 15

Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg  
20 25 30

(2) INFORMATION FOR SEQ ID NO:131:

(i) SEQUENCE CHARACTERISTICS:

- SEQUENCE CHARACTERISTICS
- (A) LENGTH: 11 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser  
1 5 10

(2) INFORMATION FOR SEQ ID NO:132:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

Arg Val Thr Met Leu Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg  
1 5 10 15  
Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg  
20 25 30

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 30 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Gln  
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Thr Phe Thr  
20 25 30

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Met Gly  
1 5 10

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 30 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Gln  
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr  
20 25 30

(1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 15 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His  
1 5 10 15

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

Ala Ser Asn Leu Glu Ser  
1 5

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

Gln His Ser Arg Glu Asn Pro Tyr Thr  
1 5

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15  
Asp Arg Val Thr Ile Thr Cys  
20

(1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 15 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr  
1 5 10 15

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 32 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr  
1 5 10 15  
Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys  
20 25 30

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
1 5 10

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 5 amino acids

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:143:

Ser Tyr Tyr Ile His  
1 5

(2) INFORMATION FOR SEQ ID NO:144:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 17 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

Tyr Ile Asp Pro Phe Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys  
1 5 10 15

Gly

(2) INFORMATION FOR SEQ ID NO:145:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 7 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

Gly Gly Asn Arg Phe Ala Tyr  
1 5

(2) INFORMATION FOR SEQ ID NO:146:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

0014455 071398

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Val | Gln | Leu | Val | Gln | Ser | Gly | Ala | Glu | Val | Lys | Lys | Pro | Gly | Ala |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Ser | Val | Lys | Val | Ser | Cys | Lys | Ala | Ser | Gly | Tyr | Ser | Phe | Thr |     |     |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

(2) INFORMATION FOR SEQ ID NO:147:

- (1) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 14 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Trp | Val | Arg | Gln | Ala | Pro | Gly | Gln | Gly | Leu | Glu | Trp | Val | Gly |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     |

(2) INFORMATION FOR SEQ ID NO:148:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 32 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Val | Thr | Met | Thr | Leu | Asp | Thr | Ser | Thr | Asn | Thr | Ala | Tyr | Met | Glu |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Leu | Ser | Ser | Leu | Arg | Ser | Glu | Asp | Thr | Ala | Val | Tyr | Tyr | Cys | Ala | Arg |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

(2) INFORMATION FOR SEQ ID NO:149:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 11 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

|     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Trp | Gly | Gln | Gly | Thr | Leu | Val | Thr | Val | Ser | Ser |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |

(2) INFORMATION FOR SEQ ID NO:150:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 32 amino acids

001485-0133

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Val | Thr | Met | Thr | Val | Asp | Thr | Ser | Thr | Asn | Thr | Ala | Tyr | Met | Glu |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Leu | Ser | Ser | Leu | Arg | Ser | Glu | Asp | Thr | Ala | Val | Tyr | Tyr | Cys | Ala | Arg |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

(2) INFORMATION FOR SEQ ID NO:151:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 14 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Trp | Val | Arg | Gln | Ala | Pro | Gly | Gln | Gly | Leu | Glu | Trp | Ile | Gly |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     |

(2) INFORMATION FOR SEQ ID NO:152:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Val | Gln | Leu | Val | Gln | Ser | Gly | Ala | Glu | Val | Lys | Lys | Pro | Gly | Ala |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Ser | Val | Lys | Val | Ser | Cys | Lys | Ala | Ser | Gly | Tyr | Ser | Phe | Thr |     |     |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

(2) INFORMATION FOR SEQ ID NO:153:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 14 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly  
1 5 10

(2) INFORMATION FOR SEQ ID NO:154:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 32 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

Arg Val Thr Ile Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu  
1 5 10 15  
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg  
20 25 30

(2) INFORMATION FOR SEQ ID NO:155:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile Gly  
1 5 10

(2) INFORMATION FOR SEQ ID NO:156:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 32 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

Lys Val Thr Ile Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu  
1 5 10 15  
Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg  
20 25 30

0014255.07160



(2) INFORMATION FOR SEQ ID NO:157:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 30 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Val | Gln | Leu | Val | Gln | Ser | Gly | Ala | Glu | Val | Lys | Lys | Pro | Gly | Ala |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Ser | Val | Lys | Val | Ser | Cys | Lys | Ala | Ser | Gly | Tyr | Ser | Phe | Thr |     |     |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

(2) INFORMATION FOR SEQ ID NO:158:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 14 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Trp | Val | Arg | Gln | Ala | Pro | Gly | Gln | Arg | Leu | Glu | Trp | Ile | Gly |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     |

20250720 08:24:50

## DESCRIPTION

Reshaped Human Antibody to Human Interleukin-6  
Receptor5      Technical Field

10      The present invention relates to variable regions (V region) of a mouse monoclonal antibody to the human interleukin-6 receptor (IL-6R), human/mouse chimeric antibody to the human IL-6R, and reshaped human antibody comprising a human antibody wherein the complementarity determining regions (CDRs) of the human light chain (L chain) V region and of the human heavy chain (H chain) V region are grafted with the CDRs of a mouse monoclonal antibody to the human IL-6R. Moreover, the present  
15      invention provides DNA coding for the above-mentioned antibodies or part thereof. The present invention further provides vectors, especially expression vectors comprising said DNA, and host cells transformed or transfected with said vector. The present invention  
20      still more provides a process for production of a chimeric antibody to the human IL-6R, and process for production of a reshaped human antibody to the human IL-6R.

Background Art

25      Interleukin-6 (IL-6) is a multi-function cytokine that is produced by a range of cells. It regulates immune responses, acute phase reactions, and hematopoiesis, and may play a central role in host defense mechanisms. It acts on a wide range of tissues,  
30      exerting growth-inducing, growth inhibitory, and differentiation-inducing effects, depending on the nature of the target cells. The specific receptor for IL-6 (IL-6R) is expressed on lymphoid as well as non-lymphoid cells in accordance with the multifunctional properties  
35      of IL-6. Abnormal expression of the IL-6 gene has been suggested to be involved in the pathogenesis of a variety of diseases, especially autoimmune diseases, mesangial

proliferative glomerulonephritis, and  
plasmacytoma/myeloma (see review by Hirano et al.,  
Immunol. Today 11, 443-449, 1990). Human myeloma cells  
are observed to produce IL-6 and express IL-6R. In  
5 experiments, antibody against IL-6 inhibited the in vitro  
growth of myeloma cells thus indicating that an autocrine  
regulatory loop is operating in oncogenesis of human  
myelomas (Kawano et al., Nature, 332, 83, 1988).

The IL-6R is present on the surface of various  
10 animal cells, and specifically binds to IL-6, and the  
number of IL-6R molecules on the cell surface has been  
reported (Taga et al., J. Exp. Med. 196, 967, 1987).  
Further, cDNA coding for a human IL-6R was cloned and a  
primary structure of the IL-6R was reported (Yamasaki et  
15 al., Science, 241, 825, 1988).

Mouse antibodies are highly immunogenic in humans  
and, for this reason, their therapeutic value in humans  
is limited. The half-life of mouse antibodies in vivo in  
human is relatively short. In addition, mouse antibodies  
20 can not be administered in multiple doses without  
generating an immune response which not only interferes  
with the planned efficacy but also risks an adverse  
allergic response in the patient.

To resolve these problems methods of producing  
25 humanized mouse antibodies were developed. Mouse  
antibodies can be humanized in two ways. The more simple  
method is to construct chimeric antibodies where the  
V regions are derived from the original mouse monoclonal  
antibody and the C regions are derived from suitable  
30 human antibodies. The resulting chimeric antibody  
contains the entire V domains of the original mouse  
antibody and can be expected to bind antigen with the  
same specificity as the original mouse antibody. In  
addition, chimeric antibodies have a substantial  
35 reduction in the percent of the protein sequence derived  
from a non-human source and, therefore, are expected to  
be less immunogenic than the original mouse antibody.

Although chimeric antibodies are predicted to bind antigen well and to be less immunogenic, an immune response to the mouse V regions can still occur (LoBuglio et al., Proc. Natl. Acad. Sci. USA 84, 4220-4224, 1989).

5           The second method for humanizing mouse antibodies is more complicated but more extensively reduces the potential immunogenicity of the mouse antibody. In this method, the complementarity determining regions (CDRs) from the V regions of the mouse antibody are grafted into  
10 human V regions to create "reshaped" human V regions. These reshaped human V regions are then joined to human C regions. The only portions of the final reshaped human antibody derived from non-human protein sequences are the CDRs. CDRs consist of highly variable protein sequences.  
15 They do not show species-specific sequences. For these reasons, a reshaped human antibody carrying murine CDRs should not be any more immunogenic than a natural human antibody containing human CDRs.

As seen from the above, it is supposed that reshaped human antibodies are useful for therapeutic purposes, but reshaped human antibodies to the human IL-6R are not known. Moreover, there is no process for construction of a reshaped human antibodies, universally applicable to any particular antibody. Therefore to construct a fully active reshaped human antibody to a particular antigen, various devices are necessary. Even though mouse monoclonal antibodies to the human IL-6R, i.e., PM1 and MT18, were prepared (Japanese Patent Application No. 2-189420), and the present inventors prepared mouse monoclonal antibodies to the human IL-6R, i.e., AUK12-20, AUK64-7 and AUK146-15, the present inventors are not aware of publications which suggest construction of reshaped human antibodies to the human IL-6R.

35       The present inventors also found that, when the mouse monoclonal antibodies to the human IL-6R were injected into nude mice transplanted with a human myeloma cell line, the growth of the tumor was remarkably

inhibited. This suggests that the anti-human IL-6 receptor antibody is useful as a therapeutic agent for the treatment of myeloma.

Disclosure of Invention

5           Therefore, the present invention is intended to provide a less immunogenic antibody to the human IL-6R. Accordingly, the present invention provides reshaped human antibodies to the human IL-6R. The present invention also provides human/mouse chimeric antibodies  
10           useful during the construction of the reshaped human antibody. The present invention further provides a part of reshaped human antibody, as well as the expression systems for production of the reshaped human antibody and a part thereof, and of the chimeric antibody.

15           More specifically, the present invention provides L chain V region of mouse monoclonal antibody to the human IL-6R; and H chain V region of a mouse monoclonal antibody to the human IL-6R.

20           The present invention also provides a chimeric antibody to the human IL-6R, comprising:

          (1) an L chain comprising a human L chain C region and an L chain V region of a mouse monoclonal antibody to the IL-6R; and

25           (2) an H chain comprising a human H chain C region and an H chain V region of a mouse monoclonal antibody to the human IL-6R.

30           The present invention also provides CDR of an L chain V region of a mouse monoclonal antibody to the human IL-6R; and CDR of an H chain V region of a mouse monoclonal antibody to the human IL-6R.

          The present invention moreover provides a reshaped human L chain V region of an antibody to the human IL-6R, comprising:

35           (1) framework regions (FRs) of a human L chain V region, and

          (2) CDRs of an L chain V region of a mouse monoclonal antibody to the human IL-6R; and

a reshaped human H chain V region of an antibody to the human IL-6R comprising:

- (1) FRs of a human H chain V region, and
- (2) CDRs of an H chain V region of a mouse monoclonal antibody to the human IL-6R.

The present invention also provides a reshaped human L chain of an antibody to the human IL-6R, comprising:

- (1) a human L chain C region; and
- (2) an L chain V region comprising human FRs, and CDRs of a mouse monoclonal antibody to the human IL-6R; and

a reshaped human H chain of an antibody to the human IL-6R, comprising:

- (1) a human H chain C region, and
- (2) an H chain V region comprising a human FRs, and CDRs of a mouse monoclonal antibody to the human IL-6R.

The present invention still more provides a reshaped human antibody to the human IL-6R, comprising:

- (A) an L chain comprising,
  - (1) a human L chain C region, and
  - (2) an L chain V region comprising human L chain FRs, and L chain CDRs of a mouse monoclonal antibody to the human IL-6R; and

- (B) an H chain comprising,
  - (1) a human H chain C region, and
  - (2) an H chain V region comprising human H chain FRs, and H chain CDRs of a mouse monoclonal antibody to the human IL-6R.

The present invention further provides DNA coding for any one of the above-mentioned antibody polypeptides or parts thereof.

The present invention also provides vectors, for example, expression vectors comprising said DNA.

The present invention further provides host cells transformed or transfected with the said vector.

The present invention still more provide a process

for production of a chimeric antibody to the human IL-6R, and a process for production of reshaped human antibody to the human IL-6R.

Brief Description of Drawings

5        Fig. 1 represents expression vectors comprising human cytomegalo virus (HCMV) promoter/enhancer system, useful for the expression of the present antibody peptide.

10       Fig. 2 is a graph showing a result of ELISA for confirmation of an ability of the present chimeric antibody AUK12-20 to bind to the human IL-6R.

      Fig. 3 is a graph showing a result of measurement of an ability of the present chimeric antibody AUK12-20 to inhibit the binding of IL-6 to the human IL-6R.

15       Fig. 4 is a graph showing a result of ELISA for binding of the present chimeric antibodies PM1a and PM1b to human IL-6R.

20       Fig. 5 is a graph showing a result of ELISA testing the ability of the present chimeric antibodies PM1a and PM1b to inhibit IL-6 from binding to the human IL-6R.

      Fig. 6 is a diagram of the construction of the first version of a reshaped human PM-1 H chain V region.

      Fig. 7 is a diagram of the construction of the first version of a reshaped human PM-1 L chain V region.

25       Fig. 8 represents a process for construction of an expression plasmid HEF-12h-gyl comprising a human elongation factor 1 $\alpha$  (HEF-1 $\alpha$ ) promoter/enhancer, useful for the expression of an H chain.

30       Fig. 9 represents a process for construction of an expression plasmid HEF-12k-gk comprising the HEF-1 $\alpha$  promoter/enhancer system, useful for the expression of an L chain.

35       Fig. 10 represents a process for construction of an expression plasmid DHFR-PMh-gyl comprising HCMV promoter/enhancer and the dihydrofolate reductase (dhfr) gene linked to a defective SV40 promoter/enhancer sequence for amplification, useful for expression of an H

95E720 6827160

chain.

Fig. 11 represents a process for the construction of an expression plasmid DHFR- $\Delta$ E-RVh-PM1-f comprising EFl $\alpha$  promoter/enhancer and dhfr gene linked to a defective SV40 promoter/enhancer sequence for amplification, useful for expression of an H chain.

Fig. 12 is a graph showing an ability of version "a" and "b" of the reshaped human PM-1 L chain V region for binding to the human IL-6R.

Fig. 13 is a graph showing an ability of version "f" of the reshaped human PM-1 H chain V region plus version "a" of the reshaped PM-1 L chain L chain V region for binding to the human IL-6R.

Fig. 14 is a graph showing an ability of version "f" of the reshaped PM-1 H chain V region plus version "a" of the reshaped PM-1 L chain V region to inhibit the binding of IL-6 to the human IL-6R.

Fig. 15 represents expression plasmids HEF-V<sub>L</sub>-gk and HEF-V<sub>H</sub>-gyl comprising a human EFl- $\alpha$  promoter/enhancer, useful for expression of an L chain and H chain respectively.

Fig. 16 shows a process for construction of DNA coding for reshaped human AUK 12-20 antibody L chain V region.

Fig. 17 is a graph showing results of an ELISA for confirm of an ability of a reshaped human AUK 12-20 antibody L chain V region to bind to human IL-6R. In the Figure, "Standard AUK 12-20 (chimera) means a result for chimeric AUK 12-20 antibody produced by CHO cells and purified in a large amount.

Fig. 18 is a graph showing a result of an ELISA for an ability of a reshaped human AUK 12-20 antibody (L chain version "a" + H chain version "b") to bind to human IL-6R.

Fig. 19 is a graph showing a result of an ELISA for an ability of a reshaped human AUK 12-20 antibody



Fig. 20 shows a process for chemical synthesis of a reshaped human sle 1220 H antibody H chain V region.

Fig. 22 is a graph showing a result of an ELISA for an ability of a reshaped human sle 1220 antibody (L chain version "a" + H chain version "b") to inhibit the binding of IL-6 to the human IL-6R.

Fig. 24 is a graph showing a result of an ELISA for an ability of a reshaped human sle 1220 antibody (L chain version "a" + H chain version "d") inhibit the binding of IL-6 to the human LI-6R.

### Cloning of DNA coding for mouse V regions

To clone desired DNAs coding for V regions, of a mouse monoclonal antibody, hybridoma cells are

To clone desired DNAs coding for V regions, of a mouse monoclonal antibody, hybridoma cells are

homogenized and a total RNA is obtained according to a conventional procedure described by Chirgwin et al., Biochemistry 18, 5294, 1977. Next, the total RNA is used to synthesize single-stranded cDNAs according to the method described by J.W. Larrick et al., Biotechnology, 7, 934, 1989.

Next, a specific amplification of a relevant portion of the cDNA is carried out by a polymerase chain reaction (PCR) method. For amplification of a  $\kappa$  L chain V region of a mouse monoclonal antibody, 11 groups of oligonucleotide primers (Mouse Kappa Variable; MKV) represented in SEQ ID NO: 1 to 11, and an oligonucleotide primer (Mouse Kappa Constant; MKC) represented in SEQ ID NO: 12 are used as 5'-terminal primers and a 3'-terminal primer respectively. The MKV primers hybridize with the DNA sequence coding for the mouse  $\kappa$  L chain leader sequence, and the MKC primer hybridizes with the DNA sequence coding for the mouse  $\kappa$  L chain constant region. For amplification of the H chain V region of a mouse monoclonal antibody, 10 groups of oligonucleotide primers (Mouse Heavy Variable; MHV) represented in SEQ ID NO: 13 to 22, and a oligonucleotide primer (Mouse Heavy Constant MHC) represented in SEQ ID NO: 23 are used as 5'-terminal primers and a 3'-terminal primer, respectively.

Note, the 5'-terminal primers contain the nucleotide sequence GTCGAC near the 5'-end thereof, which sequence provides a restriction enzyme Sal I cleavage site; and the 3'-terminal primer contains the nucleotide sequence CCCGGG near the 5-end thereof, which sequence provides a restriction enzyme Xma I cleavage site. These restriction enzyme cleavage sites are used to subclone the DNA fragments coding for a variable region into cloning vectors.

Next, the amplification product is cleaved with restriction enzymes Sal I and Xma I to obtain a DNA fragment coding for a desired V region of a mouse

monoclonal antibody. On the other hand, an appropriate cloning vector such as plasmid pUC19 is cleaved with the same restriction enzymes Sal I and Xma I and the above DNA fragment is ligated with the cleaved pUC19 to obtain a plasmid incorporating a DNA fragment coding for a desired V region of a mouse monoclonal antibody.

The sequencing of the cloned DNA can be carried out by any conventional procedure.

The cloning of the desired DNA, and the sequencing thereof, are described in detail in Examples 1 to 3.

#### Complementarity Determining Regions (CDRs)

The present invention provides hypervariable or complementarity determining regions (CDRs) of each V region of the present invention. The V domains of each pair of L and H chains from the antigen binding site. The domains on the L and H chains have the same general structure and each domain comprises four framework regions (FRs), whose sequences are relatively conserved, connected by three CDRs (see Kabat, E.A., Wu, T.T., Bilofsky, H., Reid-Miller, M. and Perry, H., in "Sequences of Proteins of Immunological Interest", US Dept. Health and Human Services 1983). The four FRs largely adopt a  $\beta$ -sheet conformation and the CDRs form loops connecting FRs, and in some cases forming part of, the  $\beta$ -sheet structure. The CDRs are held in close proximity by FRs and, with the CDRs from the other domain, contribute to the formation of the antigen binding site. The CDRs are described in Example 4.

#### Construction of Chimeric Antibody

Prior to designing reshaped human V regions of an antibody to the human IL-6R, it is necessary to confirm that the CDRs to be used actually form an effective antigen binding region. For this purpose, chimeric antibodies were constructed. In addition the amino acid sequences of V regions of mouse anti human IL-6R antibodies predicted from the nucleotide sequences of cloned DNAs of the 4 mouse monoclonal antibodies

described in Example 1 and 2 were compared to each other and to V regions from known mouse and human antibodies. For each of the 4 mouse monoclonal antibodies, a set of typical, functional mouse L and H chain V regions had been cloned. All four mouse anti-IL-6R antibodies, however, had relatively distinct V regions. The 4 antibodies were not simply minor variations of each other. Using the cloned mouse V regions, 4 chimeric anti-IL-6R antibodies were constructed.

10       The basic method for constructing chimeric antibodies comprises joining the mouse leader and V region sequences, as found in the PCR-cloned cDNAs, to human C regions-coding sequence already present in mammalian cell expression vectors. Among said  
15       4 monoclonal antibodies, construction of a chimeric antibody from the monoclonal antibody AUK12-20 is described in Example 5.

Construction of a chimeric antibody from the monoclonal antibody PM-1 is described in Example 6. The  
20       cDNA coding for the mouse PM-1  $\kappa$  L chain leader and V region was PCR-subcloned into an expression vector containing a genomic DNA coding for the human kappa C region. The cDNA coding for the mouse PM-1 H chain leader and V regions was PCR-subcloned into an expression  
25       vector containing a genomic DNA coding for the human gamma-1 C region. Using specially designed PCR primers, the cDNA coding for the mouse PM-1 V region were adapted at their 5'- and 3'-ends (1) so that they would be easy to insert into the expression vectors and (2) so that  
30       they would function properly in these expression vectors. The PCR-modified mouse PM-1 V regions were then inserted into HCMV expression vectors already containing the desired human C regions (Figure 1). These vectors are suitable for either transient or stable expression of  
35       genetically-engineered antibodies in a variety of mammalian cell lines.

In addition to constructing a chimeric PM-1 antibody

with V regions identical to the V regions present in mouse PM-1 antibody (version a), a second version of chimeric PM-1 antibody was constructed (version b). In chimeric PM-1 antibody (version b), the amino acid at position 107 in the L chain V region was changed from asparagine to lysine. In comparing the L chain V region from mouse PM-1 antibody to other mouse L chain V regions, it was noticed that the occurrence of an asparagine at position 107 was an unusual event. In mouse  $\kappa$  L chain V regions, the most typical amino acid at position 107 is a lysine. In order to evaluate the importance of having the atypical amino acid asparagine at position 107 in the L chain V region of mouse PM-1 antibody, position 107 was changed to the typical amino acid lysine at this position. This change was achieved using a PCR-mutagenesis method (M. Kamman et al., Nucl. Acids Res. (1989) 17:5404) to make the necessary changes in the DNA sequences coding for the L chain V region.

The chimeric PM-1 antibody version (a) exhibited an activity to bind to the human IL-6R. The chimeric MP-1 antibody version (b) also binds to the human IL-6R as well as version (a). Similarly, from other 2 monoclonal antibodies AUK64-7 and AUK146-15, chimeric antibodies were constructed. All 4 chimeric antibodies bound well to the human IL-6R thus indicating in a functional assay that the correct mouse V regions had been cloned and sequenced.

From the 4 mouse anti-IL-6R antibodies, PM-1 antibody was selected as the first candidate for the design and construction of a reshaped human antibody to the human IL-6R. The selection of mouse PM-1 antibody was based largely on results obtained studying the effect of the mouse anti-IL-6R antibodies on human myeloma tumor cells transplanted into nude mice. Of the 4 mouse anti-IL-6R antibodies, PM-1 antibody showed the strongest anti-tumor cell activity.

Comparison of the V regions from mouse monoclonal

antibody PM-1 to V regions from known mouse and  
human antibodies

To construct a reshaped human antibody wherein the CDRs of a mouse monoclonal antibody are grafted into a human monoclonal antibody, it is desired that there is high homology between FRs of the mouse monoclonal antibody and FRs of the human monoclonal antibody. Therefore, the amino acid sequences of the L and H chain V regions from mouse PM-1 antibody were compared to all known mouse and mouse V regions as found in the OWL (or Leeds) database of protein sequences.

With respect to V regions from mouse antibodies, the L chain V region of PM-1 antibody was most similar to the L chain V region of mouse antibody musigkcko (Chen, H.-T. et al., J. Biol. Chem. (1987) 262:13579-13583) with a 93.5% identity. The H chain V region of PM-1 antibody was most similar to the H chain V region of mouse antibody musigvhr2 (F.J. Grant et al., Nucl. Acids Res. (1987) 15:5496) with a 84.0% identity. The mouse PM-1 V regions show high percents of identity to known mouse V regions thus indicating that the mouse PM-1 V regions are typical mouse V regions. This provides further indirect evidence that the cloned DNA sequences are correct. There is generally a higher percent identity between the L chain V regions than between the H chain V regions. This is probably due to the lower amount of diversity generally observed in L chain V regions as compared to H chain V regions.

With respect to V regions from human antibodies, the L chain V region of PM-1 antibody was most similar to the L chain V region of human antibody klhure, also referred to as REI (W. Palm et al., Physiol. Chem. (1975) 356:167-191) with a 72.2% identity. The H chain V region of PM-1 antibody was most similar to the H chain V region of human antibody humighvap (VAP) (H.W. Schroeder et al., Science (1987) 238:791-793) with a 71.8% identity. The comparisons to human V regions are most important for

0914265-071338

considering how to design reshaped human antibodies from mouse PM-1 antibody. The percent identities to human V regions are less than the percent identities to mouse V regions. This is indirect evidence that the mouse PM-1 V regions do look like mouse V regions and not like human V regions. This evidence also indicates that it will be best to humanize mouse PM-1 V regions in order to avoid problems of immunogenicity in human patients.

The V regions from mouse PM-1 antibody were also compared to the consensus sequences for the different subgroups of human V regions as defined by E. A. Kabat et al. ((1987) Sequences of Proteins of Immunological Interest, Forth Edition, U.S. Department of Health and Human services, U.S. Government Printing Office). The comparisons were made between the FRs of the V regions. The results are shown in Table 1.

Table 1

Percent identities between the FRs from the mouse PM-1 V regions and the FRs from the consensus sequences<sup>(1)</sup> for the different subgroups of human V regions.

A. FRs in the L chain V regions

| HSGI | HSGII | HSGIII | HSGIV |
|------|-------|--------|-------|
| 70.1 | 53.3  | 60.7   | 59.8  |

B. FRs in the H chain V regions

| HSGI | HSGII | HSGIII |
|------|-------|--------|
| 44.1 | 52.9  | 49.2   |

<sup>(1)</sup>The consensus sequences were taken from the subgroups of human V regions as described in

Kabat et al., (1987).

5 The FRs of mouse PM-1 L chain V region are most  
similar to the FRs from the consensus sequence for  
subgroup I (HSGI) of human L chain V regions with 70.1%  
identity. The FRs of mouse PM-1 H chain V region are  
most similar to the FRs from the consensus sequence for  
subgroup II (HSGII) of human H chain V regions with 52.9%  
identity. These results support the results obtained  
10 from the comparisons to known human antibodies. The  
L chain V region in human REI belongs to subgroup I of  
human L chain V regions and the H chain V region in human  
VAP belongs to subgroup II of human H chain V regions.

15 From these comparisons to the V regions in human  
antibodies, it is possible to select human V regions that  
will be the basis for the design of reshaped human PM-1  
V regions. It would be best to use a human L chain  
V region that belongs to subgroup I (SGII) for the design  
of reshaped human PM-1 L chain V region and a human  
20 H chain V region that belongs to subgroup II (SGII) for  
the design of reshaped human PM-1 H chain V region.

Design of reshaped human PM-1 variable regions

25 The first step in designing the reshaped human PM-1  
V regions was to select the human V regions that would be  
the basis of the design. The FRs in the mouse PM-1  
L chain V region were most similar to the FRs in human  
L chain V regions belonging to subgroup I (Table 1). As  
discussed above, in comparing the mouse PM-1 L chain  
V region to known human L chain V regions, it was most  
30 similar to the human L chain V region REI, a member of  
subgroup I of human L chain V regions. In designing  
reshaped human PM-1 L chain V regions, the FRs from REI  
were used. Moreover the REI FRs were used as starting  
material for the construction of reshaped human PM-1  
35 L chain V region.

In these human FRs based on REI, there were five  
differences from the FRs in the original human REI



5

10

15

20

25

30

Table 2

Design of two different versions of reshaped human  
PM-1 L chain V region.

5

|  |  |                         |   |             |
|--|--|-------------------------|---|-------------|
|  |  | FR1                     |   | CDR1        |
|  |  | 1                       | 2 | 3           |
|  |  | 12345678901234567890123 |   | 45678901234 |

10

|                     |                         |             |
|---------------------|-------------------------|-------------|
| V <sub>L</sub> PM-1 | DIQMTQTSSLSASLGDRVTISC  | RASQDISSYLN |
| REI                 | DIQMTQSPSSLSASVGDRVTITC |             |
| RV <sub>L</sub> a   | DIQMTQSPSSLSASVGDRVTITC | RASQDISSYLN |
| RV <sub>L</sub> b   | -----                   | -----       |

15

|  |                 |         |
|--|-----------------|---------|
|  | FR2             | CDR2    |
|  | 4               | 5       |
|  | 567890123456789 | 0123456 |

20

|                     |                 |         |
|---------------------|-----------------|---------|
| V <sub>L</sub> PM-1 | WYQQKPDGTIKLLIY | YTSRLHS |
| REI                 | WYQQKPGKAPKLLIY |         |
| RV <sub>L</sub> a   | WYQQKPGKAPKLLIY | YTSRLHS |
| RV <sub>L</sub> b   | -----           | -----   |

25

|  |                                  |           |
|--|----------------------------------|-----------|
|  | FR3                              | CDR3      |
|  | 6                                | 7         |
|  | 78901234567890123456789012345678 | 901234567 |

|                     |                                               |           |
|---------------------|-----------------------------------------------|-----------|
| V <sub>L</sub> PM-1 | <sup>z</sup> GVPSRFSGSGSGTDYSLTINNLEQEDIATYFC | QQGNTLPYT |
| REI                 | GVPSRFSGSGSGTDEFTTISLQPEDATYYC                |           |
| RV <sub>L</sub> a   | GVPSRFSGSGSGTDEFTTISLQPEDATYYC                | QQGNTLPYT |
| RV <sub>L</sub> b   | -----Y-----                                   | -----     |

30

0014285 071358

FR4

10  
8901234567

|                     |                    |
|---------------------|--------------------|
| V <sub>L</sub> PM-1 | FGGGTKLEIN         |
| REI                 | FGQGTK <u>VEIK</u> |
| RV <sub>L</sub> a   | FGQGTKVEIK         |
| RV <sub>L</sub> b   | -----              |

Note: The FRs given for REI are those found in the reshaped human CAMPATH-1H antibody (Riechmann et al., 1988). The five underlined amino acid residues in the REI FRs are those that differ from the amino acid sequence of human REI (Palm et al., 1975; O. Epp et al., Biochemistry (1975) 14:4943-4952).

The FRs in the mouse PM-1 H chain V region were most similar to the FRs in human H chain V regions belonging to subgroup II (Table 1). As discussed above, in comparing the mouse PM-1 H chain V region to known human H chain V regions, it was most similar to the human H chain V region VAP, a member of subgroup II of human H chain V regions. DNA sequences coding for the FRs in human H chain V region NEW, another member of subgroup II of human H chain V regions, were used as starting material for the construction of reshaped human PM-1 H chain V region, and as a base for designing the reshaped human PM-1 H chain V region.

Six versions of reshaped human PM-1 H chain V region were designed. In all six versions, the human FRs were based on the NEW FRs present in reshaped human CAMPATH-1H (Riechmann et al., 1988) and the mouse CDRs were identical to the CDRs in mouse PM-1 H chain V region. Seven amino acid residues in the human FRs (positions 1, 27, 28, 29, 30, 48, and 71, see Table 3) were identified as having a possible adverse influence on antigen

binding. In the model of mouse PM-1 V regions, residue 1  
in the H chain V region is a surface residue that is  
located close to the CDR loops. Residues 27, 28, 29, and  
30 are either part of the canonical structure for CDR1 of  
5 the H chain V region, as predicted by C. Chothia et al.,  
Nature (1989) 34:877-883, and/or are observed in the  
model of the mouse PM-1 V regions to form part of the  
first structural loop of the H chain V region (Chothia,  
1987). Residue 48 was observed in the model of the mouse  
10 PM-1 V regions to be a buried residue. Changes in a  
buried residue can disrupt the overall structure of the  
V region and its antigen-binding site. Residue 71 is .  
part of the canonical structure for CDR2 of the H chain  
V region as predicted by Chothia et al., (1989). The six  
15 versions of reshaped human PM-1 antibody incorporate  
different combinations of amino acid changes at these  
seven positions in the human NEW FRs (see Table 3).

004430 07498  
06E720" 002440

Table 3

Design of six different versions of reshaped human PM-1 H chain V region.

|   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|---|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|---|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|

|    |                     | 7                                | FR3 | 8 | 9 |
|----|---------------------|----------------------------------|-----|---|---|
|    |                     | 67890123456789012222345678901234 |     |   |   |
|    |                     |                                  | ABC |   |   |
|    | V <sub>H</sub> PH-1 | RISITRDTSKNQFFLQLNSVTTGDTSTYYCAR |     |   |   |
|    | NEW                 | RVTMLVDTSKNQFSLRLSSVTAADTAVYYCAR |     |   |   |
|    | RV <sub>H</sub> a   | RVTMLVDTSKNQFSLRLSSVTAADTAVYYCAR |     |   |   |
| 5  | RV <sub>H</sub> b   | -----R-----                      |     |   |   |
|    | RV <sub>H</sub> c   | -----R-----                      |     |   |   |
|    | RV <sub>H</sub> d   | -----R-----                      |     |   |   |
|    |                     | -----R-----                      |     |   |   |
|    | RV <sub>H</sub> e   |                                  |     |   |   |
| 10 | RV <sub>H</sub> f   | -----R-----                      |     |   |   |

|    |                     | CDR3       | FR4         |
|----|---------------------|------------|-------------|
|    |                     | 10         | 11          |
|    |                     | 5678900012 | 34567890123 |
|    |                     | AB         |             |
|    | V <sub>H</sub> PM-1 | SLARTTAMDY | WGQGTSVTVSS |
| 15 | NEW                 |            | WGQGSLVTVSS |
|    | RV <sub>H</sub> a   | SLARTTAMDY | WGQGSLVTVSS |
|    | RV <sub>H</sub> b   | -----      | -----       |
|    | RV <sub>H</sub> c   | -----      | -----       |
|    | RV <sub>H</sub> e   | -----      | -----       |
| 20 | RV <sub>H</sub> e   | -----      | -----       |
|    | RV <sub>H</sub> f   | -----      | -----       |

25      Note:    The FRs given for NEW are those found in the  
              first version of reshaped human CAMPATH-1H  
              antibody (Riechmann et al., 1988).

30      Construction of reshaped human PM-1 V regions  
              The first versions of the reshaped human PM-1 L and  
              H chain V regions were each constructed using a novel  
              PCR-based method. Essentially, a plasmid DNA coding for  
              reshaped human V region that already contained suitable

0014305 071340

human FRs was modified using PCR primers to replace the CDRs present in the starting reshaped human V region with the CDRs from mouse PM-1 antibody. The starting material for the construction of the reshaped human PM-1 L chain V region was a plasmid DNA containing the reshaped human D1.3 L chain V region. The reshaped human D1.3 L chain V region was constructed based on the FRs present in the human L chain V region of REI. The starting material for the construction of the reshaped human PM-1 H chain V region was a plasmid DNA containing the reshaped human D1.3 H chain V region. The reshaped human D1.3 H chain V region was constructed based on the FRs present in the human H chain V region of NEW (M. Verhoeyen et al., Science (1988) 239:1534-1536).

Once the starting plasmid DNAs containing the desired human FRs were selected, PCR primers were designed to enable the substitution of the mouse PM-1 CDRs in place of the mouse D1.3 CDRs. For each reshaped human PM-1 V region, three primers containing the DNA sequences coding for the mouse PM-1 CDRs and two primers flanking the entire DNA sequence coding for the reshaped human V region were designated and synthesized. Using the five PCR primers in a series of PCR reactions yielded a PCR product that consisted of the human FRs present in the starting reshaped human V region and the CDRs present in mouse PM-1 V region (see Example 7, and Figures 7 and 8). The PCR products were cloned and sequenced to ensure that the entire DNA sequence of version "a" of reshaped human PM-1 L and H chain V region coded for correct amino acid sequence (SEQ ID NO 55).

The remaining versions of the reshaped human PM-1 V regions were constructed using slight modifications of published PCR-mutagenesis techniques (Kamman et al., 1989). As described for the design of the reshaped human PM-1 V regions, one additional version (version "b") of the reshaped human PM-1 L chain V region was constructed and five additional versions (versions "b", "c", "d",

"e", and "f") of the reshaped human PM-1 H chain V region were constructed. These additional versions contain a series of minor changes from the first versions. These minor changes in the amino acid sequences were achieved using PCR mutagenesis to make minor changes in the DNA sequences. PCR primers were designed that would introduce the necessary changes into the DNA sequence. Following a series of PCR reactions, a PCR product was cloned and sequenced to ensure that the changes in the DNA sequence had occurred as planned. Sequence of the reshaped human PM-1 antibody H chain V region version "f" is shown in SEQ ID NO 54).

Once the DNA sequences of the different versions of reshaped human PM-1 V regions were confirmed by sequencing, the reshaped human PM-1 V regions were subcloned into mammalian cell expression vectors already containing human C regions. Reshaped human PM-1 L chain V regions were joined to DNA sequences coding for human  $\kappa$  C region. Reshaped human PM-1 H chain V regions were joined to DNA sequences coding for human gamma-1 C region. In order to achieve higher levels of expression of the reshaped human PM-1 antibodies, the HCMV expression vectors, as shown in Figure 1, were modified to replace the HCMV promoter-enhancer region with the human elongation factor (HEF-1 $\alpha$ ) promoter-enhancer (see Figure 15).

Next, all combinations of the reshaped human L chain versions (a) and (b) with the H chain V region versions (a) to (f) were tested for binding to human IL-6R, and as a result, a reshaped human antibody comprising the L chain version (a) and the H chain version (f) exhibited an ability to bind to IL-6R at a same level as that of chimeric PM-1 (a) (Fig. 13) as described in detail in Example 11.

Modifications in the DNA sequences coding for the reshaped human PM-1 V regions to improve the levels of expression.



In reviewing the levels of reshaped human PM-1 antibodies being produced in cos cells, it became apparent that the levels of expression of the reshaped human H chains were always approximately 10-fold lower than the levels of expression of the reshaped human L chains or of the chimeric L or H chains. It appeared that there was a problem in DNA coding for the reshaped human H chain V region that caused low levels of expression. In order to identify whether the lower levels of protein expression were the result of lower levels of transcription, RNA was prepared from cos cells co-transfected with vectors expressing reshaped human PM-1 L and H chains. First-strand cDNA was synthesized as described for the PCR cloning of the mouse PM-1 V regions. Using PCR primers designed to flank the ends of DNA coding for the reshaped human L or H chain V regions, PCR products were generated from the cDNAs that corresponded to reshaped human L chain V region or to reshaped human H chain V region.

For the reshaped human L chain V region, there were two PCR products, one 408 bp long, as expected, and a shorter PCR product 299 bp long. The correct size PCR product made up approximately 90% of the total yield of PCR product and the shorter PCR product made up approximately 10% of the total yield. For the reshaped human H chain V region, there were also two PCR products, one 444 bp long, as expected, and a shorter PCR product 370 bp long. In this case, however, the incorrect, shorter PCR product made up the majority of the total yield of PCR product, approximately 90%. The correct size PCR product made up only approximately 10% of the total yield of PCR product. These results indicated that some of the RNAs coding for the reshaped human V regions contained deletions.

In order to determine which sequences were being deleted, the shorter PCR products were cloned and sequenced. From the DNA sequences, it became clear that

for both the L and H chain V regions specific sections of DNA were being deleted. Examination of the DNA sequences flanking the deleted sequences revealed that these sequences corresponded to the consensus sequences for splice donor-acceptor sequences (Breathnach, R. et al., Ann. Rev. Biochem (1981) 50:349-383). The explanation for the low levels of expression of the reshaped human H chains was that the design of the reshaped human H chain V regions had inadvertently created a rather efficient set of splice donor-acceptor sites. It also appeared that the design of the reshaped human L chain V regions had inadvertently created a rather inefficient set of splice donor-acceptor sites. In order to remove the splice donor-acceptor sites, minor modifications in the DNA sequences coding for versions "a" and "f", respectively, of the reshaped human PM-1 L and H chain V regions were made using the PCR-mutagenesis methods described earlier.

Another possible cause of reduced levels of expression was thought to be the presence of introns in the leader sequences in both the reshaped human L and H chain V regions (SEQ ID NOs: 54 and 55). These introns were originally derived from a mouse mu H chain leader sequence (M.S. Neuberger et al., Nature 1985 314:268-270) that was used in the construction of reshaped human D1.3 and V regions (Verhoeyen et al., 1988). Since the reshaped human D1.3 was expressed in a mammalian cell vector that employed a mouse immunoglobulin promoter, the presence of the mouse leader intron was important. The leader intron contains sequences that are important for expression from immunoglobulin promoters but not from viral promoters like HCMV (M.S. Neuberger et al., Nucl. Acids Res. (1988) 16:6713-6724). Where the reshaped human PM-1 L and H chains were being expressed in vectors employing non-immunoglobulin promoters, the introns in the leader sequences were deleted by PCR cloning cDNAs coding for

the reshaped human V regions (see Example 12).

Another possible cause of reduced levels of expression was thought to be the presence of a stretch of approximately 190 bp of non-functional DNA within the intron between the reshaped human PM-1 H chain V region and the human gamma-1 C region. The reshaped human PM-1 H chain V region was constructed from DNA sequences derived originally from reshaped human B1-8 H chain V region (P.T. Jones et al., Nature (1986) 321:522-525). This first reshaped human V region was constructed from the mouse NP H chain V region (M.S. Neuberger et al., Nature (1985); M.S. Neuberger et al., EMBO J. (1983) 2:1373-1378). This stretch of approximately 190 bp occurring in the intron between the reshaped human H chain V region and the BamHI site for joining of the reshaped human V regions to the expression vector was removed during the PCR cloning of cDNAs coding for the reshaped human V regions.

The DNA and amino acid sequences of the final versions of reshaped human PM-1 L and H chain V regions, as altered to improve expression levels, are shown in SEQ ID NOs: 57 and 56. These DNA sequences code for version "a" of the reshaped human PM-1 L chain V region as shown in Table 2 and version "f" of the reshaped human PM-1 H chain V region as shown in Table 3. When inserted into the HEF-1 $\alpha$  expression vectors (Figure 15), these vectors transiently produce approximately 2  $\mu$ g/ml of antibody in transfected cos cells. In order to stably produce larger amounts of reshaped human PM-1 antibody, a new HEF-1 $\alpha$  expression vector incorporating the dhfr gene was constructed (see Example 10, Fig. 11). The "crippled" dhfr gene was introduced into the HEF-1 $\alpha$  vector expressing human gamma-1 H chains as was described for the HCMV vector expressing human gamma-1 H chains. The HEF-1 $\alpha$  vector expressing reshaped human PM-1 L chains and the HEF-1 $\alpha$ -dhfr vector expressing reshaped human PM-1 H chains were co-transfected into CHO dhfr(-) cells.

Stably transformed CHO cell lines were selected in Alpha-Minimum Essential Medium ( $\alpha$ -MEM) without nucleosides and with 10% FCS and 500  $\mu$ g/ml of G418. Prior to any gene amplification steps, CHO cell lines were observed that  
5 produced up to 10  $\mu$ g/10<sup>6</sup> cells/day of reshaped human PM-1 antibody.

Comparison of V regions from mouse monoclonal antibody AUK 12-20 to V regions from known human antibodies

10 The homology of FRs of  $\kappa$ L chain V region of the mouse monoclonal antibody AUK 12-20 with FRs of human  $\kappa$ L chain V region subgroup (HSG) I to IV, and the homology of FRs of H chain V region of the mouse monoclonal antibody AUK 12-20 with FRs of human H chain  
15 V regions subgroup (HSG) I to III are shown in Table 4.

Table 4

Percent identities between FRs from the mouse AUK 12-20 V regions and FRs from the consensus  
20 sequence for the different subgroups of human V regions

FRs in the L chain V regions

|    | HSG1 | HSG2 | HSG3 | HSG4 |
|----|------|------|------|------|
| 25 | 65.8 | 64.0 | 67.6 | 67.6 |

FRs in the H chain V regions

|    | HSGI | HSGII | HSGIII |
|----|------|-------|--------|
| 30 | 58.6 | 53.6  | 49.1   |

As seen from Table 4, the  $\kappa$ L chain V region of the mouse monoclonal antibody AUK 12-20 is homologous in a  
35 similar extent (64 to 68%) with the human  $\kappa$ L chain V region subgroups (HSG) I to IV. In a search of the Data base "LEEDS" for protein, L chain V region of human antibody Len (M. Schneider et al., Physiol. Chem. (1975)

09114285 071736

366:507-557) belonging to the HSG-IV exhibits the highest homology 68%. On the other hand, the human antibody REI, used for construction of a reshaped human antibody from the mouse monoclonal antibody PM-1 belongs to the HSG I, exhibits a 62% homology with L chain V region of the mouse monoclonal antibody AUK 12-20. In addition, the CDRs in the AUK 12-20 antibody L chain V region particularly CDR2, corresponded better to canonical structures of the CDRs in REI rather than those in LEN.

Considering the above, it is not necessary to choose a human antibody used for humanization of the mouse monoclonal antibody AUK 12-20 L chain V region from those antibodies belonging to the HSG IV. Therefore, as in the case of the humanization of the mouse monoclonal antibody PM-1 L chain V region, the FRs of REI are used for humanization of the mouse monoclonal antibody AUK 12-20 L chain V region.

As shown in Table 4, H chain V region of the antibody AUK 12-20 exhibits the highest homology with the HSG I. Moreover, in a search of Data base "LEEDS", human antibody HAX (Stollar, B.O. et al., J. Immunol. (1987) 139:2496-2501) also belonging to the HSG I exhibits an about 66% homology with the AUK 12-20 antibody H chain V region. Accordingly, to design reshaped human AUK 12-20 antibody H chain V region, the FRs of the human antibody HAX belonging to the HSG I, and FRs of humanized 425 antibody H chain V region which has FRs consisting of HSGI consensus sequence (Ketteborough C.A. et al., Protein Engineering (1991) 4:773-783) are used. Note, the AUK 12-20 antibody H chain V region exhibits an about 64% homology with version "a" of the humanized 425 antibody H chain V region.

Design of reshaped human AUK 12-20 antibody L chain V regions

According to the above reason, reshaped human AUK 12-20 antibody L chain V regions is designed as shown in Table 5 using FRs of the REI.

Table 5

|    |                          | FR1                                                                                                        |  |  |  |  |   |  |  |  |  | CDR1            |  |  |  |  |  |  |  |
|----|--------------------------|------------------------------------------------------------------------------------------------------------|--|--|--|--|---|--|--|--|--|-----------------|--|--|--|--|--|--|--|
|    |                          | 1                                                                                                          |  |  |  |  | 2 |  |  |  |  | 3               |  |  |  |  |  |  |  |
|    |                          | 12345678901234567890123                                                                                    |  |  |  |  |   |  |  |  |  | 45677778901234  |  |  |  |  |  |  |  |
|    |                          |                                                                                                            |  |  |  |  |   |  |  |  |  | ABCD            |  |  |  |  |  |  |  |
| 5  | V <sub>L</sub> AUK 12-20 | DIVLTQSPASLGVS LGQRATISC                                                                                   |  |  |  |  |   |  |  |  |  | RASKSVSTSGYSYMH |  |  |  |  |  |  |  |
|    | REI                      | DIQMTQSPSSLSASV GDRVTITC                                                                                   |  |  |  |  |   |  |  |  |  |                 |  |  |  |  |  |  |  |
|    | RV <sub>L</sub>          | DIQMTQSPSSLSASV GDRVTITC                                                                                   |  |  |  |  |   |  |  |  |  | RASKSVSTSGYSYMH |  |  |  |  |  |  |  |
| 10 |                          | FR2                                                                                                        |  |  |  |  |   |  |  |  |  | CDR2            |  |  |  |  |  |  |  |
|    |                          | 4                                                                                                          |  |  |  |  |   |  |  |  |  | 5               |  |  |  |  |  |  |  |
|    |                          | 567890123456789                                                                                            |  |  |  |  |   |  |  |  |  | 0123456         |  |  |  |  |  |  |  |
|    | V <sub>L</sub> AUK 12-20 | WYQQKPGQTPKLLIY                                                                                            |  |  |  |  |   |  |  |  |  | ASNLES          |  |  |  |  |  |  |  |
|    | REI                      | WYQQTPGKAPKLLIY                                                                                            |  |  |  |  |   |  |  |  |  |                 |  |  |  |  |  |  |  |
|    | RV <sub>L</sub>          | WYQQKPGKAPKLLIY                                                                                            |  |  |  |  |   |  |  |  |  | ASNLES          |  |  |  |  |  |  |  |
| 15 |                          |                                                                                                            |  |  |  |  |   |  |  |  |  |                 |  |  |  |  |  |  |  |
|    |                          | FR3                                                                                                        |  |  |  |  |   |  |  |  |  | CDR3            |  |  |  |  |  |  |  |
|    |                          | 6                                                                                                          |  |  |  |  | 7 |  |  |  |  | 8               |  |  |  |  |  |  |  |
|    |                          | 78901234567890123456789012345678                                                                           |  |  |  |  |   |  |  |  |  | 901234567       |  |  |  |  |  |  |  |
|    | V <sub>L</sub> AUK 12-20 | GVPARFSGSGSGTDFTLN IHPVEEEDAATYYC                                                                          |  |  |  |  |   |  |  |  |  | QHSRENPYT       |  |  |  |  |  |  |  |
| 20 | REI                      | GVPSRFSGSGSGTDYTF TISSLQPEDIAATYYC                                                                         |  |  |  |  |   |  |  |  |  |                 |  |  |  |  |  |  |  |
|    | RV <sub>L</sub>          | GVPSRFSGSGSGTD <u>F</u> TFTISSLQPEDIAATYYC                                                                 |  |  |  |  |   |  |  |  |  | QHSRENPYT       |  |  |  |  |  |  |  |
| 25 |                          | FR4                                                                                                        |  |  |  |  |   |  |  |  |  |                 |  |  |  |  |  |  |  |
|    |                          | 10                                                                                                         |  |  |  |  |   |  |  |  |  |                 |  |  |  |  |  |  |  |
|    |                          | 8901234567                                                                                                 |  |  |  |  |   |  |  |  |  |                 |  |  |  |  |  |  |  |
|    | V <sub>L</sub> AUK 12-20 | FGGGTKLEI <u>k</u>                                                                                         |  |  |  |  |   |  |  |  |  |                 |  |  |  |  |  |  |  |
|    | REI                      | FGQGTKLQIT                                                                                                 |  |  |  |  |   |  |  |  |  |                 |  |  |  |  |  |  |  |
|    | RV <sub>L</sub>          | FGQGTK <u>V</u> <u>E</u> <u>I</u> <u>K</u>                                                                 |  |  |  |  |   |  |  |  |  |                 |  |  |  |  |  |  |  |
| 30 | Note:                    | 5 underlined nucleotides are those changed in the design of CAMPATH-1H antibody (see the note of Table 2). |  |  |  |  |   |  |  |  |  |                 |  |  |  |  |  |  |  |

05E720" 5324760

According to the above reason, reshaped human

15 In addition, version "b" to "d" of the reshaped human AUK 12-20 antibody H chain V region were designed. Amino acid sequences of the versions "a" to "d" are shown in Table 6.

20

30

|    |                          | FR2                               | CDR2              |
|----|--------------------------|-----------------------------------|-------------------|
|    |                          | 4                                 | 5 6               |
|    |                          | 67890123456789                    | 01223456789012345 |
|    |                          |                                   | A                 |
|    | V <sub>H</sub> AUK 12-20 | WVKQSHGKSLEWIG                    | YIDPFNGGTSYNQKFKG |
|    | SGI                      | WVRQAPGXGLEWVG                    |                   |
|    | RV <sub>H</sub> a        | WVRQAPGQGLEWVG                    | YIDPFNGGTSYNQKFKG |
| 5  | RV <sub>H</sub> b        | -----                             | -----             |
|    | RV <sub>H</sub> c        | -----I-                           | -----             |
|    | RV <sub>H</sub> d        | -----I-                           | -----             |
|    |                          |                                   |                   |
|    |                          | FR3                               |                   |
|    |                          | 7 8 9                             |                   |
|    |                          | 67890123456789012222345678901234  |                   |
|    |                          | ABC                               |                   |
| 10 | V <sub>H</sub> AUK 12-20 | KATLTVDKSSSTAYMHLSSLTSEDSAVYYCAR  |                   |
|    | SGI                      | RVTXTXDXSXNTAYMELSSLRSED TAVYYCAR |                   |
|    | RV <sub>H</sub> a        | RVTMTLDTSTNTAYMELSSLRSED TAVYYCAR |                   |
|    | RV <sub>H</sub> b        | K---V-----                        |                   |
|    | RV <sub>H</sub> c        | -----                             |                   |
| 15 | RV <sub>H</sub> d        | K---V-----                        |                   |
|    |                          |                                   |                   |
|    |                          | CDR3                              | FR4               |
|    |                          | 10                                | 11                |
|    |                          | 5678900012                        | 34567890123       |
|    |                          | AB                                |                   |
|    | V <sub>H</sub> AUK 12-20 | GGN-RF--AY                        | WGQGT LVT VSA     |
| 20 | SGI                      |                                   | WGQGT LVT VSS     |
|    | RV <sub>H</sub> a        | GGN-RF--AY                        | WGQGT LVT VSS     |
|    | RV <sub>H</sub> b        | -----                             | -----             |
|    | RV <sub>H</sub> c        | -----                             | -----             |
| 25 | RV <sub>H</sub> d        | -----                             | -----             |

Note: The position where one common amino acid residue is not identified in the HSG I V<sub>H</sub> regions (SGI) is shown as "X". Two under lined amino acid residues



are different from those in SGI consensus sequence. For RV<sub>b</sub>, RV<sub>c</sub> and RV<sub>d</sub>, only amino acid residues different from those of RV<sub>a</sub> are shown.

5           Moreover, version "a" to "d" of reshaped human  
AUK 12-20 antibody H chain V region are designed as shown  
in Table 7, using FRs of the human antibody HAX (J.  
Immunology (1987) 139:2496-2501; an antibody produced by  
hybridoma 21/28 cells derived from B cells of a SLE  
10 patient; its amino acid sequence is described in Fig. 6  
and nucleotide sequence of DNA coding for the amino acid  
sequence is shown in Figs. 4 and 6, of this literature).

Table 7

|    |  |  |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |     |
|----|--|--|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----|
| 15 |  |  | FR1        |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            | CDR1       |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |     |
|    |  |  | 1          |            |            |            |            |            |            |            |            |            | 2          |            |            |            |            |            |            |            |            |            | 3          |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |            |     |
|    |  |  | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 1234567890 | 123 |

0514255 073300

30

Note:

are changes from the HAX FRs. For sle1220Hb, sle1220Hc, and sle1220Hd, only the amino acids in the FRs that differ from those in the HAX FRs are shown.

5

For the production of the present chimeric or reshaped human antibodies to the human IL-6R, any expression system, including eucaryotic cells, for example, animal cells, such as established mammalian cell lines, fungal cells, and yeast cells, as well as procaryotic cells, for example, bacterial cells such as E.coli cells, may be used. Preferably the present chimeric or reshaped human antibodies are expressed in mammalian cells such as cos cells or CHO cells.

10

15

In such cases, a conventional promoter useful for the expression in mammalian cells can be used. For example, viral expression system such as human cytomegalovirus immediate early (HCMV) promoter is preferably used. Examples of the expression vector containing the HCMV promoter include HCMV-V<sub>H</sub>-HC $\gamma$ 1, HCMV-V<sub>L</sub>-HC $\kappa$ , HCMV-12h-g $\gamma$ 1, HCMV-12k-g $\kappa$  and the like derived from pSV2neo, as shown in Fig. 1.

20

25

Another embodiment of promoter useful for the present invention is the human elongation factor 1 $\alpha$  (HEF-1 $\alpha$ ) promoter. Expression vectors containing this promoter include HEF-12h-g $\gamma$ 1 and HEF-12h-g $\kappa$  (Figs. 8 and 9), as well as HEF-V<sub>H</sub>-g $\gamma$ 1 and HEF-V<sub>L</sub>-g $\kappa$  (Fig. 15).

30

For gene amplification dhfr in a host cell line, an expression vector may contain a dhfr gene. Expression vectors containing the dhfr gene, are for example, DHFR- $\Delta$ E-PMh-g $\gamma$ 1 (Fig. 10), DHFR- $\Delta$ E-RVh-PM1-f (Fig. 11) and the like.

35

In summary, the present invention first provides an L chain V region and an H chain V region of a mouse monoclonal antibody to the human IL-6R, as well as DNA coding for the L chain V region and DNA coding for the H

chain V region. These are useful for the construction of a human/mouse chimeric antibody and reshaped human antibody to the human IL-6R. The monoclonal antibodies are, for example, AUK12-20, PM-1, AUK64-7 and AUK146-15.

5 The L chain V region has an amino acid sequence shown in, for example, SEQ ID NOs: 24, 26, 28 or 30; and the H chain V region has an amino acid sequence shown in SEQ ID NOs: 25, 27, 29, or 31. These amino acid sequences are encoded by nucleotide sequences, for example, shown in  
10 SEQ ID NOs: 24 to 31 respectively.

The present invention also relates to a chimeric antibody to the human IL-6R, comprising:

- (1) an L chain comprising a human L chain C region and a mouse L chain V region; and
- 15 (2) an H chain comprising a human H chain C region and a mouse H chain V region. The mouse L chain V region and the mouse H chain V region and DNA encoding them are as described above. The human L chain C region may be any human L chain C region, and for example, is  
20 human C<sub>L</sub>. The human H chain C region may be any human H chain C region, and for example human C<sub>H1</sub>.

For the production of the chimeric antibody, two expression vectors, i.e., one comprising a DNA coding for a mouse L chain V region and a human L chain C region  
25 under the control of an expression control region such as an enhancer/promoter system, and another comprising a DNA coding for a mouse H chain V region and a human H chain C region under the expression control region such as an enhancer/promotor system, are constructed. Next, the  
30 expression vectors are co-transfected to host cells such as mammalian cells, and the transfected cells are cultured in vitro or in vivo to produce a chimeric antibody.

Alternatively, a DNA coding for a mouse L chain V  
35 region and a human L chain C region and a DNA coding for a mouse H chain V region and a human H chain C region are

0914205 07300

introduced into a single expression vector, and the vector is used to transfect host cells, which are then cultured in-vivo or in-vitro to produce a desired chimeric antibody.

5           The present invention further provides a reshaped antibody to the human IL-6R, comprising:

          (A)       an L chain comprising,

              (1)   a human L chain C region, and

10           (2)   an L chain V region comprising a human L chain FRs, and L chain CDRs of a mouse monoclonal antibody to the human IL-6R; and

          (B)       an H chain comprising,

              (1)   a human H chain C region, and

15           (2)   an H chain V region comprising human H chain FRs, and H chain CDRs of a mouse monoclonal antibody to the IL-6R.

          In a preferred embodiment, the L chain CDRs have amino acid sequences shown in any one of SEQ ID NOs: 24, 26, 28 and 30 wherein the stretches of the amino acid sequences are defined in Table 9; the L chain CDRs have amino acid sequences shown in any one of SEQ ID NOs: 25, 27, 29 and 31 wherein the stretches of the amino acid sequences are defined in Table 9; human L chain FRs are derived from the REI; and human H chain FRs are derived from the NEW or HAX.

          In the preferred embodiment, the L chain V region has an amino acid sequence shown in Table 2 as RV<sub>L</sub>a; and the H chain V region has an amino acid sequence shown in Table 3 as RV<sub>H</sub>a, RV<sub>H</sub>b, RV<sub>H</sub>c, RV<sub>H</sub>d, RV<sub>H</sub>e or RV<sub>H</sub>f. The amino acid sequence RV<sub>H</sub>f is most preferable.

          For the production of the reshaped human antibody, two expression vectors, i.e., one comprising a DNA coding for the reshaped L chain as defined above under the control of an expression control region such as an enhancer/promoter system, and another comprising a DNA coding for the reshaped human H chain as defined above

under the expression control region such as an enhancer/promoter system, are constructed. Next, the expression vectors are co-transfected to host cells such as mammalian cells, and the transfected cells are  
5 cultured in vitro or in-vivo to produce a reshaped human antibody.

Alternatively, a DNA coding for the reshaped human L chain and a DNA coding for the reshaped H chain are introduced into a single expression vector, and the  
10 vector is used to transfect host cells, which are then cultured in vivo or in vitro to produce a desired reshaped human antibody.

A chimeric antibody of a reshaped human antibody thus produced can be isolated and purified by a  
15 conventional processes such as Protein A affinity chromatography, ion exchange chromatography, gel filtration and the like.

The present chimeric L chain or reshaped human L chain can be combined with an H chain to construct a  
20 whole antibody. Similarly, the present chimeric H chain or reshaped human H chain can be combined with an L chain to construct a whole antibody.

The present mouse L chain V region, reshaped human L chain V region, mouse H chain V region and reshaped  
25 human H chain V region are intrinsically a region which binds to an antigen, human IL-6R, and therefore considered to be useful as such or as a fused protein with other protein, for preparing pharmaceuticals or diagnostic agents.

Moreover, the present L chain V region CDRs and  
30 H chain V region CDRs are intrinsically regions which bind to an antigen, human IL-6R, and therefore considered to be useful as such or as a fused protein with other protein, for preparing pharmaceuticals or diagnostic  
35 agents.

DNA coding for a mouse L chain V region of the present invention is useful for construction of a DNA

coding for a chimeric L chain or a DNA coding for a reshaped human L chain.

Similarly, DNA coding for a mouse H chain V region of the present invention is useful for construction of a DNA coding for a chimeric H chain or a DNA coding for a reshaped human H chain. Moreover, DNA coding for L chain V region CDR of the present invention is useful for construction of a DNA coding for a reshaped human L chain V region and a DNA coding for a reshaped human L chain. Similarly, DNA coding for H chain V region CDR of the present invention is useful for construction of a DNA coding for a reshaped human H chain V region and a DNA coding for a reshaped human H chain.

#### EXAMPLES

The present invention will be further illustrated by, but is by no means limited to, the following Examples.

Example 1                      Cloning of DNA coding for V region of mouse monoclonal antibody to human IL-6R (1)

A DNA coding for the V region of a mouse monoclonal antibody to a human IL-6R was cloned as follows.

1.    Preparation of total RNA

Total RNA from hybridoma AUK12-20 was prepared according to a procedure described by Chirgwin et al., Biochemistry 18, 5294 (1979). Namely,  $2.1 \times 10^8$  cells of the hybridoma AUK12-20 were completely homogenized in 20 ml of 4 M guanidine thiocyanate (Fulka). The homogenate was layered over a 5.3 M cesium chloride solution layer in a centrifuge tube, which was then centrifuged in a Beckman SW40 rotor at 31000 rpm at 20°C for 24 hours to precipitate RNA. The RNA precipitate was washed with 80% ethanol and dissolved in 150  $\mu$ l of 10 mM Tris-HCl (pH 7.5) containing 1 mM EDTA and 0.5% SDS, and after adding Proteinase (Boehringer) thereon to 0.5 mg/ml, incubated at 37°C for 20 minutes. The mixture was

extracted with phenol and chloroform, and RNA was precipitated with ethanol. Next, the RNA precipitate was dissolved in 200 µl of 10 mM Tris-HCl (pH 7.5) containing 1 mM EDTA.

5           2.   Synthesis of single stranded cDNA

To synthesize single stranded cDNA according to a procedure described by J.W. Larrick et al., Biotechnology, 7, 934 (1989), about 5 µg of the total RNA prepared as described above was dissolved in 10 µl of  
10   50 mM Tris-HCl (pH 8.3) buffer solution containing 40 mM KCl, 6 mM MgCl<sub>2</sub>, 10 mM dithiothreitol, 0.5 mM dATP, 0.5 mM dGTP, 0.5 mM dCTP, 0.5 mM dTTP, 35 µM oligo dT primer (Amersham), 48 units of RAV-2 reverse transcriptase (RAV-2: Rous associated virus 2; Amersham)  
15   and 25 units of human placenta ribonuclease inhibitor (Amersham), and the reaction mixture was incubated at 37°C for 60 minutes and directly used for the subsequent polymerase chain reaction (PCR) method.

20           3.   Amplification of cDNA coding for antibody V region by PCR method

The PCR method was carried out using a Thermal Cycler Model PHC-2 (Techne).

(1)       Amplification of cDNA coding for mouse κ light (κ L) chain variable region

25           The primers used for the PCR method were MKV (Mouse Kappa Variable) primers represented in SEQ ID NO: 1 to 11, which hybridize with a mouse κ L chain reader sequence (S.T. Jones et al., Biotechnology, 9, 88, 1991), and an MKC (Mouse Kappa Constant) primer  
30   represented in SEQ ID NO: 12, which hybridizes with a mouse κ L chain C region (S.T. Jones et al., Biotechnology, 9, 88, 1991).

First, 100 µl of a PCR solution comprising 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 0.1 mM dATP, 0.1 mM dGTP,  
35   0.1 mM dCTP, 0.1 mM dTTP, 1.5 mM MgCl, 2.5 units of DNA polymerase Ampli Taq (Perkin Elmer Cetus), 0.25 µM of



each group of MKV primer, 3 $\mu$ M MKC primer and 1  $\mu$ l of the reaction mixture of the single-stranded cDNA synthesis was heated at an initial temperature of 94°C for 1.5 minutes, and then at 94°C for 1 minute, 50°C for 1 minute and 72°C for 1 minute, in this order. After this temperature cycle was repeated 25 times, the reaction mixture was further incubated at 72°C for 10 minutes.

(2) Amplification of cDNA coding for mouse H chain V region

As primers for the PCR, MHV (Mouse Heavy Variable) primers 1 to 10 represented in SEQ ID NO: 13 to 22 (S.T. Jones et al., Biotechnology, 9, 88, 1991), and an MHC (Mouse Heavy Constant) primer represented in SEQ ID NO: 23 (S.T. Jones et al., Biotechnology, 9, 88, 1991) were used. Amplification was carried out according to the same procedure as described for the amplification of the  $\kappa$  L chain V region gene in section 3. (1).

4. Purification and Digestion of PCR Product

The DNA fragments amplified by the PCR as described above were purified using a QIAGEN PCR product purification kit (QIAGEN Inc. US), and digested with 10 units of restriction enzyme Sal I (GIBCO BRL) in 100 mM Tris-HCl (pH 7.6) containing 10 mM MgCl<sub>2</sub> and 150 mM NaCl, at 37°C for three hours. The digestion mixture was extracted with phenol and chloroform, and the DNA was recovered by ethanol precipitation. Next, the DNA precipitate was digested with 10 units of restriction enzyme Xma I (New England Biolabs), at 37°C for two hours, and resulting DNA fragments were separated by agarose gel electrophoresis using low melting agarose (FMC Bio Products USA).

An agarose piece containing DNA fragments of about 450 bp in length was excised and melted at 65°C for 5 minutes, and an equal volume of 20 mM Tris-HCl (pH 7.5) containing 2 mM EDTA and 200 mM NaCl was added thereon.

The mixture was extracted with phenol and chloroform, and the DNA fragment was recovered by ethanol precipitation and dissolved in 10 µl of 10 mM Tris-HCl (pH 7.5) containing 1 mM EDTA. In this manner, a DNA fragment comprising a gene coding for a mouse κ L chain V region, and a DNA fragment comprising a gene coding for a mouse H chain V region were obtained. Both of the above DNA fragments had a Sal I cohesive end at the 5'-end thereof and an Xma I cohesive end at the 3'-end thereof.

5. Ligation and Transformation

About 0.3 µg of the Sal I - Xma I DNA fragment comprising a gene coding for a mouse κ L chain V region, prepared as described above, was ligated with about 0.1 µg of a pUC19 vector prepared by digesting plasmid pUC19 by Sal I and Xma I, in a reaction mixture comprising 50 mM Tris-HCl (pH 7.4), 10mM MgCl<sub>2</sub>, 10 mM dithiothreitol, 1 mM spermidine, 1 mM dATP, 0.1 µg/ml of bovine serum albumin and 2 units of T4 DNA ligase (New England Biolabs), at 16°C for 16 hours.

Next, 7 µl of the above ligation mixture was added to 200 µl of competent cells of E. coli DH5α, and the cells were incubated for 30 minutes on ice, for one minute at 42°C, and again for one minute on ice. After adding 800 µl of SOC medium (Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Laboratory Press, 1989), the cell suspension was incubated at 37°C for one hour, and inoculated onto an 2xYT agar plate (Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Laboratory Press, 1989), which was then incubated at 37°C overnight to obtain an E.coli transformant. The transformant was cultured in 5 ml of 2xYT medium containing 50 µg/ml ampicillin, at 37°C overnight, and a plasmid DNA was prepared from the culture according to an alkaline method (Molecular Cloning: A Laboratory Manual, Sambrook et al., Cold Spring Harbor Laboratory Press, 1989). The thus-

obtained plasmid containing a gene coding for a mouse  $\kappa$  L chain V region derived from the hybridoma AUK12-20, was designated p12-k2.

5 According to the same procedure as described above, a plasmid containing a gene coding for a mouse H chain V region derived from the hybridoma AUK12-20 was constructed from the Sal I - Xma I DNA fragment, and designated p12-h2.

10      Example 2      Cloning of DNA coding for V region of mouse monoclonal antibody (2)

Substantially the same procedure as described in Example 1 was applied to the hybridoma PM1, AUK64-7, and AUK146-15, to obtain the following plasmids:

15      a plasmid pPM-k3 containing a gene coding for a  $\kappa$  L chain V region derived from the hybridoma PM1;

a plasmid pPM-h1 containing a gene coding for an H chain V region derived from the hybridoma PM1:

20      a plasmid p64-k4 containing a gene coding for a  $\kappa$  L chain V region derived from the hybridoma AUK64-7;

a plasmid p64-h2 containing a gene coding for an H chain V region derived from the hybridoma AUK64-7;

a plasmid p146-k3 containing a gene coding for a  $\kappa$  L chain V region derived from the hybridoma AUK146-15; and

25      a plasmid p146-h1 containing a gene coding for an H chain V region derived from the hybridoma AUK146-15.

30      Note E. coli strains containing the above-mentioned plasmid were deposited with the National Collections of Industrial and Marine Bacteria Limited under the Budapest Treaty on February 11, 1991, and were given the accession number shown in Table 8.

Table 8

|    | Plasmid   | SEQ ID NO | Accession No. |
|----|-----------|-----------|---------------|
|    | p12 - k2  | 24        | NCIMB 40367   |
| 5  | p12 - h2  | 25        | NCIMB 40363   |
|    | pPM - k3  | 26        | NCIMB 40366   |
|    | pPM - h1  | 27        | NCIMB 40362   |
|    | p64 - k4  | 28        | NCIMB 40368   |
|    | p64 - h2  | 29        | NCIMB 40364   |
| 10 | p146 - k3 | 30        | NCIMB 40369   |
|    | p146 - h1 | 31        | NCIMB 40365   |

Example 3      Sequencing of DNA

15      Nucleotide sequences of a cDNA coding region in the above-mentioned plasmids were determined using a kit, Sequenase<sup>(TM)</sup> Version 2.0 (U.S. Biochemical Corp. USA).

20      First, about 3 µg of plasmid DNA obtained as described above was denatured with 0.2 N NaOH, annealed with a sequencing primer, and labeled with <sup>35</sup>S-dATP according to a protocol of the supplier. Next, the labeled DNA was applied to 6% polyacrylamide gel containing 8 M urea, and, after electrophoresis, the gel was fixed with 10% methanol and 10% acetic acid, dried, and subjected to autoradiography to determine the nucleotide sequence.

25      The nucleotide sequence of cDNA coding region in each plasmid is shown in SEQ ID NOS 24 to 31.

Example 4      Determination of CDRs

30      General structures of L chain and H chain V regions are similar each other, wherein 4 frame works (FRs) are linked through 3 super variable regions, i.e.,

complementarity determining regions (CDRs). While amino acid sequences in the FRs are relatively well conserved, amino acid sequences in CDRs are very highly variable (Kabat, E.A. et al., "Sequences of Proteins of Immunological Interest", US Dept. Health and Human Services 1983).

On the basis of the above-determined amino acid sequences of V regions of mouse monoclonal antibodies to human IL-6R, and according to Kabat, E.A. et al., "Sequences of Proteins of Immunological Interest", US Dept. Health and Human Services 1983, CDRs of each V region of mouse monoclonal antibodies to the human IL-6R were determined as shown in Table 9.

Table 9

| plasmid          | SEQ ID NO | CDR(1) | CDR(2) | CDR(3) |
|------------------|-----------|--------|--------|--------|
| (Amino acid No.) |           |        |        |        |
| p12-K2           | 24        | 24-38  | 54-60  | 93-101 |
| p12-h2           | 25        | 31-35  | 50-66  | 99-105 |
| pPM-k3           | 26        | 24-34  | 50-56  | 89-97  |
| pPM-h1           | 27        | 31-36  | 51-66  | 99-108 |
| p64-k4           | 28        | 24-38  | 54-60  | 93-101 |
| p64-h2           | 29        | 31-35  | 50-66  | 99-109 |
| p146-k3          | 30        | 24-34  | 50-56  | 89-97  |
| p146-h1          | 31        | 31-35  | 50-66  | 99-106 |

Example 5

Confirmation of expression of cloned cDNA(1) (Construction of Chimeric AUK12-20 antibody)

### Construction of Expression Plasmid

A chimeric L chain/H chain was constructed from PCR-cloned cDNAs coding for V regions  $\kappa$  L chain and H chain of AUK12-20. In order to easily join a cDNA coding for the mouse AUK12-20 V region to a DNA coding for a human C region in a mammalian expression vector containing an enhancer and promoter of human cytomegalovirus (HCMV) expression vector, it is necessary to introduce convenient restriction enzyme cleavage sites to the 5'- and 3'- termini of the mouse cDNA.

This modification of the 5'- and 3'- termini was carried out by PCR method. Two sets of primers were designed and synthesized. An L chain V region backward primer (SEQ ID NO: 32) and H chain V region backward primer (SEQ ID NO: 33) were designed so that the primers hybridize with a DNA coding for the beginning of the leader sequence, maintain a DNA sequence essential for efficient translation (Kozak, M., J. Mol. Biol. 196: 947-950, 1987) and form a HindIII site for cloning into the HCMV expression vector. An L chain V region forward primer (SEQ ID NO: 34) and an H chain V region forward primer (SEQ ID NO: 35) were designed so that the primers hybridize with a DNA coding for the terminal portion of the J region, maintain a DNA sequence essential for splicing into the C region and form a Bam HI site for joining to the human C region in the HCMV expression vector.

Following the amplification by the PCR, the PCR product was digested with Hind III and BamHI, cloned into the HCMV vector containing the human  $\kappa$  and  $\gamma$ 1 chain C regions DNA and sequenced to confirm that errors were not introduced during the PCR amplification. The resulting expression vectors are designated as HCMV-12k-gk and HCMV-12h-gyl.

The structures of the HCMV expression plasmids are shown in Fig. 1. In the plasmid HCMV-V<sub>L</sub>-HC <sub>$\kappa$</sub> , V<sub>L</sub> region

may be any mouse L chain V region. In this example, AUK12-20  $\kappa$ L chain V region was inserted to obtain the HCMV-12k. In the plasmid HCMV-V<sub>H</sub>-HC $\gamma$ 1, V<sub>H</sub> region may be any mouse H chain V region. In this example, AUK12-20 H chain V region was inserted to obtain HCMV-12h-g $\gamma$ 1.

Transient expression in COS cells

To observe transient expression of a chimeric AUK12-20 antibody in COS cells, the expression vectors constructed as described above were tested in the COS cells. The vector DNAs were introduced into COS cells by electroporation using a Gene Pulsar apparatus (Bio Rad). Namely, COS cells were suspended in phosphate-buffered saline (PBS) to a cell concentration of  $1 \times 10^7$  cells / ml, and to 0.8 ml aliquot of the suspension was added 10  $\mu$ g (per each plasmid) of DNA. Pulses were applied at 1,900 V and 25  $\mu$ F.

After recovery period of 10 minutes at a room temperature, the electroporated cells were added to 8 ml of DMEM (GIBCO) containing 10% fetal bovine serum. After incubation for 72 hours, a culture supernatant is collected, centrifuged to eliminate cell debris, and aseptically stored for a short period at 4°C or for a long period at -20°C.

Quantification of chimeric antibody by ELISA

A culture supernatant of the transfected COS cells was assayed by ELISA to confirm the production of chimeric antibody. To detect the chimeric antibody, a plate was coated with goat anti-human IgG whole molecule (Sigma). The plate was blocked, and serially diluted supernatant from the COS cell culture was added to each well. After incubation and washing, alkaline phosphatase-linked goat anti-human IgG ( $\gamma$ -chain specific, Sigma) was added to each well. After incubation and washing, substrate buffer was added thereon. The reaction mixture was incubated, and after termination of the reaction, optical density at 405 nm was measured. As

a standard, purified human IgG (Sigma) was used.

ELISA for confirmation of an ability to bind to human IL-6R

5 A culture supernatant of the transformed COS cells  
was assayed by ELISA to determine whether the produced  
antibody can bind to the antigen. To detect the binding  
to the antigen, a plate was coated with MT18 mouse  
monoclonal antibody (Reference Example 1), and after  
blocking with 1% bovine serum albumin (BSA) soluble  
10 recombinant human IL-6R (SR 344) was added thereon.  
After washing, a serially diluted culture supernatant  
from the COS cells was added to each well. After  
incubation and washing alkaline phosphatase-linked goat  
anti-human IgG was added. The reaction mixture was  
15 incubated, and after washing a substrate buffer was  
added. After incubation, the reaction was terminated,  
and optical density at 405 nm was measured.

20 A result is shown in Fig. 2. Transfection of gene  
coding for a chimeric antibody AUK12-20 into COS cells  
was twice repeated. Both the culture supernatant samples  
exhibited a strong binding to IL-6R, and optical density  
at 405 nm was changed in a sample dilution (monoclonal  
antibody concentration) - dependent manner as shown in  
Fig. 2 by open circles and closed circles revealing the  
25 presence of an antibody to IL-6R in the sample.

Determination of an ability to inhibit the binding to IL-6R with IL-6

30 To determine whether an antibody present in a medium  
inhibits the binding of IL-6R with IL-6, a plate was  
coated with MT18 monoclonal antibody (Reference Example  
1). After blocking, soluble recombinant human IL-6R (SR  
344) was added thereon. After washing, serially diluted  
sample from COS cell culture was added to each well with  
biotinated IL-6.

35 After washing, alkaline phosphatase-linked  
streptoavidin was added, and after incubation and  
washing, a substrate buffer was added. The reaction



mixture was incubated, and after termination of the reaction, optical density at 405 nm was measured, purified mouse AUK12-20 monoclonal antibody was added as a positive control, and a culture medium from COS cells expressing a non-related antibody was used as a negative control.

A result is shown in Fig. 3. A culture supernatant of COS cells transfected with genes coding for chimeric antibody AUK 12-20 exhibited the binding of IL-6R with IL-6 at the highest and second highest concentrations. Namely, as shown by closed circles in Fig. 3, optical density at 405 nm changed in a sample dilution (antibody concentration) dependent manner, revealing the inhibition of the binding to IL-6R with IL-6 by an antibody in the sample. This is further confirmed by substantive conformity with antibody concentration dependent change of the positive control (open circles). Note, the negative control did not exhibit inhibition activity (open triangles).

Example 6      Confirmation of expression of cloned cDNA (2) (Construction of chimeric PM-1 antibody)  
(Construction of expression vectors)

In order to construct vectors expressing chimeric PM-1 antibody, the cDNA clones pPM-k3 and pPM-h1, coding for the mouse PM-1  $\kappa$ L chain and the H chain V regions, respectively, were modified by a PCR technique, and then introduced into the HCMV expression vectors (see Figure 1). The backward primers pmk-s (SEQ NO: 38) for L chain V region and pmh-s (SEQ NO: 40) for H chain V region were designed to hybridize to the DNA sequences coding for the beginning of the leader sequences, and to have Kozak consensus sequence and a HindIII restriction site. The forward primers pmk-a (SEQ No: 36) for L chain V region and pmh-a (SEQ No: 39) for H chain V region were designed to hybridize to the DNA sequences coding for the ends of the J regions, and to have a

splice donor sequence and a BamHI restriction site.

For the kappa L chain V region, two forward primers were synthesized. Although in most kappa L chains lysine at position 107 is conserved, in mouse PM-1 kappa L chain position 107 is an asparagine. In order to investigate the effect of this change on the antigen-binding activity of the chimeric PM-1 antibody, the forward primer pmk-b (SEQ NO: 37) was designed to mutate position 107 from an asparagine to a lysine. Following the PCR reaction, the PCR products were purified, digested with HindIII and BamHI, and subcloned into a pUC19 vector (Yanische-Perron et al., Gene (1985) 33:103-109). After DNA sequencing; the HindIII-BamHI fragments were excised and cloned into the expression vector HCMV-V<sub>H</sub>-HC<sub>γ1</sub> to obtain HCMV-pmh-gyl for the chimeric H chain, and into the expression vector HCMV-V<sub>L</sub>-HC<sub>κ</sub> to obtain HCMV-pmka-gk and HCMV-pmkb-gk for the chimric L chain.

#### Transfection of cos cells

The vectors were tested in cos cells to look for transient expression of chimeric human PM-1 antibodies. The HCMV-pmh-gyl, and either HCMV-pmka-gk or HCMV-pmkb-gk were co-transfected into the cos cells by electroporation using the Gene Pulsar apparatus (BioRad). DNA (10 µg of each plasmid) was added to a 0.8 ml aliquot of  $1 \times 10^7$  cells/ml in PBS. A pulse was delivered at 1,900 volts, 25 microfarads capacitance. After a 10 min recovery period at a room temperature, the electroporated cells were added to 20 ml of Dulbecco's Modified Eagle Medium (DMEM) (GIBCO) containing 10% gamma-globulin-free fetal calf serum. After 72 h incubation, the medium was collected, centrifuged to remove cellular debris, and stored under sterile conditions at 4°C for short periods of time, or at -20°C for longer periods.

#### Expression and analysis of the chimeric PM-1 antibodies

After 3 days of transient expression, medium from

the cos cells was collected and tested for chimeric PM-1 antibody. The medium was first analyzed by ELISA to determine if human-like antibody was being produced by the transfected cos cells. By using known amounts of purified human IgG as a standard in this assay, it is also possible to estimate an amount of human-like antibody (in this case, chimeric PM-1 antibody) present in the medium from the cos cells. For the detection of human antibody, plates were coated with goat anti-human IgG (whole molecule, Sigma). Following blocking, the samples from cos cells were serially diluted and added to each well. After incubation and washing, alkaline phosphatase-conjugated goat anti-human IgG (gamma chain specific, Sigma) was added. After incubation and washing, substrate buffer was added. After incubation, the reaction was stopped and the optical density at 405 nm measured. Purified human IgG (Sigma) was used as a standard.

The medium from the cos cells transfected with the vectors carrying the chimeric PM-1 genes was positive for the expression of a human-like antibody and the approximate amounts were quantified as described.

Next, the same medium from the cos cells transfected with the vectors carrying the chimeric PM-1 genes was assayed for a an ability to bind to human IL-6R. For the detection of binding to the antigen, plates were coated with MT18 mouse monoclonal anitbody (Reference Example 1), an antibody to the human IL-6R. Following blocking, soluble recombinant human IL-6R (SR344) was added. After washing, the samples were serially diluted and added to each well. After incubation and washing, alkaline phosphatase-conjugated goat anti-human IgG (gamma chain specific sigma) was added. After incubation and washing, substrate buffer was added. After incubation, the reaction was stopped and the optical density at 405 nm measured. There was no standard available for this assay.

Two samples were from transfection with genes coding for a chimeric antibody with V regions identical to those found in mouse PM-1 antibody (chimeric PM-1a antibody, Figure 4). One sample was from transfection with genes coding for a chimeric antibody with a single amino acid change at position 107 in the L chain V region as described above (chimeric PM-1b antibody, Figure 4). All samples showed strong binding to IL-6R that decreased with dilution of the sample. Thus, the chimeric PM-1 antibody, as constructed, is functional and can bind well to its antigen. Most importantly, the demonstration of a functional chimeric PM-1 is direct evidence that the correct mouse PM-1 V regions have been cloned and sequenced. The chimeric PM-1 antibody, with either amino acid at position 107 in the L chain V region, bound well to its antigen, IL-6R. It appears that position 107 in the mouse PM-1 L chain V region is not very critical in antigen-binding and that either an asparagine or a lysine at this position will function satisfactorily. Since the mouse PM-1 antibody has an asparagine at this position in its L chain V region, all future work with chimeric PM-1 antibody was done with version a, the version that has V regions identical to those found in mouse PM-1 antibody.

In order to stably produce larger amounts of chimeric PM-1 antibody, a new HCMV expression vector incorporating the dhfr gene was constructed. The first step in achieving higher levels of expression of the chimeric PM-1 antibody was to modify the vector HCMV-V<sub>H</sub>-HC<sub>V1</sub> (Figure 1) so that this vector contained a dhfr gene being expressed by a "crippled" SV40 promoter-enhancer. The SV40 enhancer elements were deleted from the pSV2-dhfr vector (S. Subramani et al., Mol. Cell. Biol. (1981) 1:854-864) and the dhfr gene being expressed by the "crippled" SV40 promoter was inserted into the HCMV-V<sub>H</sub>-HC<sub>V1</sub> vector in place of the neo gene being expressed by

the SV40 promoter-enhancer. The mouse PM-1 V region was then inserted into this new HCMV-V<sub>H</sub>-HC<sub>γ1</sub>-dhfr vector. Construction of the improved expression vector is described in Example 10 in detail.

5 CHO dhfr(-) cells (G. Urlaub et al., Proc. Natl. Acad. Sci. USA (1980) 77:4216-4220) were co-transfected with two plasmid DNAs, the HCMV-V<sub>L</sub>-HC<sub>κ</sub> vector for expressing chimeric PM-1a L chain (HCMV-pmka-gk) and the HCMV-V<sub>H</sub>-HC<sub>γ1</sub>-dhfr vector for expressing chimeric PM-1 H  
10 chain (DHFR-ΔE PMh-gyl; Example 10). DNA (10 μg/ml of each plasmid) was added to a 0.8 ml aliquot of  $1 \times 10^7$  cells/ml in PBS. A pulse was delivered at 1900 volts, 25 microfarads capacitance. After a 10 min recovery period at a room temperature, the electroporated cells were  
15 added to 10 ml of Alpha minimum essential medium (α-MEM) containing nucleosides and 10% FCS. After overnight incubation, the medium was changed to α-MEM without nucleosides and with 10% FCS and 500 μg/ml of G418 (GIBCO) for the selection of dhfr<sup>+</sup> and neo<sup>+</sup> transformed  
20 cells. After selection, the selected clones were used for gene amplification. After one round of amplification in  $2 \times 10^{-8}$  M methotrexate (MTX), a cell line (PM1k3-7) was selected that produced approximately  $3.9 \mu\text{g}/10^6$  cells/day of chimeric PM-1a antibody.

25 ELISA assay for the ability of chimeric antibodies to inhibit IL-6 from binding to human IL-6R.

Antibodies produced in transfected cos cells or in stable CHO cell lines were assayed to determine whether the antibodies could compete with biotinylated IL-6 for  
30 binding to IL-6R. Plates were coated with MT18 mouse monoclonal antibody. Following blocking, soluble recombinant human IL-6R (SR344) was added. After washing, the samples from the cos cells were serially diluted and added together with biotinylated IL-6 to each  
35 well. After washing, alkaline phosphatase-conjugated streptavidin was added. After incubation and washing,

substrate buffer was added. After incubation, the reaction was stopped and the optical density at 405 nm measured. The Results are shown in Fig. 5.

Example 7      Construction of reshaped human PM-1  
antibodies

In order to achieve CDR-grafting more rapidly and efficiently, a method for sequential CDR-grafting by PCR was developed. This method is based on PCR-mutagenesis methods (Kamman et al., 1989).

In order to prepare the template DNAs containing the selected human FRs for CDR-grafting, it was necessary to reclone suitable reshaped human V regions into convenient vectors. Plasmid DNAs alys11 and F10 code for reshaped human D1.3 L and H chains and contain the FRs from human REI and NEW, respectively. An approximately 500 bp NcoI-BamHI fragment containing DNA sequence coding for the reshaped human D1.3 L chain V region was excised from alys11 and subcloned into HindIII-BamHI cleaved- pBR327 to obtain a vector V1-lys-pBR327. HindIII-BamHI fragment from the V1-lys-pBR327 was inserted into HindIII-BamHI cleaved pUC19 to obtain a vector V1-lys-pUC19. An approximately 700 bp NcoI-BamHI fragment containing DNA sequence coding for the reshaped human D1.3 H chain V region was excised from F10 and subcloned into the HindIII-BamHI site of pBR327 vector, using a HindIII-NcoI adaptor, yielding Vh-lys-pBR327. A HindIII-BamHI fragment was then excised from this vector and subcloned into HindIII-BamHI cleaved pUC19 vector yielding Vh-lys-pUC19.

Note the construction of the plasmid alys11 and the DNA sequence coding for the reshaped human D1.3 L chain V region used in a template is described. The DNA sequence coding for the reshaped human D1.3 H chain V region in the plasmid F10 used as a template is described in V. Verhoey et al., Science 237:1534-1536 (1988) Fig. 2.

Figure 6 diagrams the primers and the PCR reactions

used in the construction of the first version of reshaped human PM-1 H chain V region. A backward primer A (APCR1; SEQ NO: 41) and a forward primer E (APCR4; SEQ NO: 42) hybridize to DNA sequences on the vector. Although APCR1 and APCR4 were specifically designed for pUC19 vector, universal M13 sequence primers could be used.

The CDR1-grafting/mutagenic primer B (phv-1; SEQ NO: 43), CDR2-grafting primer C (phv-2; SEQ NO: 44) and CDR3-grafting primer D (phv-3; SEQ NO: 45) were 40-60 bp in length, consisting of DNA sequences coding for CDRs from the mouse PM-1 H chain V region and the human FRs in the template DNA that flank the CDR regions. In the first PCR reaction, the forward primer APCR4 and the backward primer D were used. The first PCR product, which contains the mouse PM-1 CDR3 sequence, was purified and used in the second PCR reaction as a forward primer with primer C as the backward primer. In the same manner, the second and third PCR products, which contain mouse PM-1 CDR2 and CDR3, and all three mouse PM-1 CDRs, respectively, were used as primers in the following PCR step. The fourth PCR product, which has the complete reshaped human PM-1 H chain V region, was purified, digested with HindIII and BamHI, and subcloned into a pUC19 vector for further analysis.

Three mutagenic primers phv-1, phv-2, and phv-3 were synthesized for the construction of reshaped human PM-1 H chain V region. They were purified on 12% polyacrylamide gels containing 8M urea. The mutagenic primer phv-1 was designed not only for mouse PM-1 CDR1-grafting but also for mutations at positions 27 and 30 in human FR1, Ser to Tyr and Ser to Thr, respectively. Each 100  $\mu$ l PCR reaction typically contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM  $MgCl_2$ , 250  $\mu$ M dNTPs, 50 ng of the template DNA (Vh-lys-pUC19), 2.5 u of AmpliTaq (Perkin Elmer Cetus) and the primers. The first PCR reaction containing 1  $\mu$ M of each of the phv-3 and APCR4

primers was carried out, after an initial denaturation at 94°C for 1.5 min, for 30 cycles of 94°C for 1 min, 37°C for 1 min and 72°C for 1 min were repeated. The ramp time between the annealing and synthesis steps was set for 2.5 min. The completion of the last cycle was followed by a final extension at 72°C for 10 min. A 523 bp PCR product was purified using a 1.6% low melting temperature agarose gel and then used as a primer in the second PCR reaction.

In the second PCR reaction approximately 1 µg of the purified first PCR product and 25 pmoles of the mutagenic primer phv-2 were used as primers. The PCR conditions were the same as described for the first PCR reaction. In the same manner, a 665 bp PCR product from the second PCR reaction and a 737 bp PCR product from the third reaction were used as primers in the third PCR reaction with the primer phv-1, and in the fourth PCR reaction with the primer APCR1, respectively. A 1.172 kb PCR product from the fourth PCR reaction was purified, digested with HindIII and BamHI, and then an approximately 700 bp fragment containing the reshaped human PM-1 H chain V region was subcloned into a pUC19 vector. Two of four clones sequenced had the DNA sequence coding for the correct amino acid sequence and were designated pUC-RVh-PM1a.

In order to construct other versions of reshaped PM-1 H chain V region, five mutagenic PCR primers were synthesized. Each PCR reaction was essentially carried out under the same condition as described above. For version "b", mutagenic primer phv-m4 (Val-71 to Arg-71; the number is according to Kabat et al; see Table 3) (SEQ ID NO: 46) and APCR4 were used in the first PCR reaction with template DNA, pUC-RVh-PM1a. The PCR product from this first PCR reaction was purified and was used as a forward primer in the second PCR reaction with the primer APCR1. The PCR product from the second PCR reaction was purified using a 1.6% low melting temperature agarose



gel, digested with HindIII and BamHI, and subcloned into a pUC19 vector yielding pUC-RVh-PM1b. In the same manner, version "c" (pUC-RVh-PM1c) was obtained using a mutagenic primer phv-nm (Asp-1 to Gln-1) (SEQ ID NO: 47) and a template pUC-RVh-PM1b; version "d" (pUC-RVh-PM1d) was obtained using a mutagenic primer phv-m6 (Ile-48 to Met-48) (SEQ ID NO: 48) and a template pUC-RVh-PM1b; version "e" (pUC-RVh-PM1e) was obtained using the mutagenic primer phv-m6 and a template pUC-RVh-PM1c; and "version f" (pUC-RVh-PM1f) was obtained using a mutagenic primer phv-m7 (Thr-28 to Ser-28, and Phe-29 to Ile-29) (SEQ ID NO: 49) and a template pUC-RVh-PM1b. Amino acid sequence of the version "f" of the reshaped human H chain V region, and a nucleotide sequence codin therefor is shown in SEQ ID NO: 54.

Figure 7 diagrams the primers and the PCR reactions used in the construction of the first version of reshaped human PM-1 L chain V region. For the construction of the first version of reshaped human PM-1 L chain V region, CDR1-grafting primer pkv-1 (SEQ ID NO: 50), CDR2-grafting primer pkv-2 (SEQ ID NO: 51) and CDR3-grafting primer pkv-3 (SEQ ID NO: 52) were synthesized and purified on a 12% polyacrylamide gel containing 8M urea. PCR reactions were carried out as described above. The first PCR reaction contained 1  $\mu$ M of each of the pkv-3 and APCR4 primers. A 350 bp PCR product from the first PCR reaction was purified using a 1.5% low melting temperature agarose gel and used as a forward primer in the second PCR reaction. The PCR product from the second PCR reaction was purified, digested with BamHI and HindIII, and the 500 bp fragment containing the CDR3-grafted DNA was subcloned into a pUC19 vector for DNA sequencing. A plasmid DNA having the correct sequence was identified and used as the template DNA in the following PCR reaction. In the third PCR reaction, 25 pmoles of mutagenic primers pkv-2 and APCR4 were used. The PCR product from the third PCR reaction was purified

and used as a primer, with the primer pkv-1, in the fourth PCR reaction. In the same manner, the PCR product from the fourth PCR reaction was used as a primer, with the APCR1 primer, in the fifth PCR reaction.

5           A 972 bp PCR product from the fifth PCR reaction was purified, digested with BamHI and HindIII, and subcloned into a pUC19 vector for DNA sequencing. A problem was identified in the CDR2 region. Two additional PCR reactions were necessary. In the sixth and seventh PCR  
10 reactions, the PCR product from the fifth PCR reaction, as cloned into pUC19 vector, was used as template DNA. In the sixth PCR reaction, the primers were pkv-2 and . APCR4. The PCR product from the sixth PCR reaction was purified and used as a primer, with the APCR1 primer, in  
15 the seventh PCR reaction. The PCR product of the seventh PCR reaction was purified, digested with BamHI and HindIII, and a 500 bp DNA fragment was subcloned into a pUC19 vector for DNA sequencing. Two of five clones sequenced had the correct DNA sequence. The clone was  
20 designated pUC-RV1-PM1a. The sequence is shown in SEQ ID NO: 55.

For the construction of the other version of reshaped human PM-1 L chain V region, a mutagenic primer pvk-m1 (SEQ ID NO: 53) was synthesized. The PCR  
25 reactions were essentially as described above. In the first PCR reaction, the mutagenic primer pkv-m1 (Phe-71 to Tyr-71) and the APCR4 primer were used with the template DNA pUC-RV1-PM1a. The PCR product of the first PCR reaction was purified and used as a primer, with the  
30 APCR1 primer, in the second PCR reaction. The PCR product of the second PCR reaction was purified, digested with BamHI and HindIII, and subcloned into a pUC19 vector for DNA sequencing. The clone was designated pUC-RV1-PM1b.

Example 8      Construction of vectors that employ the human cytomegalovirus immediate early (HCMV) promoter to express genetically-engineered antibodies in mammalian cells (Fig. 1).

5

The DNA fragments coding for the chimeric PM-1 L and H chain V regions were initially inserted into HCMV vectors (HCMV-V<sub>L</sub>-HC<sub>K</sub> and HCMV-V<sub>H</sub>-HC<sub>γ</sub>1) designed to express either human kappa L chains or human gamma-1 H chains in mammalian cells (see Figure 1). A detailed description of the construction of the HCMV expression vectors is published in Maeda et al., Human Antibodies and Hybridomas (1991) 2:124-134; C. A. Kettleborough et al., Protein Engineering (1991) 4:773-783. Both vectors are based on pSV2neo (P.J. Southern et al., J. Mol. Appln. Genet. (1982) 1:327-341) and contain the human cytomegalovirus (HCMV) promoter and enhancer (M. Boshart et al., Cell (1985) 41:521-530) for high level transcription of the immunoglobulin L and H chains. The L chain expression vector contains genomic DNA coding for the human kappa C region (T. H. Rabbitts et al., Curr. Top. Microbiol. Immunol. (1984) 113:166-171) and the H chain expression vector contains genomic DNA coding for the human gamma-1 C region (N. Takahashi et al. Cell (1982) 29:671-679). The HCMV expression vectors are versatile and can be used for both transient and stable expression in a variety of mammalian cell types.

10

15

20

25

Example 9      Construction of vectors that employ the human elongation factor 1 $\alpha$  (HEF-1 $\alpha$ ) promoter to express genetically-engineered antibodies in mammalian cells (Fig. 8 and Fig. 9)

30

35

The human polypeptide chain elongation factor 1 $\alpha$  (HEF-1 $\alpha$ ) is one of the most abundant proteins. It is expressed in most cells. The transcriptional activity of the human EF-1 $\alpha$  promoter-enhancer is about 100-fold

stronger than that of the SV40 early promoter-enhancer  
(D.W. Kim et al., Gene (1990) 91:217-223, and T. Uetsuki  
et al., J. Biol. Chem. (1989) 264:5791-5798). The 2.5 kb  
HEF-1 $\alpha$  promoter-enhancer region consists of approximately  
5 1.5 kb of DNA flanking the 5'-end of the gene, 33 bp in  
the first exon, 943 bp in the first intron, and 10 bp of  
the first part of the 2nd exon. The approximately 2.5 kb  
HindIII-EcoRI fragment was excised from plasmid DNA  
pEF321-CAT (D.W. Kim et al., Gene (1990) 91:217-223, and  
10 T. Uetsuki et al., J. Biol. Chem. (1989) 264:5791-5798)  
and cloned into pdKCR vector DNA (M. Tsuchiya et al.,  
EMBO J. (1987) 6:611-616) (K. O'Hare et al., Proc. Natl.  
Acad. Sci USA Vol. 78, No. 3, 1527-1531, 1981) to replace  
an approximately 300 bp HindIII-EcoRI fragment containing  
15 the SV40 early promoter-enhancer sequence thus yielding  
pTEF-1. pTEF-1 was digested with EcoRI, filled-in with  
the Klenow polymerase, and ligated to HindIII linkers.  
An approximately 1.6 kb HindIII-SmaI fragment was then  
excised from the modified pTEF-1 vector DNA.

20 Plasmid DNA HCMV-12h-gyl ( $\Delta$ E2) was constructed from  
the HCMV-12h-gyl constructed in Example 5 by partially  
digesting HCMV-12h-gyl with EcoRI, filling-in with klenow  
polymerase, and self-ligating.

25 The plasmid HCMV-12h-gyl ( $\Delta$ E2) was digested with  
EcoRI, filled-in with Klenow polymerase, and digested  
with HindIII. The resulting approximately 7 kb fragment  
containing the DNA sequence coding for human gamma-1  
C region was ligated to the above-prepared 1.6 kb  
HindIII-SmaI fragment containing the HEF-1 $\alpha$  promoter-  
30 enhancer yielding HEF-12h-gyl. The HEF-1 $\alpha$  promoter-  
enhancer region in this vector was the same as that in  
pTEF-1 except for 380 bp of DNA flanking the 5'-region.  
The H chain V region, present as a HindIII-BamHI  
fragment, was easily interchangeable with other H chain V  
35 regions.

HindIII-BamHI DNA fragments containing the reshaped  
H chain V region were excised from the pUC-RVh-PM1a, pUC-

HEF-1 $\alpha$  promoter-enhancer

RVh-PM1b, pUC-RVh-PM1c, pUC-RVh-PM1d, pUC-RVh-PM1e, and  
pUC-RVh-PM1f (Example 7), and inserted into the HindIII-  
BamHI portion of the HEF-12h-gyl to obtain expression  
vectors RVh-PM1a, RVh-PM1b, RVh-PM1c, RVh-PM1d, RVh-PM1e  
and RVh-PM1f, respectively. The expression vectors RVh-  
PM1a, RVh-PM1b, RVh-PM1c, RVh-PM1d, RVh-PM1e and RVh-  
PM1f, as well as HEF-PMh-gyl have the reshaped human PM-1  
H chain V regions versions "a", "b", "c", "d", "e" and  
"f", as well as the mouse PM-1 H chain V region,  
respectively.

To construct the L chain expression vector, HEF-12k-  
gk, an approximately 3.0 kb PvuI-HindIII fragment  
containing the HEF-1 $\alpha$  promoter-enhancer region was  
excised from the HEF-12h-gyl and ligated to an  
approximately 7.7 kb PvuI-HindIII fragment from the HCMV  
L chain expression vector HCMV-12k-gk constructed in  
Example 5 to obtain HEF-12k-gk. As for the H chain  
expression vector HEF-12h-gyl, the L chain V region in  
HEF-12k-gk, present as a HindIII-BamHI fragment, is  
easily interchangeable with other L chain V regions.

HindIII-BamHI DNA fragments containing the reshaped  
human L chain V region were excised from the pUC-RV1-  
PM1a and pUC-RV1-PM1b (Example 7), and inserted into the  
HindIII-BamHI portion of the HEF-12k-gk to obtain  
expression vectors RV1-PM1a and RV1-PM1b, respectively.  
The expression vectors RV1-PM1a, RV1-PM1b, and HEF-PMk-gk  
have the reshaped human L chain V regions "a", "b", and  
the mouse PM-1 L chain V region, respectively.

Example 10      Construction of vectors that employ  
the dihydrofolate reductase (dhfr)  
gene linked to a defective SV40  
promoter-enhancer sequence to achieve  
high levels of expression of  
genetically-engineered antibodies in  
CHO cells (Fig. 10 and Fig. 11).

In order to remove the enhancer sequence from the

SV40 early promoter, the plasmid DNA pSV2-dhfr  
(S.Subramani et al., Mol. Cell. Biol. (1981) 1: 854-864)  
(ATCC 33694) was digested with SphI and PvuII, filled-in  
with Klenow polymerase, and self-ligated to yield pSV2-  
5 dhfr-ΔE (see Figure 10). An approximately 3.7 kb EcoRI  
fragment containing the HCMV promoter, the H chain  
V region, and the human gamma-1 C region was excised from  
HCMV-PMh-gyl by partially digesting with EcoRI. This  
fragment was ligated to EcoRI-digested pSV2-dhfr-ΔE to  
10 yield DHFR-ΔE-PMh-gyl.

A similar vector was constructed based on the  
H chain expression vector that employs the HEF-1α  
promoter-enhancer (see Figure 11). An approximately  
3.7 kb EcoRI fragment derived from HCMV-12h-gyl was  
15 ligated with EcoRI-digested pSV2-dhfr-ΔE to yield DHFR-  
ΔE-12h-gyl. The BamHI site following the dhfr cDNA  
sequence in DHFR-ΔE-12h-gyl was removed by partially  
digesting with BamHI, filling-in with Klenow polymerase,  
and self-ligating. An approximately 4 kb PvuI-BamHI  
20 fragment containing the dhfr cDNA was excised from the  
modified DHFR-ΔE-12h-gyl DNA and ligated to an  
approximately 3 kb PvuI-BamHI fragment from RVh-PM1f-4  
(constructed in Example 12) to yield DHFR-ΔE-RVh-PM1f.

The improved expression plasmids as prepared above  
25 can be used for the production of the reshaped human PH-1  
antibodies of the present invention.

Example 11      Expression and analysis of different  
versions of reshaped human PM-1  
antibody

30      The HEF-1α vectors expressing reshaped human PM-1 L  
and H chains were co-transfected into cos cells. As a  
standard control, HEF-1α vectors expressing chimeric PM-1  
L and H chains were also co-transfected into cos cells.  
After 3 days the medium from the transfected cos cells  
35 was collected and analyzed by ELISA (1) for the amount of  
human IgG antibody present in the supernatant and (2) for  
the ability of that human IgG to bind to IL-6R. Later

the same samples were also tested by ELISA for the ability of the antibody to inhibit human IL-6 from binding to human IL-6R.

5 Evaluation of the two versions of reshaped human PM-1 L chain V regions were conducted by co-transfecting cos cells with one of the two vectors expressing reshaped human PM-1 L chains (RV1-PM1a or RV1-PM1b) and the vector expressing chimeric PM-1 H chain (HCMV-PMh-gyl). Cells were also co-transfected with vectors expressing chimeric PM-1 L and H chains (HCMV-PMka-gk and HCMV-PMh-gyl).  
10 Data using unpurified cos cell supernatants showed that version "a" of reshaped human PM-1 L chain was equivalent to chimeric PM-1 L chain in assays for binding to IL-6R. Version "b" of reshaped human PM-1 L chain, however,  
15 virtually abolished binding to IL-6R (Figure 12). From these results, it was concluded that the change at position 71 in FR3 from phenylalanine (as present in the human REI as modified for CAMPATH-1H) to tyrosine (as present in natural human REI and in mouse PM-1) was very  
20 detrimental to the formation of a functional antigen-binding site.

Version "a" of the reshaped human PM-1 L chain V region was selected as the best version. In subsequent experiments evaluating the different versions of reshaped human PM-1 H chain V regions, version "a" of the reshaped human PM-1 L chain V region was always used.  
25

Evaluation of the six versions of reshaped human PM-1 H chain V regions were conducted by co-transfecting cos cells with one of the six vectors expressing reshaped human PM-1 H chains (RVh-PM1a, RVh-PM1b, RVh-PM1c, RVh-PM1d, RVh-PM1e or RVh-PM1f) and the vector expressing version "a" of the reshaped human PM-1 L chain (RV1-PM1a). Cells were also co-transfected with vectors expressing chimeric PM-1 L and H chains (HEF-PMK-gk and HEF-PMh-gyl). Preliminary data using unpurified cos cell supernatants showed that version "a" of reshaped human PM-1 L chain and version "f" of reshaped human PM-1  
30  
35

SECRETED

H chain were equivalent to chimeric PM-1 L and H chains in assays for binding to IL-6R.

To confirm this preliminary data, chimeric and reshaped human PM-1 antibodies were concentrated and purified from cos cell supernatants using Protein A. Namely the media from cos cells was concentrated using a 100 kd cut-off ultrafiltration device (Amicon). The concentrated media was purified using Protein A agarose (Affi-Gel Protein A MAPSII kit, BioRad). Briefly, the concentrated media was applied to a Protein A agarose column that was equilibrated with five bed volumes of binding buffer. The column was washed with 15 bed volumes of the binding buffer, followed by 5 bed volumes of the elution buffer. The eluate was concentrated and the buffer changed to PBS using a microconcentrator (Centricon 10, Amicon). The purified antibodies were used for further analysis.

The analysis of purified samples of chimeric PM-1 antibody, and reshaped human PM-1 antibodies with version "a" of the L chain V region and versions "a", "b", "c", "d", "e", and "f" of the reshaped human H chain V region was carried out. Version "a" of the L chain plus version "f" of the H chain is clearly the best reshaped human PM-1 antibody. It binds to IL-6R as well as chimeric PM-1 antibody does (Figure 13). It also inhibits human IL-6 from binding to the IL-6R as well as both the mouse and chimeric PM-1 antibodies do (Figure 14).

Example 12      Reconstruction of the reshaped human PM-1 V regions to improve the levels of expression.

In order to remove the introns within the DNA sequences coding for the leader sequences of the reshaped human PM-1 L and H chain V regions (see SEQ ID Nos: 54 and 55), the cDNAs coding for the V regions were recloned using the PCR primers. The L and H chain expression vectors RV1-PM1a and RVh-PM1f were co-transfected into cos cells. After 48 hrs, total RNA was prepared



(Chirgwin et al., Biochemistry (1979) 18:5294-5299) and 5 µg of total RNA was used for the first strand cDNA synthesis as described for the PCR cloning of mouse antibody V regions. Three PCR primers were designed and synthesized. LEV-P1 (SEQ ID NO: 60) and HEV-P1 (SEQ ID NO: 58) contain the splice donor sequence and the BamHI site and were used as forward primers for the L and H chain V regions, respectively. HEV-P2 (SEQ ID NO: 59) contains the Kozak consensus sequence before the ATG initiation codon and the HindIII site and was used as a backward primer for both the L and H chain V regions. Each 100 µl PCR reaction contained 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 2 mM MgSO<sub>4</sub>, 0.1% Triton X-100, 0.1 µg BSA, 250 µM dNTPs, 2.5 u of Vent DNA polymerase (Biolabs, U.K.), 50% of the first-strand cDNA synthesis reaction and 100 pmoles each of the forward and backward primers. Each PCR tube was overlaid with 50 µl of mineral oil and then cycled, after an initial melt at 94°C for 1.5 min, at 94°C for 1 min, 50°C for 1 min, and 72°C for 1 min, and then at 72°C for 10 min. The 408 bp PCR product containing the L chain V region and the 444 bp PCR product containing the H chain V region were purified using 2.0% low melting temperature agarose gels, digested with BamHI and HindIII, and subcloned into a pUC19 vector to obtain pUC-RV1-PM1a-3 and pUC-RVh-PM1f-3 respectively.

It was revealed that the DNA sequences of the reshaped human PM-1 L and H chain V regions contain inappropriate splice donor and acceptor sites (see SEQ ID NOs: 54 and 55). The sites within the L chain V region are not frequently used (approximately 10% of the mRNA), but the sites within the H chain V region are used frequently (approximately 90% of the mRNA). This aberrant splicing resulted in low levels of expression of the reshaped human PM-1 antibody. In order to avoid aberrant splicing in the V regions, the splice donor

sites were removed using a PCR-based method. For the H chain V region, the backward primer NEW-SP1 (SEQ ID NO: 61) and the forward primer NEW-SP2 (SEQ ID NO: 62) were synthesized, changing the DNA sequence TGG GTG AGA to the DNA sequence TGG GTT CGC. The conditions for the PCR reactions were as described above for cDNA cloning except that the template DNA was 50 ng of pUC-RVh-PM1f-3 and the primers were either HEV-P2 and NEW-SP2, or HEV-P1 and NEW-SP1.

The PCR products from the two PCR reactions were purified using a 2.0% low melting temperature agarose gel and used in a PCR joining reaction. A 98 µl PCR reaction containing 0.5 µg of each of the first PCR products and 5 u of Vent DNA polymerase was incubated at 94°C for 2 min, 50°C for 2 min, and 72°C for 5 min, and then 100 pmoles each of HEV-P1 and HEV-P2 primers were added. The PCR tube was overlayed with 30 µl of mineral oil and subjected to 25 cycles of PCR, at 94°C for 1 min, 50°C for 1 min, and 72°C for 1 min, and then incubated at 72°C for 10 min.

In the same manner, the splice donor site in the reshaped human PM-1 L chain V region was removed using PCR primers REI-SP1 (SEQ ID NO: 63) and REI-SP2 (SEQ ID NO: 64) that changed the DNA sequence CAG GTA AGG to the DNA sequence CAG GAA AGG (see). Both PCR products, a 408 bp DNA fragment for the L chain V region and a 444 bp DNA fragment for the H chain V region, were purified using a 2.0% low melting temperature agarose gel, digested with HindIII and BamHI, and subcloned into a pUC19 vector to yield pUC-RV1-PM1a-4 and pUC-RVh-RM1f-4, respectively.

RVh-PM1f-4 was constructed by replacing the HindIII-BamHI fragment of RVh-PM1f with the HindIII-BamHI fragment excised from pUC-RVh-PM1f-4. Sequence of reshaped human PM-1 antibody L chain V region version "a" wherein introns have been deleted is shown in SEQ ID NO: 57, and sequence of reshaped human PM-1 antibody

H chain V region version "f" wherein have been deleted is shown in SEQ ID NO: 56.

Example 13      Construction of DNA coding for  
reshaped human AUK 12-20 antibody  
L chain V region

5

A process for construction of DNA coding for a reshaped human AUK 12-20 antibody L chain V region is shown in Fig. 16. A gene coding for a human antibody L chain V region is incorporated into pUC19 vector using restriction enzymes HindIII and BamHI. Eight PCR primers (A to H) are prepared, and in the first PCR 4 regions which form a gene coding for the V region are amplified. The primers A and H have homology to DNA sequences on the pUC19 vector. The primers B, C and D are primers of 40 to 60 bp length each having a gene sequence of CDR to be grafted, respectively. The primers E, F and G have homology to DNA sequence of 15 to 20 bp length of the 5'-terminus of the primers B, C and D, respectively. Four first PCR use pairs of primers A and E, B and F, C and G, as well as D and H, respectively.

15  
20

The PCR product A-E encodes FR1, and the PCR product B-F encodes CDR1 and FR2. The 3'-terminal portion of the A-E fragment and the 5'-terminal portion of the B-F fragment have homology in their 15 to 20 bp length, allowing to join there fragments at latter stage. Similarly, the B-F fragment has a homology with the C-G fragment which encodes CDR2 and FR3. The C-G fragment further has a homology with the D-H fragment which encodes CDR3 and FR4. Thus, these 4 fragments can be joined by their mutual homology. After joining these 4 fragments in a PCR reaction mixture, primers A and H are added thereon in the second PCR to amplify a product formed by correct joining of the 4 fragment. The second PCR product thus obtained has three grafted CDRs, and after digestion with HindIII and BamHI, is subcloned into pUC19 vector.

25

30

35

0014285-074398

More specifically, as a template, plasmid pUC-RV1-PM1a-4 constructed by inserting a DNA encoding reshaped human PM-1 antibody L chain V region version "a" into plasmid pUC19 was used.

5 The above-mentioned primers A to H have the following sequences.

|    | Backward Primer | SEQ ID NO. | Forward primer | SEQ ID NO. |
|----|-----------------|------------|----------------|------------|
|    | A. REVERSE      | 83         | 1220-L16       | 66         |
| 10 | B. 1220-L1      | 65         | 1220-L2b       | 68         |
|    | C. 1220-L2      | 67         | 1220L3b        | 70         |
|    | D. 1220-L3      | 69         | UNIVERSAL      | 82         |

15 The backward primers 1220-L1, 1220-L2 and 1220L3 for CDR grafting were purified with 12% polyacrylamide gel containing 8M urea prior to using them.

20 A 100 µl PCR reaction mixture contained 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 2 mM MgSO<sub>4</sub>, 0.1% Triton X-100, 1 µg BSA, 250 µM dNTPs, 5 units Vent DNA polymerase (BioLabs. U.K.), 50 ng pUC-RV1-PM1a-4 DNA, and 100 p moles each of the forward and backward primers. Each PCR tube was overlaid with 50 µl of mineral oil, and after an initial denaturation at 94°C for 1.5 minutes, 25 30 cycles of reaction at 94°C for 1 minute, 50°C for 1 minute and 72°C for 1 minute was carried out, followed by an incubation at 72°C for 10 minutes.

30 Each of the PCR products, 252 bp (A-E), 96 bp (B-F), 130 bp (C-G) and 123 bp (D-H) was purified with a 2.0% low melting agarose (FMC, Bio. Products, USA). Namely, an agarose piece containing a DNA fragment was excised, melted at 65°C for 5 minutes, and added to the same volume of 20 mM Tris-HCl (pH 7.5) containing 2 mM EDTA and 200 mM NaCl. The mixture was extracted with phenol and chloroform. 35 The DNA fragment was recovered by an ethanol precipitation, dissolved in 10 mM Tris-HCl

(pH 7.5) containing 1 mM EDTA, and used for PCR joining reaction.

5       Next, 98 µl of a PCR reaction mixture containing  
0.2 µg each of the first PCR products and 5 units of Vent  
DNA polymerase was incubated at 94°C for 2 minutes, 50°C  
for 2 minutes and 72°C for 5 minutes for a joining  
reaction. Next, 100 p moles each of the primers A  
(REVERSE) and H(UNIVERSAL) were added to the reaction  
mixture to make it to 100 µl volume, and the reaction  
10       mixture was overlaid with 50 µl of mineral oil and  
subjected to 30 cycles of a reaction at 94°C for  
1 minute, 50°C for 1 minute and 72°C for 1 minute,  
followed by an incubation at 72°C for 10 minutes.

15       The second PCR product of 558 bp length containing  
an L chain V region into which CDRs of the mouse  
monoclonal antibody AUK 12-20 L chain had been grafted  
was purified by a 2.0% low melting agarose gel, and after  
digestion with BamHI and HindIII, subcloned into a pUC19  
vector to obtain pUC-RL-1220a, and sequenced. A  
20       resulting amino acid sequence of the L chain V region and  
a nucleotide sequence encoding the amino acid sequence is  
shown in SEQ ID NO: 71.

25       Next, for construction of an L chain expression  
vector, a HindIII-BamHI DNA fragment containing a  
reshaped human AUK 12-20 antibody L chain V region was  
excised from the above-mentioned plasmid pUC-RV<sub>L</sub>-1220a,  
and inserted to HindIII-BamHI site of an L chain  
expression vector HEF-12k-gk to obtain an expression  
vector RV<sub>L</sub>-1220a for reshaped human AUK 12-20 antibody  
30       L chain V region version "a".

Example 14.       Expression and analysis of reshaped  
human AUK 12-20 antibody L chain  
Transient expression in COS cells

35       The expression vector RV<sub>L</sub>-1220a for reshaped human  
AUK 12-20 antibody L chain and the expression vector HEF-  
12h-gyl for chimeric 12-20 antibody H chain (Example 5)

were cotransfected into COS cells to evaluate the reshaped human AUK 1220 antibody L chain version "a". Namely, COS cells were suspended in a phosphate-buffered saline (PBS) at a concentration of  $1 \times 10^7$  cells 1 ml, and to 0.8 ml of the suspension were added the plasmid DNAs (10  $\mu$ g for each plasmid). Pulses were applied to the suspension at an electric capacity of 1,900 V, 25  $\mu$ F using a Gene Pulser apparatus (Bio Rad).

After restoration at a room temperature for 10 minutes, electroporated cells were added to 8 ml of DMEM medium (GIBCO) containing 10% bovine fetal serum. After incubation for 72 hours, supernatant was collected, centrifuged to eliminate cell debris, and stored in an aseptic condition at 4°C for short period or at -20°C for longer period.

#### Determination of human-like antibody by ELISA

A supernatant of the transfected COS cells was assayed by ELISA and the production of chimeric antibody was confirmed. To detect human-like antibody, a plate was coated with a goat anti-human IgG (whole molecule) (Sigma). After blocking, the supernatant from COS cells was sequentially diluted and added to each well.

The plate was incubated and washed, and an alkaline phosphatase-conjugated goat anti-human IgG ( $\alpha$ -chain specific, Sigma) was added thereon. After incubation and washing, a substrate solution was added. After further incubation, the reaction was terminated and an optical density at 405 nm was measured. As a standard, purified IgG (Sigma) was used.

#### ELISA for confirmation of an ability to bind to human IL-6R

A supernatant from the transfected COS cells was assayed by ELISA to determine whether the produced human-like antibody can bind to the antigen, human IL-6R. A plate was coated with a mouse monoclonal antibody MT18 (Reference Example 1). After blocking with 1% BSA,

soluble recombinant human IL-6R (SR 344) was added to the plate. After washing the plate, supernatant from COS cells was sequentially diluted and added to each well of the plate. After inclusion and washing, alkaline phosphatase-conjugated goat anti-human IgG was added to the wells, and after further incubation and washing, a substrate solution was added thereon. After incubation, the reaction was terminated and optical density at 405 nm was measured.

A result is shown in Fig. 17. The human-like antibody comprising a combination of a reshaped human AUK 12-20 antibody L chain version "a" and a chimeric 12-20 antibody H chain exhibited a binding ability to IL-6R as strong as chimeric 12-20 antibody. Optical density at 405 nm changed in a dilution rate-dependent manner, confirming that the sample contains an antibody to IL-6R. In addition, this result shows that the reshaped human AUK 12-20 antibody L chain version "a" has an antigen binding ability as high as chimeric AUK 12-20 antibody L chain.

Example 15. Construction of gene coding for reshaped human AUK 12-20 antibody H chain using HSGI consensus sequence

According to the same procedure as described in Example 13. CDRs of AUK 12-20 antibody H chain V region were grafted into the reshaped human V<sub>H</sub>a425 containing HSG I consensus sequences as its FRs (Kettleborough et al., Protein Engineering (1991) 4:773-783). First, a HindIII-BamHI DNA fragment encoding the reshaped human V<sub>H</sub>a425 (Fig. 3 in the literature) was excised from a plasmid HCMV-RV<sub>H</sub>a-425-γ1 and subcloned at HindIII-BamHI sites in pUC 19 vector to obtain pUC-RV<sub>H</sub>-425a, which was then used as a template. 8 PCR primers (A1 to H1) were synthesized. The primer 1220-H1 was designed to graft CDR1 and to induce a mutation from T-28 to S-28, and the primer 1220-H3 was designed to graft CDR3 and to

induce a mutation from S-94 to R-94. The primers 1220-H1, 1220-H2 and 1220-H3 were purified using a 12% polyacrylamide gel containing 8 M urea prior to using them. Nucleotide sequence of each primer was as follow.

5

|    | Backward primer | SEQ ID NO. | Forward primer | SEQ ID NO. |
|----|-----------------|------------|----------------|------------|
|    | A1. REVERSE     | 83         | E1. 1220-H1b   | 73         |
|    | B1. 1220-H1     | 72         | F1. 1220-H2b   | 75         |
| 10 | C1. 1220-H2     | 74         | G1. 1220-H3b   | 77         |
|    | D1. 1220-H3     | 76         | H1. UNIVERSAL  | 82         |

15 Condition of PCR was the same as that described in Example 13, except that the pUC-RV<sub>H</sub>-425a was used as a template DNA and the above-mentioned primers were used for grafting H chain CDRs. Primer pairs of A1 and E1, B1 and F1, C1 and G1, as well as D1 and H1 were used to

20 carry out first PCR reactions, and the respective first PCR products, 186 bp (A1-E1), 75 bp (B1-F1), 173 bp (C1-G1) and 105 bp (D1-H1) were purified with 2.0% low melting agarose gel, and used in subsequent second PCR

25 joining reaction. According to the condition described in Example 13, 0.2 µg each of the first PCR products were used to carry out the second PCR reaction (including PCR joining reaction) to obtain a PCR product of 495 bp containing DNA coding for a human H chain V region into which mouse AUK 12-20 antibody H chain V region CDRs had

30 been grafted, and the PCR product was purified using 2.5% low melting agarose gel. After digesting the PCR product with BamHI and HindIII, resulting BamHI-HindIII DNA fragment was subcloned into pUC19 and sequenced to obtain pUC-RV<sub>H</sub>-1220a.

35 It was revealed that DNA sequence coding for reshaped human AUK 12-20 antibody H chain V region contains a sequence well conforming to a splicing donor

00144885-071390



sequence, which may cause an abnormal splicing which was troublesome in the production of the reshaped human PM-1 antibody. Therefore, this DNA sequence was modified by PCR. Mutagenetic primers, SGI-SP1 (SEQ ID NO: 97) and SGI-SP2 (SEQ ID NO: 98) were synthesized. These primers convert the DNA sequence AAG GTG AGC to the DNA sequence AAA GTC AGC. Condition of PCR reaction was same as described above, except that 50 ng of pUC-RV<sub>H</sub>-1220a was used as a template DNA, and the SGI-SP1 and UNIVERSAL (SEQ ID NO: 82), or the SGI-SP2 and REVERS (SEQ ID NO: 83) were used as primers.

PCR products from two PCR reactions were purified by 2% low melting agarose gel and used in a PCR joining reaction. 98 µl of PCR reaction mixture containing 0.2 µg each of the first PCR products and 5 units of Vent DNA polymerase was incubated at 94°C for 2 minutes, at 55°C for 2 minutes and at 72°C for 5 minutes for a joining reaction. Next, 100 pmoles each of UNIVERSAL and REVERSE primers were added to the reaction mixture, which was then overlaid with 50 µl of mineral oil and subjected to 30 cycles of second PCR reaction consisting of incubations at 94°C for 1 minutes, at 50°C for 1 minute and at 72°C for 1 minute, followed by an incubations at 72°C for 10 minutes. DNA fragment of 495 bp obtained in the second PCR was purified by a 2.0% low melting agarose gel, and subcloned into pUC19 vector and sequenced to obtain pUC-RV<sub>H</sub>-1220a-2.

Next, HindIII-BamHI DNA fragment containing DNA coding for reshaped human AUK 12-20 antibody H chain V region was excised from the pUC-RV<sub>H</sub>-1220a-2, and inserted at HindIII-BamHI sites of an H chain expression vector HEF-12h-gyl to obtain an expression vector RV<sub>H</sub>-1220a for the reshaped human AUK 12-20 antibody H chain version "a".

For construction of genes coding for reshaped human AUK 12-20 antibody H chain V region versions "b" to "d",

two paires of mutagenic primers were synthesized. Each PCR reaction was carried out under substantially the same condition as described above. For construction of version "b", in two first PCR reactions, either UNIVERSAL primer (SEQ ID NO: 82) and mutagenic primer 120H-m1 (SEQ ID NO: 78), or REVERSE primer (SEQ ID NO: 83) and mutagenic primer 1220H-mlb (SEQ ID NO: 79), as well as pUC-RV<sub>H</sub>-1220a as a template were used. The first PCR products of 202 bp and 323 bp were purified by a 2.0% low melting agarose gel, and used in second PCR (including PCR joining reaction) under the same condition as described above to obtain a 495 bp product (version "b"). The product was digested with HindIII and BamHI, and subcloned into pUC19 vector to obtain pUC-RV<sub>H</sub>-1220b.

Similarly, mutagenic primer 1220H-m2 (SEQ ID NO: 80), 1220H-m2b (SEQ ID NO: 81) and a template pUC-RV<sub>H</sub>-1220a were used in a PCR to obtain a PCR product (version "c"). The product was digested with HindIII-BamHI and inserted at HindIII-BamHI sites of pUC19 vector to obtain pUC-RV<sub>H</sub>-1220c. Moreover, mutagenic primers 1220H-m1a (SEQ ID NO: 78), 1220H-mlb (SEQ ID NO: 79), and a template pUC-RV<sub>H</sub>-1220c were used to obtain a PCR Product (version "d"), which was then digested with HindIII and BamHI and inserted into HindIII-BamHI sites of pUC19 vector to obtain pUC-RV<sub>H</sub>-1220d.

Note, an amino acid sequence of the reshaped human AUK 12-20 antibody H chain V region version "b" and a nucleotide sequence coding therefor in the plasmid pUC-RV<sub>H</sub>-1220b is shown in SEQ No. 84; and an amino acid sequence of the reshaped human AUK 12-20 antibody H chain V region version "d" and a nucleotide sequence coding therefor in the plasmid pUC-RV<sub>H</sub>-1220d is shown in SEQ ID NO: 85.

Next, to construct the expression vectors, HindIII-BamHI fragments containing a reshaped human AUK 12-20 antibody H chain V region were excised from pUC-RV<sub>H</sub>-

5        Example 16.        Expression and analysis of various  
                                  versions of reshaped human AUK 12-20  
                                  antibody.

25           Example 17.       Construction of gene coding for  
                reshaped human sle 1220 antibody  
                H chain using human antibody HAX

A human antibody having the highest homology with the mouse monoclonal antibody AUK 12-20 H chain V region is HAX (J. Immunology (1987) 139:2496-2501; an antibody produced by hybridoma 21/28 derived from B cells of an SLE patient; its amino acid sequence is shown in Fig. 6, and nucleotide sequence therefor is shown in Figs. 4 and 5 of this literature), according to a protein data base "Leeds". Reshaped human sle 1220H antibody H chain V region was constructed using FRs of the antibody HAX

and CDRs of mouse monoclonal antibody AUK 12-20 H chain V region.

5 An entire DNA coding for a reshaped human sle 1220 H antibody H chain V region version "a" was chemically synthesized. DNA coding for sle 1220 H antibody H chain V region of an entire length 439 bp was designed by dividing the DNA into 6 oligonucleotides of 90 to 94 bp length overlapping each other by 21 bp (sle 1220 h 1 to 6; SEQ ID NOs: 86 to 91, respectively). In designing the  
10 oligonucleotides, secondary structure was tested and for sites having structural problems the third nucleotide in a codon was changed without change of amino acid encoded thereby. The relationship of these oligonucleotides and a process for construction of double-stranded synthetic  
15 DNA are shown in Fig. 20.

The reaction shown in Fig. 20 is carried out using PCR technique. Namely, 6 synthetic oligonucleotides were added to a single PCR reaction tube to carry out the first PCR reaction, thereby two oligonucleotides are  
20 annealed and extended, and further 4 oligonucleotides or an entire oligonucleotide are obtained.

Next, terminal primers A (SEQ ID NO: 92) and B (SEQ ID NO: 93) are added to carry out the second PCR reaction, wherein only a correct oligonucleotide having  
25 an entire length can be amplified. The resulting product is digested with BamHI and HindIII, and subcloned into pUC19 vector, followed by sequencing.

More specifically, 98 µl of a reaction mixture containing 100 mM tris-HCl (pH 8.5), 50mM KCl,  
30 0.1mM dATP, 0.1mM dGTP, 0.1mM dCTP, 0.1mM dTTP, 1.5mM MgCl<sub>2</sub> and 2.5 U of DNA polymerase AmpliTaq (Perkin Elmer Cetus) as well as 5 pmoles each of the oligonucleotides was denaturated at 94°C for 1.5 minutes and subjected to 3 cycles of reaction by incubation at  
35 92°C for 3 minutes, 50°C for 2 minutes and 72°C for 5 minutes, followed by an incubation at 72°C for 10

minutes. One  $\mu$ l each of 50 mM terminal primers A and B were added to the reaction mixture, which was then overlaid with 80  $\mu$ l of mineral oil, and after denaturation of 94°C for 1.5 minutes, subjected to 30 cycles of reaction by incubation at 94°C for 1 minute, 50°C for 1 minute and at 72°C for 1 minute, followed by an incubation at 72°C for 10 minutes. The PCR product of 439 bp was purified by a 1.5% low melting agarose gel, digested with restriction enzymes BamHI HindIII, and subcloned into pUC19 vector, followed by confirmation of sequence. A clone thus obtained was designated pUC-RV<sub>H</sub>-sle 1220Ha. An amino acid sequence of reshaped human sle 1220H antibody H chain V region version "a" and a nucleotide coding therefor in the plasmid pUC-RV<sub>H</sub>-sle 1220Ha are shown in SEQ ID NO: 94.

Next, HindIII-BamHI DNA fragment containing a gene coding for reshaped human 12-20 (sle 1220H) antibody H chain V region was excised from the pUC-RV<sub>H</sub>-sle 1220Ha and inserted at HindIII-BamHI sites of an H chain expression vector HEF-12h-gyl to obtain RV<sub>H</sub>-sle 1220Ha.

For construction of version "b" to "d" of reshaped human sle 1220H antibody H chain V region, two mutagenic primers sle 1220Hm1 (SEQ ID NO 95) and sle 1220Hm2 (SEQ ID NO: 96) were synthesized. In each PCR, Vent DNA polymerase and reaction mixture composition described in Example 13 were use. In each PCR reaction, a reaction mixture containing pUC-RV<sub>H</sub>-sle 1220Ha as template, 50 pmoles of a mutagenic primer sle 1220Hm1 or sle 1220Hm2, and 50 pmoles of the terminal primer B was denaturated at 94°C for 1.5 minutes, and subjected to 30 cycles of reaction by incubation at 94°C for 1 minute, at 50°C for 1 minute and at 72°C for 1 minute, followed by an incubation at 72°C for 10 minutes. The product of 235 bp or 178 bp was purified by a 1.5% low melting agarose gel to use as a primer in the second PCR reaction. Namely the second PCR reaction was carried out using 50 pmoles

of the terminal primer A, 0.2 µg of the PCR product and pUC-RV<sub>H</sub>-sle 1220Ha as a template, and resulting product of 439 bp was purified by a 1.5% low melting agarose gel, digested with BamHI and HindIII, and subcloned into pUC19 vector to obtain pUC-RV<sub>H</sub>-sle 1220Hb or pUC-RV<sub>H</sub>-sle 1220Hc, which encodes reshaped human sle 1220 antibody H chain V region version "b" or "c", respectively.

A DNA coding for reshaped human sle 1220 H antibody H chain V region version "d" was constructed also follow. As a template pUC-RV<sub>H</sub>-sle 1220Hb was used. 50 pmoles each of a mutagenic primer sle 1220Hm2 and the terminal primer B was used to carry out 30 cycles of the first PCR reaction. Resulting 176bp PCR product was purified on a 1.6% low melting agarose gel to use as a primer in the second PCR. This primer and 50p moles of the terminal primer A was used in the second PCR to obtain a 439 bp DNA fragment. The PCR product thus obtained was purified, digested with BamHI and HindIII, and subcloned into pUC 19 vector to obtain pUC-RV<sub>H</sub>-sle 1220Hd.

Next, to construct expression vectors for various versions of reshaped human sle 1220H antibody H chain V region, BamHI-HindIII fragments containing a DNA encoding reshaped human sle 1220 antibody H chain V region were excised from pUC-RV<sub>H</sub>-sle 1220Hb, pUC-RV<sub>H</sub>-sle 1220Hc and pUC-RV<sub>H</sub>-sle 1220Hd, and inserted into HindIII-BamHI sites of the H chain expression vector HEF-12h-gyl to obtain expression vectors RV<sub>H</sub>-sle 1220Hb, RV<sub>H</sub>-sle 1220Hc and RV<sub>H</sub>-sle 1220Hd respectively.

Each of four vectors expressing reshaped human sle 1220H antibody H chain (RV<sub>H</sub>-sle 1220Ha, RV<sub>H</sub>-sle 1220Hb and RV<sub>H</sub>-sle 1220Hc or RV<sub>H</sub>-sle 1220Hd) and the vector RV<sub>L</sub>-1220a expressing reshaped human AUK 12-20 antibody L chain were cotransfected to COS cells to evaluate the four versions of the reshaped human sle 1220H antibody H chain V region for an ability to

inhibit the binding of IL-6 to IL-6R. Results is shown in Figs. 21 to 24. Note, these result were obtained after purifying the produced antibodies by protein A.

As seen from the above, according to the present invention, in a chimeric L chain or a reshaped human L chain, or a chimeric H chain or a reshaped human H chain, and especially in RF, one or more than one amino acid can be replaced with other amino acid maintaining an ability to bind to human IL-6R. Therefore, the present invention includes chimeric antibody and reshaped human antibody, chimeric L chain and reshaped human L chain, chimeric H chain and reshaped human H chain, reshaped L chain V region, and reshaped H chain V region, wehre in one or more than one amino acid is replaced with other as well as DNA coding therefor, as far as they maintain their native property.

Starting hybridomas used in the present invention were constructed as follows.

|    |                            |                                  |
|----|----------------------------|----------------------------------|
| 20 | <u>Reference Example 1</u> | <u>Construction of Hybridoma</u> |
|    |                            | <u>MT18</u>                      |

To construct a hybridoma producing monoclonal antibody to human IL-6R, as an immunogen, a mouse T cell line expressing human IL-6R on the cell surface was constructed as follows. Namely, a plasmid pBSF2R.236 disclosed in Japanese Patent Application No. H1-9774 and pSV2neo was transfected into a mouse T cell line CTLL-2 (ATCC TIB214) according to a conventional procedure, and the resultant transformant was screened using G418 according to a conventional procedure to obtain a cell line expressing about 30,000 IL-6Rs per cell. This cell line was designated CTBC3.

The CTBC3 cells were cultured in RPMI 1640 according to a conventional procedure, the cultured cells were washed four times with PBS buffer, and  $1 \times 10^7$  cells were intraperitoneally injected to C57BL/6 mice for immunization. The immunization was carried out once a

week for 6 weeks.

Spleen cells were obtained from the immunized mice and fused with myeloma P3U1 cells using polyethylene glycol according to a conventional procedure, and the fused cells were screened as follows. The IL-6R negative human T cell line JURKAT (ATCC CRL 8163) was co-transfected with the plasmids pBSF2R.236 and pSV2neo, and transformed cells were screened to obtain a cell line expressing about 100,000 IL-6Rs per cell. The cell line was designated NJBC8. A hybridoma cell clone producing an antibody which recognized NP40-lysed NJBC8 but did not recognize NP40-lysed JURKAT was cloned and designated MT18. The hybridoma MT18 was deposited with the Fermentation Research Institute Agency of Industrial Science and Technology (FRI), under the Budapest Treaty, as FERM BP-2999 on July 10, 1990.

Reference Example 2

Construction of Hybridoma  
PM1

To construct a hybridoma producing monoclonal antibody to the IL-6R, as an antigen, human IL-6R was extracted as follows.  $3 \times 10^9$  human myeloma U266 cells (IL-6R-producing cells) were lysed in 1 ml of 1% digitonin, 10 mM triethanolamine buffer (pH 7.4), 0.15 M NaCl and 1 mM PMSF (phenylmethylsulfonyl fluoride; Wako Pure Chemicals). On the other hand, an MT18 antibody produced by the MT18 hybridoma prepared in Reference Example 1 was bonded to cyanogen bromide-activated Sepharose 4B (Pharmacia) according to a conventional procedure. This MT18 antibody-conjugated Sepharose 4B was mixed with the above-prepared cell lysate to bind the solubilized IL-6R to the MT18 antibody on Sepharose 4B. Substances non-specifically bonded to the Sepharose 4B were washed off, and the IL-6R bound to Sepharose 4B via the MT18 antibody was used as an immunogen.

BALB/c mice were intraperitoneally immunized with the above-prepared immunogen, once a week for 4 weeks.

0511285-07398  
SECRET



Next, spleen cells were obtained from the immunized mice, and fused with myeloma cells P3U1 using polyethylene glycol according to a conventional procedure. The fused cells were screened as follows. First, a culture supernatant and 0.01 ml of Protein G Sepharose (Pharmacia) were mixed to adsorb immunoglobulin in the supernatant to the Protein G Sepharose. On the other hand,  $10^7$  U266 cells internally labeled with  $^{35}\text{S}$ -methionine were lysed, and the IL-6R was affinity-purified using the MT18-conjugated Sepharose 4B. Next, the  $^{35}\text{S}$ -methionine-labeled IL-6R was immunoprecipitated with the above-prepared Protein G Sepharose on which an immunoglobulin had been bonded, and the precipitate was analyzed by SDS/PAGE. As a result, one hybridoma clone producing antibody which specifically bound to the IL-6R was isolated, and designated PM1. The hybridoma PM1 was deposited with the FRI under the Budapest Treaty as FERM BP-2998, on July 10, 1990.

Reference Example 3

Construction of Hybridoma  
AUK12-20, AUK64-7 and  
AUK146-15

As an immunogen, a soluble IL-6R (SR 344) was prepared according to a procedure described by Yasukawa, K. et al., J. Biochem. 108, 673-676, 1990. Namely, a plasmid pECEdhfr 344 containing a cDNA coding for IL-6R wherein the 345th codon from the N-terminus had been replaced by a stop codon was transfected to CHO (5E27) cells, the transfected cells were cultured in a serum-free medium (SF-O medium, Sanko Junyaku), and a resulting supernatant was concentrated with an HF-Lab1 system (Tosoh), and purified by Blue-5PW column and Phenyl-5PW column. The purified soluble IL-6R showed a single band in an SDS-PAGE.

A female BALB/cAnNCrj mouse (Nippon CREA) was subcutaneously injected with 10  $\mu\text{g}$ /mouse of the immunogen

in Freund's complete adjuvant (Bacto Adjuvant Complete H 37 Ra, Difco), followed by the second and third injections of the same amount of the immunogen in Freund's incomplete adjuvant (Bacto Adjuvant Incomplete Freund, Difco) two and three weeks after the first injection, respectively. A final immunization (the fourth injection) was carried out without adjuvant into a tail vein one week after the third injection. A serum sample was prepared from the immunized mice, serially diluted with a dilution buffer, and assayed by ELISA according to a procedure described by Goldsmith, P.K., Analytical Biochemistry, 117, 53-60, 1981. Namely, an SR344 (0.1  $\mu$ /ml)-coated plate was blocked with 1% BSA, and the diluted sample was added thereon. Mouse IgG bound to the SR344 was measured using goat anti-mouse IgG/alkaline phosphatase (A/P) (ZYMED) and a substrate for alkaline phosphatase (Sigma-104).

After confirming an increase of the anti-SR344 antibody in the serum, spleen cells were obtained from 5 BALB/c mice three days after the final immunization. The spleen cells and myeloma cells (P3U1) were mixed at a ratio of 25 : 1, fused using PEG1500, and cultured in 2000 wells at a cell concentration of 0.7 to  $1.1 \times 10^6$  cells/well. Supernatants from the wells were screened for their ability to bind SR344 (the first screening designated as R344 recognition assay), and for their ability to inhibit a binding of SR344 with an interleukin-6 by a IL-6/sIL-6R binding inhibition assay (RBIA). The first screening provided 240 positive wells, and the second screening provided 36 positive wells.

The above-mentioned R344 recognition assay was carried out as follows. Goat anti-mouse Ig (Cappel) (1  $\mu$ g/ml)-coated plate (MaxiSorp, Nunc) was blocked with 1% BSA, and 100  $\mu$ l/well of hybridoma culture supernatant was added thereon, followed by an incubation at room temperature for one hour. After washing the plate, 20

µg/ml of SR344 was added to each well, and incubation was carried out at room temperature for one hour. The amount of SR344 captured by the immobilized antibody derived from the supernatant was determined by addition of rabbit anti-SR344 IgG (#2, 5 µg/ml), goat anti-rabbit IgG-alkaline phosphatase (A/P) (1:3000, Tago), and of a substrate (1 mg/ml, Sigma-104), followed by measurement of the optical density at 405-600 nm.

The above-mentioned RBIA was carried out as follows. MT18 antibody-coated plate was filled with 100 µg/ml of SR344 (100 µl/well), and incubation was carried out at a room temperature for one hour. After washing the plate, 50 µl/well of hybridoma supernatant and 50 µg/well of biotin-interleukin-6 conjugate (20 µg/ml) were simultaneously added to each well, and the wells were incubated at room temperature for one hour. An amount of biotin-IL-6 bound to SR344 was measured by an addition of streptavidin-A/P (1 : 7000, PIERCE) and a corresponding substrate (Sigma-104), followed by a measurement of the optical density at 405-600 nm.

Finally, positive clones were purified by a twice-repeated limiting dilution method, and three hybridoma clones, i.e., AUK12-20, AUK145-15 and AUK64-7, which inhibit the binding of SR344 with the IL-6; and a hybridoma clone AUK181-6, which does not inhibit the binding of SR344 with the IL-6, were obtained.

#### Industrial Applicability

The present invention provides a reshaped human antibody to the human IL-6R, comprising a human antibody wherein the CDRs of the human V regions are replaced with the CDRs of a mouse monoclonal antibody to the human IL-6R. Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less antigenic, the present reshaped human antibody is less immunogenic to human, and therefore is promised for therapeutic uses.

Reference to Deposited Microorganisms under Rule 13-  
2 of Budapest Treaty

5                    Depository Authority: National Collections of  
                     Industrial and Marine Bacteria Limited  
                     Address: 23 St Macher Drive, Aberdeen AB2 1RY,  
                                 UNITED KINGDOM

|    | Identification of<br>Microorganism    | Deposition No. | Deposition Date |
|----|---------------------------------------|----------------|-----------------|
| 10 | <u>E. Coli</u> DH5 $\alpha$ , pPM-h1  | NCIMB 40362    | Feb. 12, 1991   |
|    | <u>E. Coli</u> DH5 $\alpha$ , p12-h2  | NCIMB 40363    | Feb. 12, 1991   |
|    | <u>E. Coli</u> DH5 $\alpha$ , p64-h2  | NCIMB 40364    | Feb. 12, 1991   |
|    | <u>E. Coli</u> DH5 $\alpha$ , p146-h1 | NCIMB 40365    | Feb. 12, 1991   |
|    | <u>E. Coli</u> DH5 $\alpha$ , pPM-k3  | MCIMB 40366    | Feb. 12, 1991   |
| 15 | <u>E. Coli</u> DH5 $\alpha$ , p12-k2  | NCIMB 40367    | Feb. 12, 1991   |
|    | <u>E. Coli</u> DH5 $\alpha$ , p64-k4  | NCIMB 40368    | Feb. 12, 1991   |
|    | <u>E. Coli</u> DH5 $\alpha$ , p146-k3 | NCIMB 40369    | Feb. 12, 1991   |

20                    Depository Authority: Fermentation Research  
                                 Institute, Agency of industrial  
                                 Science and Technology  
                     Address: 103, Higashi 1-chome Tsukuba-shi Ibaraki  
                                 Japan

|    | Identification of<br>Microorganism | Deposition No. | Deposition Date |
|----|------------------------------------|----------------|-----------------|
| 25 | MT 18                              | FERM BP-2999   | July 10, 1990   |
|    | PM 1                               | FERM BP-2998   | July 10, 1990   |

SEQ. ID NO : 1

SEQUENCE LENGTH : 40

SEQUENCE TYPE : Nucleic acid

STRANDEDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

## SEQUENCE

ACTAGTCGAC ATGAAGTTGC CTGTTAGGCT GTTGGTGCTG

40

SEQ. ID NO : 2

SEQUENCE LENGTH : 39

SEQUENCE TYPE : Nucleic acid

STRANDEDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

## SEQUENCE

ACTAGTCGAC ATGGAGWCAG ACACACTCCT GYTATGGGT

39

SEQ. ID NO : 3

SEQUENCE LENGTH : 40

SEQUENCE TYPE : Nucleic acid

STRANDEDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

## SEQUENCE

ACTAGTCGAC ATGAGTGTGC TCACTCAGGT CCTGGSGTTG

40

43

40

37

SEQ. ID NO : 7

SEQUENCE LENGTH : 41

SEQUENCE TYPE : Nucleic acid

STRANDEDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

ACTAGTCGAC ATGGGCWTCA AGATGGAGTC ACAKWYYCWG G

41

SEQ. ID NO : 8

SEQUENCE LENGTH : 41

SEQUENCE TYPE : Nucleic acid

STRANDEDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

ACTAGTCGAC ATGTGGGGAY CTKITTYCMM TTTTCAATT G

41

SEQ. ID NO : 9

SEQUENCE LENGTH : 35

SEQUENCE TYPE : Nucleic acid

STRANDEDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

ACTAGTCGAC ATGGTRTCCW CASCTCAGTT CCTTG

35

09114505 1074390

37

38

27



37

36

37

35

40

37

SEQUENCE LENGTH : 36

SEQUENCE TYPE : Nucleic acid

STRANDEDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

## SEQUENCE

ACTAGTCGAC ATGGRATGGA GCKGGRTCTT TMTCTT

36

SEQ. ID NO : 20

SEQUENCE LENGTH : 33

SEQUENCE TYPE : Nucleic acid

STRANDEDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

## SEQUENCE

ACTAGTCGAC ATGAGAGTGC TGATTCTTTT GTG

33

SEQ. ID NO : 21

SEQUENCE LENGTH : 40

SEQUENCE TYPE : Nucleic acid

STRANDEDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

## SEQUENCE

ACTAGTCGAC ATGGMTTGGG TGTGGAMCTT GCTATTCCCTG

40

SEQ. ID NO : 22

SEQUENCE LENGTH : 37

SEQUENCE TYPE : Nucleic acid

STRANDEDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

ACTAGTCGAC ATGGGCAGAC TTACATTCTC ATTCCTG

37

SEQ. ID NO : 23

SEQUENCE LENGTH : 28

SEQUENCE TYPE : Nucleic acid

STRANDEDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GGATCCCGGG CCAGTGGATA GACAGATG

28

SEQ. ID NO : 24

SEQUENCE LENGTH : 393

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Double

TOPOLOGY : Linear

MOLECULE TYPE : cDNA

ORIGINAL SOURCE

ORGANISM : Mouse

09114285 074300

80                      85                      90

CAG CAC AGT AGG GAG AAT CCG TAC ACG TTC GGA GGG GGG ACC AAG CTG 384

Gln His Ser Arg Glu Asn Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu

95

100

105

GAA ATA AAA

393

Glu Ile Lys

110

SEQ. ID NO : 25

SEQUENCE LENGTH : 405

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Double

TOPOLOGY : Linear

MOLECULE TYPE : cDNA

ORIGINAL SOURCE

ORGANISM : Mouse

IMADIATE SOURCE

CLONE : p12-h2

FEATURE : 1..57 sig peptide

58..405 mat peptide

SEQUENCE

ATG GGA TGG AGC GGG ATC TTT CTC TTC CTT CTG TCA GGA ACT GCA GGT 48

Met Gly Trp Ser Gly Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly

-15

-10

-5

GTC CAC TCT GAG ATC CAG CTG CAG CAG TCT GGA CCT GAG CTG ATG AAG 96

Val His Ser Glu Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Met Lys

-1

5

10

001403 0733  
0524 0733

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| CCT GGG GCT TCA GTG AAG ATA TCC TGC AAG GCT TCT GGT TAC TCA TTC | 144 |
| Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe |     |
| 15 20 25                                                        |     |
| ACT AGC TAT TAC ATA CAC TGG GTG AAG CAG AGC CAT GGA AAG AGC CTT | 192 |
| Thr Ser Tyr Tyr Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu |     |
| 30 35 40 45                                                     |     |
| GAG TGG ATT GGA TAT ATT GAT CCT TTC AAT GGT GGT ACT AGC TAC AAC | 240 |
| Glu Trp Ile Gly Tyr Ile Asp Pro Phe Asn Gly Gly Thr Ser Tyr Asn |     |
| 50 55 60                                                        |     |
| CAG AAA TTC AAG GGC AAG GCC ACA TTG ACT GTT GAC AAA TCT TCC AGC | 288 |
| Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser |     |
| 65 70 75                                                        |     |
| ACA GCC TAC ATG CAT CTC AGC AGC CTG ACA TCT GAG GAC TCT GCA GTC | 336 |
| Thr Ala Tyr Met His Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val |     |
| 80 85 90                                                        |     |
| TAT TAC TGT GCA AGG GGG GGT AAC CGC TTT GCT TAC TGG GGC CAA GGG | 384 |
| Tyr Tyr Cys Ala Arg Gly Gly Asn Arg Phe Ala Tyr Trp Gly Gln Gly |     |
| 95 100 105                                                      |     |
| ACT CTG GTC ACT GTC TCT GCA                                     | 405 |
| Thr Leu Val Thr Val Ser Ala                                     |     |
| 110 115                                                         |     |

SEQ. ID NO : 26

SEQUENCE LENGTH : 381

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Double

TOPOLOGY : Linear

ORIGINAL SOURCE

IMADIATE SOURCE

FEATURE : 1..60 sig peptide

61..381 mat peptide

## SEQUENCE

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| ATG GTG TCC TCA GCT CAG TTC CTT GGT CTC CTG TTG CTC TGT TTT CAA | 48  |
| Met Val Ser Ser Ala Gln Phe Leu Gly Leu Leu Leu Cys Phe Gln     |     |
| -20 -15 -10 -5                                                  |     |
| GGT ACC AGA TGT GAT ATC CAG ATG ACA CAG ACT ACA TCC TCC CTG TCT | 96  |
| Gly Thr Arg Cys Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser |     |
| 1 5 10                                                          |     |
| GCC TCT CTG GGA GAC AGA GTC ACC ATC AGT TGC AGG GCA AGT CAG GAC | 144 |
| Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp |     |
| 15 20 25                                                        |     |
| ATT AGC AGT TAT TTA AAC TGG TAT CAG CAG AAA CCA GAT GGA ACT ATT | 192 |
| Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Ile |     |
| 30 35 40                                                        |     |
| AAA CTC CTG ATC TAC TAC ACA TCA AGA TTA CAC TCA GGA GTC CCA TCA | 240 |
| Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser |     |
| 45 50 55 60                                                     |     |
| AGG TTC AGT GGC AGT GGG TCT GGA ACA GAT TAT TCT CTC ACC ATT AAC | 288 |
| Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Asn |     |
| 65 70 75                                                        |     |



Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn

90

Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Asn

105

SEQUENCE LENGTH : 411

SEQUENCE TYPE : Nucleic acid

STRANDEDNESS : Double

TOPOLOGY : Linear

STRANDNESS : Double

MOLECULE TYPE : cDNA

ORIGINAL SOURCE

ORGANISM : Mouse

IMADIATE SOURCE

CLONE : pPM-h1

FEATURE : 1..54 sig peptide

55..411 mat peptide

## SEQUENCE

ATG AGA GTG CTG ATT CTT TTG TGG CTG TTC ACA GCC TTT CCT GGT ATC 48

Met Arg Val Leu Ile Leu Leu Trp Leu Phe Thr Ala Phe Pro Gly Ile

-5

CTG TCT GAT GTG CAG CTT CAG GAG TCG GGA CCT GTC CTG GTG AAG CCT 96

Leu Ser Asp Val Gln Leu Gln Glu Ser Gly Pro Val Leu Val Lys Pro

10

115

SEQUENCE LENGTH : 393

STRANDNESS : Double

TOPOLOGY : Linear

MOLECULE TYPE : cDNA

ORIGINAL SOURCE

ORGANISM : Mouse

IMADIATE SOURCE

CLONE : p64-k4

FEATURE : 1..60 sig peptide

61..393 mat peptide

SEQUENCE

ATG GAG TCA GAC ACA CTC CTG CTA TGG GTG CTG CTG CTC TGG GTT CCA 48  
Met Glu Ser Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro  
-20 -15 -10 -5  
GGT TCC ACA GGT GAC ATT GTG TTG ATC CAA TCT CCA GCT TCT TTG GCT 96  
Gly Ser Thr Gly Asp Ile Val Leu Ile Gln Ser Pro Ala Ser Leu Ala  
-1 5 10  
GTG TCT CTA GGG CAG AGG GCC ACC ATA TCC TGC AGA GCC AGT GAA AGT 144  
Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser  
15 20 25  
GTT GAT AGT TAT GGC AAT AGT TTT ATG CAC TGG TAC CAG CAG AAA CCA 192  
Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro  
30 35 40  
GGA CAG CCA CCC AAA CTC CTC ATC TAT CGT GCA TCC AAC CTA GAA TCT 240  
Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser  
45 50 55 60  
GGG ATC CCT GCC AGG TTC AGT GGC AGT GGG TCT AGG ACA GAC TTC ACC 288  
Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr  
65 70 75

-5

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| GTC CAC TCC CAG GTT CAA TTG CAG CAG TCT GGA GCT GAG TTG ATG AAG | 96  |
| Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys |     |
| -1 5 10                                                         |     |
| CCT GGG GCC TCA GTG AAG ATC TCC TGC AAG GCT ACT GGC TAC ACA TTC | 144 |
| Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe |     |
| 15 20 25                                                        |     |
| AGT AGT TAT TGG ATA GTG TGG ATA AAG CAG AGG CCT GGA CAT GGC CTT | 192 |
| Ser Ser Tyr Trp Ile Val Trp Ile Lys Gln Arg Pro Gly His Gly Leu |     |
| 30 35 40 45                                                     |     |
| GAG TGG ATT GGA GAG ATT TTA CCT GGA ACC GGT AGT ACT AAC TAC AAT | 240 |
| Glu Trp Ile Gly Glu Ile Leu Pro Gly Thr Gly Ser Thr Asn Tyr Asn |     |
| 50 55 60                                                        |     |
| GAG AAA TTC AAG GGC AAG GCC ACA TTC ACT GCA GAT ACA TCT TCC AAC | 288 |
| Glu Lys Phe Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn |     |
| 65 70 75                                                        |     |
| ACA GCC TAC ATG CAA CTC AGC AGC CTG ACA TCT GAG GAC TCT GCC GTC | 336 |
| Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val |     |
| 80 85 90                                                        |     |
| TAT TAC TGT GCA AGT CTA GAC AGC TCG GGC TAC TAT GCT ATG GAC TAT | 384 |
| Tyr Tyr Cys Ala Ser Leu Asp Ser Ser Gly Tyr Tyr Ala Met Asp Tyr |     |
| 95 100 105                                                      |     |
| TGG GGT CAA GGA ACC TCA GTC ACC GTC TCC TCA                     | 417 |
| Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser                     |     |
| 110 115 120                                                     |     |

SEQ. ID NO : 30

SEQUENCE LENGTH : 381

0044285 07330

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Double

TOPOLOGY : Linear

MOLECULE TYPE : cDNA

ORIGINAL SOURCE

ORGANISM : Mouse

IMADIATE SOURCE

CLONE : p146-k3

FEATURE : 1..60 sig peptide

61..381 mat peptide

SEQUENCE

ATG GTG TCC ACA CCT CAG TTC CTT GGT CTC CTG TTG ATC TGT TTT CAA 48  
Met Val Ser Thr Pro Gln Phe Leu Gly Leu Leu Leu Ile Cys Phe Gln  
-20 -15 -10 -5  
GGT ACC AGA TGT GAT ATC CAG ATG ACA CAG ACT ACA TCC TCC CTG TCT 96  
Gly Thr Arg Cys Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser  
-1 5 10  
GCC TCT CTG GGA GAC AGA GTC ACC ATC AGT TGC AGG GCA AGT CAG GAC 144  
Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp  
15 20 25  
ATT AGT AAT TAT TTA AAC TGG TAT CAA CAG AAA CCA GAT GGA ACT GTT 192  
Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val  
30 35 40  
AAA CTC CTG ATC TAC TAT ACA TCA AGA TTA CAC TCA GGA GTC CCA TCA 240  
Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser  
45 50 55 60

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| AGG TTC AGT GGC AGT GGG TCT GGA ACA CAT TAT TCT CTC ACC ATT AGC | 288 |
| Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser |     |
| 65 70 75                                                        |     |
| AAC CTG GAG CAA GAA GAT ATT GCC AGT TAC TTT TGC CAA CAG GGT TAT | 336 |
| Asn Leu Glu Gln Glu Asp Ile Ala Ser Tyr Phe Cys Gln Gln Gly Tyr |     |
| 80 85 90                                                        |     |
| ACG CCT CCG TGG ACG TTC GGT GGA GGC ACC AAG TTG GAA ATC AAA     | 381 |
| Thr Pro Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys     |     |
| 95 100 105                                                      |     |

SEQ. ID NO : 31

SEQUENCE LENGTH : 402

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Double

TOPOLOGY : Linear

MOLECULE TYPE : cDNA

ORIGINAL SOURCE

ORGANISM : Mouse

IMADIATE SOURCE

CLONE : p146-h1

FEATURE : 1..51 sig peptide

52..402 mat peptide

SEQUENCE

|                                                                 |    |
|-----------------------------------------------------------------|----|
| ATG GAG CTG GAT CTT TAT CTT ATT CTG TCA GTA ACT TCA GGT GTC TAC | 48 |
| Met Glu Leu Asp Leu Tyr Leu Ile Leu Ser Val Thr Ser Gly Val Tyr |    |

-15

-10

-5

0014485 071990

115



35

36

35

SEQ. ID NO : 35

SEQUENCE LENGTH : 36

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GTTGGATCCA CTCACCTGCA GAGACAGTTA CCAGAG

36

SEQ. ID NO : 36

SEQUENCE LENGTH : 35

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

CTTGGATCCA CTCACGATTT ATTTCCAGCT TGGTC

35

SEQ. ID NO : 37

SEQUENCE LENGTH : 35

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

CTTGGATCCA CTCACGTTTT ATTTCCAGCT TGGTC

35

001496-0739

36

39

36

SEQ. ID NO : 41

SEQUENCE LENGTH : 17

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

TACGCAAACC GCCTCTC

17

SEQ. ID NO : 42

SEQUENCE LENGTH : 18

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GAGTGCACCA TATGCGGT

18

SEQ. ID NO : 43

SEQUENCE LENGTH : 55

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

ACCGTGTCTG GCTACACCTT CACCAGCGAT CATGCCTGGA GCTGGGTGAG ACAGC

55

09141265 071358



SEQ. ID NO : 47

SEQUENCE LENGTH : 24

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GGTGTCCACT CCGATGTCCA ACTG

24

SEQ. ID NO : 48

SEQUENCE LENGTH : 27

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GGTCTTGAGT GGATGGGATA CATTAGT

27

SEQ. ID NO : 49

SEQUENCE LENGTH : 29

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GTGTCTGGCT ACTCAATTAC CAGCATCAT

29

001140001 0717390

48

42

50

SEQ. ID NO : 53

SEQUENCE LENGTH : 27

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

AGCGGTACCG ACTACACCTT CACCATC

27

SEQ. ID NO : 54

SEQUENCE LENGTH : 706

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Double

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

ORIGINAL SOURCE

ORGANISM : Mouse and Human

IMADIATE SOURCE

CLONE : pUC-RVh-PM1f

FEATURE : gene coding for H chain V region version (f) of reshaped

human PM-1 antibody to human IL-6R

amino acid -20--1: leader

amino acid 1-30: FR1

amino acid 31-36: CDR1

amino acid 37-50: FR2

amino acid 51-66: CDR2

amino acid 67-98: FR3



amino acid 99-108:CDR3

amino acid 109-119:FR4

nucleotide 1 - 6 Hind III site

nucleotide 54-135 intron

nucleotide 258-348 intron/aberrant splicing

nucleotide 505-706 intron

nucleotide 701-706 Bam HI site

# SEQUENCE

AAGCTTC ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA GCA ACA GCT 49

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala

-15

-10

ACA G GTAAGGGGCT CACAGTAGCA GGCTTGAGGT CTGGACATAT ATATGGGTGA 103

Thr

-5

CAATGACATC CACTTTGCCT TTCTCTCCAC AG GT GTC CAC TCC CAG GTC CAA 155

Gly Val His Ser Gln Val Gln

1

CTG CAG GAG AGC GGT CCA GGT CTT GTG AGA CCT AGC CAG ACC CTG AGC 203

Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Gln Thr Leu Ser

5

10

15

CTG ACC TGC ACC GTG TCT GGC TAC TCA ATT ACC AGC GAT CAT GCC TGG 251

Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asp His Ala Trp

20

25

30

35

AGC TGG GTG AGA CAG CCA CCT GGA CGA GGT CTT GAG TGG ATT GGA TAC 299

Ser Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile Gly Tyr

40

45

50

0014205-071399

ORGANISM : Mouse and Human

# IMADIATE SOURCE

CLONE : pUC-RV1-PM1a

FEATURE : gene coding for L chain V region version (a) of reshaped  
human PM-1 antibody to human IL-6R

amino acid -20- -1: leader

amino acid 1-23: FR1

amino acid 24-34: CDR1

amino acid 35-49: FR2

amino acid 50-56: CDR2

amino acid 57-88: FR3

amino acid 89-97: CDR3

amino acid 98-117:FR4

nucleotide 1-6 : Hind III site

nucleotide 54-135: intron

nucleotide 268-376: intron/aberrant splicing

nucleotide 469-506: intron

nucleotide 501-506: Bam HI site

## SEQUENCE

AAGCTTC ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA GCA ACA GCT 49

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala

-15

-10

ACA G GTAAGGGGCT CACAGTAGCA GCCTTGAGGT CTGGACATAT ATATGGGTGA 103

Thr

-5

CAATGACATC CACTTTGCCT TTCTCTCCAC AG GT GTC CAC TCC GAC ATC CAG 155

Gly Val His Ser Asp Ile Gln

ATG ACC CAG AGC CCA AGC AGC CTG AGC GCC AGC GTG GGT GAC AGA GTG 203  
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val  
5 10 15  
ACC ATC ACC TGT AGA GCC AGC CAG GAC ATC AGC AGT TAC CTG AAT TGG 251  
Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Tyr Leu Asn Trp  
20 25 30 35  
TAC CAG CAG AAG CCA GGT AAG GCT CCA AAG CTG CTG ATC TAC TAC ACC 299  
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Tyr Thr  
40 45 50  
TCC AGA CTG CAC TCT GGT GTG CCA AGC AGA TTC AGC GGT AGC GGT AGC 347  
Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser  
55 60 65  
GGT ACC GAC TTC ACC TTC ACC ATC AGC AGC CTC CAG CCA GAG GAC ATC 395  
Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile  
70 75 80  
GCT ACC TAC TAC TGC CAA CAG GGT AAC ACG CTT CCA TAC ACG TTC GGC 443  
Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly  
85 90 95  
CAA GGG ACC AAG GTG GAA ATC AAA C GTGAGTAGAA TTAAACTTT 488  
Gln Gly Thr Lys Val Glu Ile Lys  
100 105  
GCTTCCTCAG TTGGATCC 506

SEQ. ID NO : 56

SEQUENCE LENGTH : 438

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Double

001425 071390

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

ORIGINAL SOURCE

ORGANISM : Mouse and Human

IMADIATE SOURCE

CLONE : pUC-RVh-PM1f-4

FEATURE : gene, excluding introns, coding for H chain V region

version (f) of reshaped human PM-1 antibody to human IL-6R

amino acid -20--1 : leader

amino acid 1 - 30 : FR1

amino acid 31 - 36 : CDR1

amino acid 37 - 50 : FR2

amino acid 51 - 66 : CDR2

amino acid 67 - 98 : FR3

amino acid 99 - 108 : CDR3

amino acid 109 - 119 : FR4

nucleotide 1 - 6 : Hind III site

nucleotide 432 - 438 : Bam HI site

SEQUENCE

AAGCTTCCAC C ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA GCA ACA 50

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr

-15

-10

GCT ACA GGT GTC CAC TCC CAG GTC CAA CTG CAG GAG AGC GGT CCA GGT 98

Ala Thr Gly Val His Ser Gln Val Gln Leu Gln Glu Ser Gly Pro Gly

-5

1

5

10

00142001 071300

|                                                                  |     |
|------------------------------------------------------------------|-----|
| CTT GTG AGA CCT AGC CAG ACC CTG AGC CTG ACC TGC ACC GTG TCT GGC  | 146 |
| Leu Val Arg Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly  |     |
| 15 20 25                                                         |     |
| TAC TCA ATT ACC AGC GAT CAT GCC TGG AGC TGG GTT CGC CAG CCA CCT  | 194 |
| Tyr Ser Ile Thr Ser Asp His Ala Trp Ser Trp Val Arg Gln Pro Pro  |     |
| 30 35 40                                                         |     |
| GGA CGA GGT CTT GAG TGG ATT GGA TAC ATT AGT TAT AGT GGA ATC ACA  | 242 |
| Gly Arg Gly Leu Glu Trp Ile Gly Tyr Ile Ser Tyr Ser Gly Ile Thr  |     |
| 45 50 55                                                         |     |
| ACC TAT AAT CCA TCT CTC AAA TCC AGA GTG ACA ATG CTG AGA GAC ACC  | 290 |
| Thr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Met Leu Arg Asp Thr  |     |
| 60 65 70                                                         |     |
| AGC AAG AAC CAG TTC AGC CTG AGA CTC AGC AGC GTG ACA GCC GCC GAC  | 338 |
| Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp  |     |
| 75 80 85 90                                                      |     |
| ACC GCG GTT TAT TAT TGT GCA AGA TCC CTA GCT CGG ACT ACG GCT ATG  | 386 |
| Thr Ala Val Tyr Tyr Cys Ala Arg Ser Leu Ala Arg Thr Thr Ala Met  |     |
| 95 100 105                                                       |     |
| GAC TAC TGG GGT CAA GGC AGC CTC GTC ACA GTC TCC TCA G GTGAGTGGAT | 436 |
| Asp Tyr Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser              |     |
| 110 115                                                          |     |
| CC                                                               | 438 |

SEQ. ID NO : 57

SEQUENCE LENGTH : 402

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Double

10

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| CTG AGC GCC AGC GTG GGT GAC AGA GTG ACC ATC ACC TGT AGA GCC AGC | 146 |
| Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser |     |
| 15 20 25                                                        |     |
| CAG GAC ATC AGC AGT TAC CTG AAT TGG TAC CAG CAG AAG CCA GGA AAG | 194 |
| Gln Asp Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys |     |
| 30 35 40                                                        |     |
| GCT CCA AAG CTG CTG ATC TAC TAC ACC TCC AGA CTG CAC TCT GGT GTG | 242 |
| Ala Pro Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val |     |
| 45 50 55                                                        |     |
| CCA AGC AGA TTC AGC GGT AGC GGT AGC GGT ACC GAC TTC ACC TTC ACC | 290 |
| Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr |     |
| 60 65 70                                                        |     |
| ATC AGC AGC CTC CAG CCA GAG GAC ATC GCT ACC TAC TAC TGC CAA CAG | 338 |
| Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln |     |
| 75 80 85 90                                                     |     |
| GGT AAC ACG CTT CCA TAC ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC | 386 |
| Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile |     |
| 95 100 105                                                      |     |
| AAA C GTGAGTGGAT CC                                             | 402 |
| Lys                                                             |     |

SEQ. ID NO : 58

SEQUENCE LENGTH : 36

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA



SEQUENCE

TAAGGATCCA CTCACCTGAG GAGACTGTGA CGAGGC

36

SEQ. ID NO : 59

SEQUENCE LENGTH : 32

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

ATCAAGCTTC CACCATGGGA TGGAGCTGTA TC

32

SEQ. ID NO : 60

SEQUENCE LENGTH : 30

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

AATGGATCCA CTCACGTTTG ATTTCCACCT

30

SEQ. ID NO : 61

SEQUENCE LENGTH : 33

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

66E120 5824760

SEQUENCE

CATGCCTGGA GCTGGGTTCC CCAGCCACCT GGA

33

SEQ. ID NO : 62

SEQUENCE LENGTH : 33

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

TCCAGGTGGC TGGCGAACCC AGCTCCAGGC ATG

33

SEQ. ID NO : 63

SEQUENCE LENGTH : 30

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

CAGCAGAAGC CAGGAAAGGC TCCAAAGCTG

30

SEQ. ID NO : 64

SEQUENCE LENGTH : 30

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

00114005-071240

SEQUENCE

CAGCTTTGGA GCCTTTCCTG GCTTCTGCTG

30

SEQ. ID NO : 65

SEQUENCE LENGTH : 66

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

ACCTGTAGAG CCAGCAAGAG TGTTAGTACA TCTGGCTATA GTTATATGCA

50

CTGGTACCAG CAGAAG

66

SEQ. ID NO : 66

SEQUENCE LENGTH : 15

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GCTGGCTCTA CAGGT

15

SEQ. ID NO : 67

SEQUENCE LENGTH : 48

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

091425 071349  
000000 000000

## SEQUENCE

48

MOLECULE TYPE : Synthetic DNA

## SEQUENCE

15

MOLECULE TYPE : Synthetic DNA

## SEQUENCE

48

TOPOLOGY : Linear

## SEQUENCE

15

SEQUENCE LENGTH : 414

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Double

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

ORIGINAL SOURCE

ORGANISM : Mouse and Human

IMADIATE SOURCE

CLONE : pUC-RV1-1220a

FEATURE : gene, excluding introns, coding for L chain V region version

(a) of reshaped human AUK12-20 antibody to human IL-6R

amino acid -19- -1:1 leader

amino acid 1 - 23 : FR1

amino acid 24-38 : CDR1

amino acid 39-53 : FR2

amino acid 54-60 : CDR2

amino acid 61-92: FR3

amino acid 93-101:CDR3

amino acid 102-111:FR4

nucleotide 1 - 6 : Hind III site

nucleotide 408-414: Bam HI site

SEQUENCE

|                                                                  |     |     |    |    |
|------------------------------------------------------------------|-----|-----|----|----|
| AAGCTTCCAC C ATG GGA TGG AGC TGT ATC ATC CTC TTC TTG GTA GCA ACA | 50  |     |    |    |
| Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr              |     |     |    |    |
| -15                                                              | -10 |     |    |    |
| GCT ACA GGT GTC CAC TCC GAC ATC CAG ATG ACC CAG AGC CCA AGC AGC  | 98  |     |    |    |
| Ala Thr Gly Val His Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser  |     |     |    |    |
| -5                                                               | -1  | 1   | 5  | 10 |
| CTG AGC GCC AGC GTG GGT GAC AGA GTG ACC ATC ACC TGT AGA GCC AGC  | 146 |     |    |    |
| Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser  |     |     |    |    |
| 15                                                               | 20  | 25  |    |    |
| AAG AGT GTT AGT ACA TCT GGC TAT AGT TAT ATG CAC TGG TAC CAG CAG  | 194 |     |    |    |
| Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln  |     |     |    |    |
| 30                                                               | 35  | 40  |    |    |
| AAG CCA GGA AAG GCT CCA AAG CTG CTG ATC TAC CTT GCA TCC AAC CTG  | 242 |     |    |    |
| Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu  |     |     |    |    |
| 45                                                               | 50  | 55  |    |    |
| GAA TCT GGT GTG CCA AGC AGA TTC AGC GGT AGC GGT AGC GGT ACC GAC  | 290 |     |    |    |
| Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp  |     |     |    |    |
| 60                                                               | 65  | 70  |    |    |
| TTC ACC TTC ACC ATC AGC AGC CTC CAG CCA GAG GAC ATC GCT ACC TAC  | 338 |     |    |    |
| Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr  |     |     |    |    |
| 75                                                               | 80  | 85  | 90 |    |
| TAC TGC CAG CAC AGT AGG GAG AAC CCA TAC ACG TTC GGC CAA GGG ACC  | 386 |     |    |    |
| Tyr Cys Gln His Ser Arg Glu Asn Pro Tyr Thr Phe Gly Gln Gly Thr  |     |     |    |    |
| 95                                                               | 100 | 105 |    |    |

00114285-074390

414

Lys Val Glu Ile Lys

110

SEQ. ID NO : 72

SEQUENCE LENGTH : 45

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

## SEQUENCE

GGTTATTCAT TCACTAGTTA TTACATACAC TGGGTTAGAC AGGCC

45

SEQ. ID NO : 73

SEQUENCE LENGTH : 27

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

## SEQUENCE

ACTGAATGAA TAACCGCTAG CTTTACA

27

SEQ. ID NO : 74

SEQUENCE LENGTH : 69

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GAGTGGGTGG GCTATATTGA TCCTTTCAAT GGTGGTACTA GCTATAATCA 50

GAAGTTCAAG GGCAGGGTT 69

SEQ. ID NO : 75

SEQUENCE LENGTH : 15

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

ATAGCCCACC CACTC 15

SEQ. ID NO : 76

SEQUENCE LENGTH : 36

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GGGGGTAACC GCTTTGCTTA CTGGGGACAG GGTACC 36

SEQ. ID NO : 77

SEQUENCE LENGTH : 36

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

0914255 071330



TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

AGCAAAGCGG TTACCCCTC TGGCGCAGTA GTAGAC

36

SEQ. ID NO : 78

SEQUENCE LENGTH : 30

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

CAAGGTTACC ATGACCGTGG ACACCTCTAC

30

SEQ. ID NO : 79

SEQUENCE LENGTH : 30

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

CACGGTCATG GTAACCTTGC CCTTGAAGTT

30

SEQ. ID NO : 80

SEQUENCE LENGTH : 30

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

00114285.07190

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GGGCTCGAAT GGATTGGCTA TATTGATCCT

30

SEQ. ID NO : 81

SEQUENCE LENGTH : 30

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

AGGATCAATA TAGCCAATCC ATTCGAGCCC

30

SEQ. ID NO : 82

SEQUENCE LENGTH : 16

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GTAAAACGAG GCCAGT

16

SEQ. ID NO : 83

SEQUENCE LENGTH : 17

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

0914285-074398

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

AACAGCTATG ACCATGA

17

SEQ. ID NO : 84

SEQUENCE LENGTH : 433

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Double

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

ORIGINAL SOURCE

ORGANISM : Mouse and Human

IMADIATE SOURCE

CLONE : pUC-RVh-1220b

FEATURE : gene, excluding intron, coding for H chain V region version

(b) of reshaped human AUK12-20 antibody to human IL-6R

amino acid -19--1:leader

amino acid 1 - 30 : FR1

amino acid 31 - 35 : CDR1

amino acid 36 - 49 : FR2

amino acid 50 - 66 : CDR2

amino acid 67 - 98 : FR3

amino acid 99 - 105:CDR3

amino acid 106 - 116:FR4

nucleotide 1 - 6 : Hind III site

nucleotide 427 - 433: Bam HI site

065720-5824759

SEQUENCE

|                                                                  |            |
|------------------------------------------------------------------|------------|
| AAGCTTGCCG CCACC ATG GAC TGG ACC TGG CGC GTG TTT TGC CTG CTC GCC | 51         |
| Met Asp Trp Thr Trp Arg Val Phe Cys Leu Leu Ala                  |            |
| -15                                                              | -10        |
| GTG GCT CCT GGG GCC CAC AGC CAG GTG CAA CTA GTG CAG TCC GGC GCC  | 99         |
| Val Ala Pro Gly Ala His Ser Gln Val Gln Leu Val Gln Ser Gly Ala  |            |
| -5                                                               | -1 1 5     |
| GAA GTG AAG AAA CCC GGT GCT TCC GTG AAA GTC AGC TGT AAA GCT AGC  | 147        |
| Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser  |            |
| 10                                                               | 15 20 25   |
| GGT TAT TCA TTC ACT AGT TAT TAC ATA CAC TGG GTT AGA CAG GCC CCA  | 195        |
| Gly Tyr Ser Phe Thr Ser Tyr Tyr Ile His Trp Val Arg Gln Ala Pro  |            |
| 30                                                               | 35 40      |
| GGC CAA GCG CTC GAG TGG GTG GGC TAT ATT GAT CCT TTC AAT GGT GGT  | 243        |
| Gly Gln Gly Leu Glu Trp Val Gly Tyr Ile Asp Pro Phe Asn Gly Gly  |            |
| 45                                                               | 50 55      |
| ACT AGC TAT AAT CAG AAG TTC AAG GGC AAG GTT ACC ATG ACC GTG GAC  | 291        |
| Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Val Thr Met Thr Val Asp  |            |
| 60                                                               | 65 70      |
| ACC TCT ACA AAC ACC GCC TAC ATG GAA CTG TCC AGC CTG CGC TCC GAG  | 339        |
| Thr Ser Thr Asn Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu  |            |
| 75                                                               | 80 85      |
| GAC ACT GCA GTC TAC TAC TGC GCC AGA GGG GGT AAC CGC TTT GCT TAC  | 387        |
| Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Asn Arg Phe Ala Tyr  |            |
| 90                                                               | 95 100 105 |

054433-07-370

TGG GGA CAG GGT ACC CTT GTC ACC GTC AGT TCA GGTGAGTGGG TCC 433

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser

110

115

SEQ. ID NO : 85

SEQUENCE LENGTH : 433

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Double

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

ORIGINAL SOURCE

ORGANISM : Mouse and Human

IMMEDIATE SOURCE

CLONE : pUC-RVh-1220d

FEATURE : gene, excluding intron, coding for H chain V region version

(d) of reshaped human antibody AUK12-20 to human IL-6R

amino acid -19- -1:leader

amino acid 1 - 30 : FR1

amino acid 31 - 35 : CDR1

amino acid 36 - 49 : FR2

amino acid 50 - 66 : CDR2

amino acid 67 - 98 : FR3

amino acid 99 - 105:CDR3

amino acid 106 - 116:FR4

nucleotide 1 - 6 : Hind III site

nucleotide 427 - 433: Bam HI site

052120" 8824T60

|                                                 |       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-------------------------------------------------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| AAGCTTGCCG                                      | CCACC | ATG | GAC | TGG | ACC | TGG | CGC | GTG | TTT | TGC | CTG | CTC | GCC | 51  |     |
| Met Asp Trp Thr Trp Arg Val Phe Cys Leu Leu Ala |       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| -15                                             |       |     |     |     |     |     | -10 |     |     |     |     |     |     |     |     |
| GTG                                             | GCT   | CCT | GGG | GCC | CAC | AGC | CAG | GTG | CAA | CTA | GTG | CAG | TCC | GGC | 99  |
| Val                                             | Ala   | Pro | Gly | Ala | His | Ser | Gln | Val | Gln | Leu | Val | Gln | Ser | Gly | Ala |
| -5                                              |       |     |     | -1  |     |     | 1   |     | 5   |     |     |     |     |     |     |
| GAA                                             | GTG   | AAG | AAA | CCC | GGT | GCT | TCC | GTG | AAA | GTC | AGC | TGT | AAA | GCT | 147 |
| Glu                                             | Val   | Lys | Lys | Pro | Gly | Ala | Ser | Val | Lys | Val | Ser | Cys | Lys | Ala | Ser |
| 10                                              |       | 15  |     |     |     |     | 20  |     |     |     |     | 25  |     |     |     |
| GGT                                             | TAT   | TCA | TTC | ACT | AGT | TAT | TAC | ATA | CAC | TGG | GTT | AGA | CAG | GCC | 195 |
| Gly                                             | Tyr   | Ser | Phe | Thr | Ser | Tyr | Tyr | Ile | His | Trp | Val | Arg | Gln | Ala | Pro |
| 30                                              |       |     |     |     | 35  |     |     |     |     | 40  |     |     |     |     |     |
| GGC                                             | CAA   | GGG | CTC | GAA | TGG | ATT | GGC | TAT | ATT | GAT | CCT | TTC | AAT | GGT | 243 |
| Gly                                             | Gln   | Gly | Leu | Glu | Trp | Ile | Gly | Tyr | Ile | Asp | Pro | Phe | Asn | Gly | Gly |
| 45                                              |       |     |     | 50  |     |     |     |     | 55  |     |     |     |     |     |     |
| ACT                                             | AGC   | TAT | AAT | CAG | AAG | TTC | AAG | GGC | AAG | GTT | ACC | ATG | ACC | GTG | 291 |
| Thr                                             | Ser   | Tyr | Asn | Gln | Lys | Phe | Lys | Gly | Lys | Val | Thr | Met | Thr | Val | Asp |
| 60                                              |       |     | 65  |     |     |     |     | 70  |     |     |     |     |     |     |     |
| ACC                                             | TCT   | ACA | AAC | ACC | GCC | TAC | ATG | GAA | CTG | TCC | AGC | CTG | CGC | TCC | 339 |
| Thr                                             | Ser   | Thr | Asn | Thr | Ala | Tyr | Met | Glu | Leu | Ser | Ser | Leu | Arg | Ser | Glu |
| 75                                              |       |     | 80  |     |     |     |     | 85  |     |     |     |     |     |     |     |
| GAC                                             | ACT   | GCA | GTC | TAC | TAC | TGC | GCC | AGA | GGG | GGT | AAC | CGC | TTT | GCT | 387 |
| Asp                                             | Thr   | Ala | Val | Tyr | Tyr | Cys | Ala | Arg | Gly | Gly | Asn | Arg | Phe | Ala | Tyr |
| 90                                              |       | 95  |     |     |     |     | 100 |     |     |     |     | 105 |     |     |     |

TGG GGA CAG GGT ACC CTT GTC ACC GTC AGT TCA GGTGAGTGGG TCC 433

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser

110

115

SEQ. ID NO : 86

SEQUENCE LENGTH : 90

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GATAAGCTTG CCGCCACCAT GGACTGGACC TGGAGGGTCT TCTTCTTGCT 50

GGCTGTAGCT CCAGGTGCTC ACTCCCAGGT GCAGCTTGTG 90

SEQ. ID NO : 87

SEQUENCE LENGTH : 90

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

CACTCCCAGG TGCAGCTTGT GCAGTCTGGA GCTGAGGTGA AGAAGCCTGG 50

GGCCTCAGTG AAGGTTTCCT GCAAGGCTTC TGGATACTCA 90

SEQ. ID NO : 88

SEQUENCE LENGTH : 90

SEQUENCE TYPE : Nucleic acid

20250324T60

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

## SEQUENCE

TGCAAGGCTT CTGGATACTC ATTCAGTAGT TATTACATAC ACTGGGTGGG 50

CCAGGCCCCC GGACAAAGGC TTGACTGGAT GGGATATATT 90

SEQ. ID NO : 89

SEQUENCE LENGTH : 90

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

## SEQUENCE

CTTCAGTGGG TGGGATATAT TGACCCCTTTC AATGGTGCTA CTAGCTATAA 50

TCAGAACTTC AAGGGCAGAG TCACCATTAC CGTAGACACA 90

SEQ. ID NO : 90

SEQUENCE LENGTH : 90

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

## SEQUENCE

GTCACCATTA CCGTAGACAC ATCCGCGAGC ACAGCCTACA TGGAGCTGAG 50

CAGCCTGAGA TCTGAAGACA CGGCTGTGTA TTA CTGTGCCG 90



SEQ. ID NO : 91

SEQUENCE LENGTH : 94

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

ACGGCTGTGT ATTACTGTGC GAGAGGGGGT AACCGCTTTG CTTACTGGGG 50

CCAGGGAACC CTGGTCACCG TCTCCTCAGG TGAGTGGATC CGAC 94

SEQ. ID NO : 92

SEQUENCE LENGTH : 15

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GATAAGCTTG CCGCC 15

SEQ. ID NO : 93

SEQUENCE LENGTH : 15

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GTCGGATCCA CTCAC 15

091425 071396

- 10

GTA GCT CCA GGT GCT CAC TCC CAG GTG CAG CTT GTG CAG TCT GGA GCT 99

Val Ala Pro Gly Ala His Ser Gln Val Gln Leu Val Gln Ser Gly Ala

-5 -1 1 5

GAG GTG AAG AAG CCT GGG GCC TCA GTG AAG GTT TCC TGC AAG GCT TCT 147

Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser

10 15 20 25

GGA TAC TCA TTC ACT AGT TAT TAC ATA CAC TGG GTG CGC CAG GCC CCC 195

Gly Tyr Ser Phe Thr Ser Tyr Tyr Ile His Trp Val Arg Gln Ala Pro

30 35 40

GGA CAA AGG CTT GAG TGG ATG GGA TAT ATT GAC CCT TTC AAT GGT GGT 243

Gly Gln Arg Leu Glu Trp Met Gly Tyr Ile Asp Pro Phe Asn Gly Gly

45 50 55

ACT AGC TAT AAT CAG AAG TTC AAG GGC AGA GTC ACC ATT ACC GTA GAC 291

Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Val Thr Ile Thr Val Asp

60 65 70

ACA TCC GCG AGC ACA GCC TAC ATG GAG CTG AGC AGT CTG AGA TCT GAA 339

Thr Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu

75 80 85

GAC ACG GCT GTG TAT TAC TGT GCG AGA GGG GGT AAC CGC TTT GCT TAC 387

Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Asn Arg Phe Ala Tyr

90 95 100 105

TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA GGTGAGTGA TCC 433

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser

110 115

SEQ. ID NO : 95

SEQUENCE LENGTH : 27

054420-034760

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

AGGCTTGAGT GGATTGGATA TATTGAC

27

SEQ. ID NO : 96

SEQUENCE LENGTH : 27

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

AAGTTCAAGG GCAAGGTCAC CATTACC

27

SEQ. ID NO : 97

SEQUENCE LENGTH : 30

SEQUENCE TYPE : Nucleic acid

STRANDNESS : Single

TOPOLOGY : Linear

MOLECULE TYPE : Synthetic DNA

SEQUENCE

GGTGCTTCCG TGAAAGTCAG CTGTAAAGCT

30

SEQ. ID NO : 98

SEQUENCE LENGTH : 30

00114685-1771798



CLAIMS

1. A light chain (L chain) variable region (V region) of mouse monoclonal antibody to the human interleukin-6 receptor (IL-6R).

5           2. An L chain V region according to claim 1, having an amino acid sequence shown in any one of SEQ ID NOs: 24, 26, 28 and 30.

3. A heavy chain (H chain) V region of a mouse monoclonal antibody to the human IL-6R.

10           4. An H chain V region according to claim 3, having an amino acid sequence shown in SEQ ID NOs: 25, 27, 29 and 31.

5. A chimeric antibody to the human IL-6R, comprising:

15           (1) an L chain comprising a human L chain constant region (C region) and an L chain V region of a mouse monoclonal antibody to the human IL-6R; and

            (2) an H chain comprising a human H chain C region and an H chain V region of a mouse monoclonal  
20 antibody to the human IL-6R.

6. A chimeric antibody according to claim 5, wherein the mouse L chain V region has an amino acid sequence shown in any one of SEQ ID NOs: 24, 26, 28 and 30; and the mouse H chain V region has an amino acid  
25 sequence shown in any one of SEQ ID NOs: 25, 27, 29 and 31.

7. Complementarity determining regions (CDRs) of an L chain V region of a mouse monoclonal antibody to the human IL-6R.

30           8. CDR according to claim 7, having amino acid sequence shown in any one of SEQ ID NOs: 24, 26, 28 and 30 wherein the stretch of the amino acid sequence is defined in Table 9.

9. CDR of an H chain V region of a mouse  
35 monoclonal antibody to the human IL-6R.

10. CDR according to claim 9, having amino acid sequence shown in any one of SEQ ID NOs: 25, 27, 29, and

04485-0739  
04485-0739

31 wherein the stretch of the amino acid sequence is defined in Table 9.

11. A reshaped human L chain V region of an antibody to the human IL-6R, comprising:

- 5                   (1) framework regions (FRs) of a human L chain V region, and  
                    (2) CDRs of an L chain V region of a mouse monoclonal antibody to the human IL-6R.

10           12. A reshaped human L chain V region according to claim 11, wherein the CDRs have amino acid sequences shown in any one of SEQ ID Nos.: 24, 26, 28 and 30 wherein the stretches of the amino acid sequences are defined in Table 9.

15           13. A reshaped human L chain V region according to claim 11, wherein the FRs are derived from the human antibody REI.

14. A reshaped human L chain V region according to claim 11, having an amino acid sequence shown as RV<sub>L</sub>a or RV<sub>L</sub>b in Table 2.

20           15. A reshaped human L chain V region according to claim 11, having an amino acid sequence shown as RV<sub>L</sub> in Table 5.

16. A reshaped human H chain V region of an antibody to the human IL-6R, comprising:

- 25                   (1) FRs of a human H chain V region, and  
                    (2) CDRs of an H chain V region of a mouse monoclonal antibody to the human IL-6R.

30           17. A reshaped human H chain V region according to claim 16, wherein the CDRs have amino acid sequences shown in SEQ ID NOs: 25, 27, 29 and 31 wherein the stretches of the amino acid sequences are defined in Table 9.

35           18. A reshaped human H chain V region according to claim 16, wherein the FRs are derived from the human antibody NEW or HAX.

19. A reshaped human H chain V region according to

0014205 074390

claim 16, having an amino acid sequence shown in Table 3 as RV<sub>H</sub>a, RV<sub>H</sub>b, RV<sub>H</sub>c, RV<sub>H</sub>d, RV<sub>H</sub>e or RV<sub>H</sub>f.

20. A reshaped human H chain V region according to claim 17, having an amino acid sequence shown as RV<sub>H</sub>a, RV<sub>H</sub>b, RV<sub>H</sub>c or RV<sub>H</sub>d in Table 7.

21. An L chain of a reshaped human antibody to human IL-6R comprising:

- (1) a human L chain C region; and
- (2) an L chain V region comprising human L chain FRs and L chain CDRs of mouse monoclonal antibody to human IL-6R.

22. A reshaped human antibody L chain according to claim 21, wherein the human L chain C region is a human  $\gamma$ -1C region, the human L chain FRs are derived from REI, and the L chain CDRs have amino acid sequences shown in SEQ ID Nos. 24, 26, 28 and 30 wherein the stretches of the amino acid sequences are defined in Table 9.

23. A reshaped human antibody L chain according to claim 21, wherein the L chain V region has an amino acid sequence shown as RV<sub>L</sub>a or RV<sub>L</sub>b in Table 2.

24. A reshaped human antibody L chain according to claim 21, wherein the L chain V region has an amino acid sequence shown as RV<sub>L</sub> in Table 5.

25. An H chain of a reshaped human antibody to human IL-6R comprising:

- (1) a human H chain C region, and
- (2) an H chain V region comprising human H chain FRs, and H chain CRDs of mouse monoclonal antibody to human IL-6.

26. A reshaped human antibody H chain according to claim 25, wherein the human H chain C region is human  $\kappa$ C region, the human H chain FRs are derived from NEW or HAX, the H chain CDRs have amino acid sequences shown in SEQ ID NOS: 25, 27, 29 or 31 wherein the stretches of the amino acid sequences are defined in Table 9.

27. A reshaped human antibody H chain according to



claim 25, wherein the H chain V region has an amino acid sequence shown as RV<sub>H</sub>a, RV<sub>H</sub>b, RV<sub>H</sub>c or RV<sub>H</sub>d in Table 3.

28. A reshaped human antibody H chain according claim 25, wherein the H chain V region has an amino acid sequence shown as RV<sub>H</sub>a, RV<sub>H</sub>b, RV<sub>H</sub>c or RV<sub>H</sub>d in Table 6, or RV<sub>H</sub>a, RV<sub>H</sub>b, RV<sub>H</sub>c or RV<sub>H</sub>c in Table 7.

29. A reshaped antibody to the human IL-6R, comprising:

- (A) an L chain comprising,
  - (1) a human L chain C region, and
  - (2) an L chain V region comprising human L chain FRs, and L chain CDRs of a mouse monoclonal antibody to the human IL-6R; and
- (B) an H chain comprising,
  - (1) a human H chain C region, and
  - (2) an H chain V region comprising human H chain FRs, and H chain CDRs of a mouse monoclonal antibody to the human IL-6R.

30. A reshaped human antibody according to claim 29, wherein the L chain CDRs have amino acid sequences shown in any one of SEQ ID NOs: 24, 26, 28 and 30 wherein the stretches of the amino acid sequences are defined in Table 9; the H chain CDRs have amino acid sequence shown in any one of SEQ ID NOs: 25, 27, 29 and 31 wherein the stretches of the amino acid sequences are defined in Table 9; the human L chain C region and human L chain FRs are derived from the REI; and the human H chain C region and human FRs are derived from the NEW or HAX.

31. A reshaped human antibody according to claim 29, wherein the L chain V region has an amino acid sequence shown as RV<sub>L</sub>a or RV<sub>L</sub>b in Table 2.

32. A reshaped human antibody according to claim 29, wherein the L chain V region has an amino acid sequence shown as RV<sub>L</sub> in Table 5.

33. A reshaped human antibody according to

claim 29, wherein the H chain V region has an amino acid sequence shown in Table 3 as RV<sub>H</sub>a, RV<sub>H</sub>b, RV<sub>H</sub>c, RV<sub>H</sub>d, RV<sub>H</sub>e or RV<sub>H</sub>f.

5 34. A reshaped human antibody according to claim 29, wherein the H chain V region has an amino acid sequence shown as RV<sub>H</sub>a, RV<sub>H</sub>b, RV<sub>H</sub>c or RV<sub>H</sub>d in Table 6, or RV<sub>H</sub>a, RV<sub>H</sub>b, RV<sub>H</sub>d in Table 7.

35. A DNA coding for an L chain V region of a mouse monoclonal antibody to the human IL-6R.

10 36. A DNA according to claim 35, wherein the L chain V region has an amino acid sequence shown in any one of SEQ ID NOs: 24, 26, 28 and 30.

37. A DNA coding for an H chain V region of a mouse monoclonal antibody to the human IL-6R.

15 38. A DNA according to claim 37, wherein the H chain V region has an amino acid sequence shown in any one of SEQ ID NOs: 25, 27, 29 and 31.

39. A DNA coding for CDR of an L chain V region of a mouse monoclonal antibody to the human IL-6R.

20 40. A DNA coding for CDR according to claim 39, wherein the CDR has an amino acid sequence in any one of SEQ ID NOs: 24, 26, 28 and 30 wherein the stretch of the amino acid sequence is defined in Table 9.

41. A DNA coding for CDR of an H chain V region of a mouse monoclonal antibody to the human IL-6R.

42. A DNA coding for CDR according to claim 41, wherein the CDR has an amino acid sequence shown in any one of SEQ ID NOs: 25, 27, 29 and 31 wherein the stretch of the amino acid sequence is defined in Table 9.

30 43. A DNA coding for a reshaped human L chain V region of an antibody to the human IL-6R, wherein the reshaped human L chain V region comprises:

(1) FRs of a human L chain V region, and  
(2) CDRs of a mouse L chain V region of a  
35 monoclonal antibody to the human IL-6R.

44. A DNA coding for a reshaped human L chain

09144285-071233  
SECRET 201508241150

V region according to claim 43, wherein the CDRs have amino acid sequences shown in any one of SEQ ID NOs: 24, 26, 28 and 30 wherein the stretches of the amino acid sequences are defined in Table 9.

5           45. A DNA coding for a reshaped human L chain V region according to claim 43, wherein the FRs are derived from the REI.

          46. A DNA according to claim 43, wherein the L chain V region has an amino acid sequence shown as RV<sub>L</sub>a or RV<sub>L</sub>b in Table 2.

10           47. A DNA according to claim 43, wherein the L chain V region has an amino acid region shown as RV<sub>L</sub> in Table 5.

          48. A DNA according to claim 43, having a nucleotide sequence shown in SEQ ID No: 57.

          49. A DNA coding for a reshaped human H chain V region of an antibody to the human IL-6R, wherein the reshaped Human V region comprises:

- 20           (1) FRs of a human H chain V region, and  
          (2) CDRs of an H chain V region of a mouse monoclonal antibody to the human IL-6R.

          50. A DNA coding for a reshaped human H chain V region according to claim 49, wherein the CDRs have amino acid sequences shown in SEQ ID NOs: 25, 27, 29 and 31 wherein the stretches of the amino acid sequences are defined in Table 9.

          51. A DNA coding for a reshaped human H chain V region according to claim 49, wherein the FRs are derived from the NEW or HAX.

30           52. A DNA coding for a reshaped human H chain V region according to claim 49, wherein the H chain V region has an amino acid sequence shown as RV<sub>H</sub>a, RV<sub>H</sub>b, RV<sub>H</sub>c, RV<sub>H</sub>d, RV<sub>H</sub>e or RV<sub>H</sub>f in Table 3.

          53. A DNA according to claim 49, wherein the H chain V region has an amino acid sequence shown as RV<sub>L</sub>a, RV<sub>H</sub>b, RV<sub>H</sub>c or RV<sub>H</sub>d in Table 6, or RV<sub>H</sub>a, RV<sub>H</sub>b, RV<sub>H</sub>c or

0914485-07139

RV<sub>2</sub>d in Table 7.

54. A DNA according to claim 49, having a nucleotide sequence shown in SEQ ID NO: 56.

55. A DNA coding for a reshaped human L chain of an antibody to the human IL-6R, wherein the reshaped human L chain comprises:

- (1) a human L chain C region; and
- (2) an L chain V region comprising a human FRs, and CDRs of a mouse monoclonal antibody to the human IL-6R.

56. A DNA according to claim 55, wherein the L chain V region has the nucleotide sequence shown in SEQ ID NO: 57.

57. A DNA coding for a reshaped human H chain of an antibody to the human IL-6R, wherein the reshaped human H chain comprises:

- (1) a human H chain C region, and
- (2) a H chain V region comprising human FRs, and CDRs of a mouse monoclonal antibody to the human IL-6R.

58. A DNA according to claim 57, wherein the H chain V region has the nucleotide sequence shown in SEQ ID NO: 56.

59. A vector comprising a DNA according to any one of claims 35, 37, 39, 41, 43, 49, 55 and 57.

60. A host cell transformed or transfected with a vector comprising a DNA according to any one of claims 35, 37, 39, 41, 43, 49, 55 and 57.

61. A DNA coding for a chimeric L chain of an antibody to the human IL-6R, wherein the chimeric L chain comprises:

- (1) a human L chain C region; and
- (2) an L chain V region of a mouse monoclonal antibody to the human IL-6R.

62. A DNA coding for a chimeric H chain of an antibody to the human IL-6R wherein the chimeric H chain

comprises:

- (1) a human H chain C region; and
- (2) an H chain V region of a mouse monoclonal antibody to the human IL-6R.

5        63. A process for production of a chimeric antibody to the human IL-6R, comprising the steps of:

          culturing host cells cotransfected with an expression vector comprising a DNA according to claim 61 and with an expression vector comprising a DNA according to claim 62; and

10        recovering a desired antibody.

          64. A process for production of a reshaped human antibody to the human IL-6R, comprising the steps of:

          culturing host cells cotransfected with an expression vector comprising a DNA according to claim 55 and with an expression vector comprising a DNA according to claim 57; and recovering desired antibody.

          65. A DNA according to claim 49, having a nucleotide sequence shown in SEQ ID NO: 85, 86 or 94.

20        66. A DNA according to claim 44, having a nucleotide sequence shown in SEQ IN NO: 71.

352420" 58247160

ABSTRACT

A reshaped human antibody to the human IL-6R,  
comprising:

- 5                   (A) an L chain comprising,  
                  (1) a human L chain C region, and  
                  (2) an L chain V region comprising human L  
chain framework regions (FRs), and mouse L chain  
complementary determination regions (CDRs) of a  
momoclonal antibody to the IL-6 receptor (IL-6R); and  
10               (B) an H chain comprising,  
                  (1) a human H chain C region, and  
                  (2) an H chain V region comprising human H  
chain FRs, and mouse H chain CDRs of a monoclonal  
antibody to the IL-6R.

- 15               Since major portion of the reshaped human antibody  
is derived from a human antibody and the mouse CDRs which  
are less immunogenic, the present reshaped human antibody  
is less immunogenic to human, and therefor is promised  
for therapeutic uses.

094435-07498

Fig. 1






Fig. 2






3/24

Fig. 3



4/24

Fig. 4



5/24

Fig. 5




Fig. 6






Fig. 7



8/24


Fig. 8



HEF-12h-gr1


9/24

Fig. 9



10/24

Fig. 10




0514285-074390




11/24

Fig. 11



12/24

Fig. 12



13/24

Fig. 13





Fig. 13



14/24

Fig. 14





Fig. 15




The diagram illustrates the DNA shuffling process in three main stages:

- Template DNA:** A DNA strand with regions A, B, C, and D. Restriction sites HindIII (E) and BamHI (H) are located at the ends. CDR1, CDR2, and CDR3 are indicated within regions B, C, and D respectively.
- FIRST PCR:** Amplification of the template DNA, resulting in fragments with overhangs (indicated by arrows).
- ASSEMBLY 1 CYCLE:** The fragments anneal and fill the gaps, creating a continuous strand.
- SECOND PCR:** Further amplification, resulting in a single, continuous **RESHAPED DNA FRAGMENT**.

17/24


Fig.17






18/24

Fig.18




19/24

Fig.19



20/24

Fig.20



001403 07149

Fig.21






Fig.22




23/24

Fig.23



24/24

Fig.24



**WEGNER, CANTOR, MUELLER & PLAYER**  
UNITED STATES LETTERS PATENT  
DECLARATION AND POWER OF ATTORNEY

ATTORNEY'S DOCKET NO.

As a below named inventor, I declare that I believe I am the original, first and sole inventor if only one name is listed at item 201 below, or a joint inventor if plural names are listed below at items 201 et. seq. of subject matter which is claimed and for which a patent is sought for

the invention entitled, **Reshaped Human Antibody to Human Interleukin-6 Receptor**

☐ the attached specification ☐ the specification in application Serial No. .... filed ..... which is described and claimed in:  
for declaration not accompanying application papers)

and (if applicable) amended on .....  
☒ International (PCT) application No. **PCT/JP92/00544** filed **April 24, 1992** and as amended on ..... and  
I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above

I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.  
I hereby claim the benefit of priority, under Title 35, United States Code, §119, of any foreign application(s) for patent or inventors certificate having a filing date before that of the application for which priority is claimed.

I hereby claim the benefit, under Title 35, United States Code, §120, of any U.S. application(s) listed in item 105 below. If this application is a continuation-in-part, insofar as the subject matter of any of the claims thereof is not disclosed in the prior U.S. application(s) identified in item 105 below in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior U.S. application(s) identified in item 105 below and the national or PCT international filing date of this application.

FOREIGN APPLICATION(S), IF ANY, FILED WITHIN 12 (6 if a Design) MONTHS PRIOR TO THE FILING DATE OF THIS APPLICATION THE PRIORITY OF WHICH WHERE PERMITTED IS HEREBY CLAIMED UNDER 35 U.S.C. §119

| COUNTRY  | APPLICATION NUMBER       | DATE OF FILING<br>(day, month, year) | PRIORITY CLAIMED<br>YES NO |
|----------|--------------------------|--------------------------------------|----------------------------|
| 1) Japan | 3-95476<br>(Pat. Appln.) | 25/April/1991                        | X                          |
| 2) Japan | 4-32084<br>(Pat. Appln.) | 19/February/1992                     | X                          |

|     |                                                                                                      |                                                                            |            |       |
|-----|------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|------------|-------|
| 106 | THIS APPLICATION IS A:<br><input type="checkbox"/> CONTINUATION<br><input type="checkbox"/> DIVISION | <input type="checkbox"/> CONTINUATION-IN-PART<br>OF PRIOR U.S. APPLICATION | SERIAL NO. | FILED |
|-----|------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|------------|-------|

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

HAROLD C. WEGNER  
Registration No. 25.258

HERBERT I. CANTOR  
Registration No. 24.392

HELMUTH A. WEGNER  
Registration No. 17.033

FRANKLIN D. WOLFFE  
Registration No. 19.724

DOUGLAS P. MUELLER  
Registration No. 30.300

WILLIAM E. PLAYER  
Registration No. 31.409

|                         |                                                                                   |                                            |
|-------------------------|-----------------------------------------------------------------------------------|--------------------------------------------|
| SEND CORRESPONDENCE TO: | WEGNER, CANTOR, MUELLER & PLAYER<br>P.O. Box 18218<br>Washington, D.C. 20036-8218 | DIRECT TELEPHONE CALLS TO:<br>202-887-0400 |
|-------------------------|-----------------------------------------------------------------------------------|--------------------------------------------|

(inventor(s) name must include at least one unabbreviated first or middle name.)

|     |                          |                                                                                                        |                           |                         |
|-----|--------------------------|--------------------------------------------------------------------------------------------------------|---------------------------|-------------------------|
| 201 | FULL NAME OF INVENTOR    | LAST NAME<br>Tsuchiya                                                                                  | FIRST NAME<br>Masayuki    | MIDDLE NAME             |
|     | RESIDENCE<br>CITIZENSHIP | CITY OR OTHER LOCATION<br>Gotenba-shi, Shizuoka,                                                       | STATE OR COUNTRY<br>Japan | CITIZENSHIP<br>Japanese |
|     | POST OFFICE ADDRESS      | POST OFFICE ADDRESS c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 1-135, Komakado, Gotenba-shi, Shizuoka, Japan |                           |                         |
| 202 | FULL NAME OF INVENTOR    | LAST NAME<br>Sato                                                                                      | FIRST NAME<br>Koh         | MIDDLE NAME             |
|     | RESIDENCE<br>CITIZENSHIP | CITY OR OTHER LOCATION<br>Gotenba-shi, Shizuoka,                                                       | STATE OR COUNTRY<br>Japan | CITIZENSHIP<br>Japanese |
|     | POST OFFICE ADDRESS      | POST OFFICE ADDRESS c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 1-135, Komakado, Gotenba-shi, Shizuoka, Japan |                           |                         |
| 203 | FULL NAME OF INVENTOR    | LAST NAME<br>Bendig                                                                                    | FIRST NAME<br>Mary        | MIDDLE NAME<br>Margaret |
|     | RESIDENCE<br>CITIZENSHIP | CITY OR OTHER LOCATION<br>West Hamstead, London                                                        | STATE OR COUNTRY          | CITIZENSHIP<br>USA      |
|     | POST OFFICE ADDRESS      | POST OFFICE ADDRESS 64 Solent Road, West Hampstead, London NW6 1TX, GB                                 |                           |                         |

X Fourth (and more) coinventors on page 2

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

|                                                       |                                              |                                                          |
|-------------------------------------------------------|----------------------------------------------|----------------------------------------------------------|
| SIGNATURE OF INVENTOR 201<br><i>Masayuki Tsuchiya</i> | SIGNATURE OF INVENTOR 202<br><i>Koh Sato</i> | SIGNATURE OF INVENTOR 203<br><i>Mary Margaret Bendig</i> |
| DATE 6/10/93                                          | DATE 6/OCT/93                                | DATE 13/10/93                                            |



DECLARATION  
(PAGE 2)

FOREIGN APPLICATION(S), IF ANY, FILED WITHIN 12 (6 if a Design) MONTHS PRIOR TO THE FILING DATE OF THIS APPLICATION THE PRIORITY OF WHICH WHERE PERMITTED IS HEREBY CLAIMED UNDER 35 U.S.C. §119

| COUNTRY | APPLICATION NUMBER | DATE OF FILING<br>(day, month, year) | PRIORITY CLAIMED |    |
|---------|--------------------|--------------------------------------|------------------|----|
|         |                    |                                      | YES              | NO |
|         |                    |                                      |                  |    |

|     |                         |                                                             |                        |                              |
|-----|-------------------------|-------------------------------------------------------------|------------------------|------------------------------|
| 204 | FULL NAME OF INVENTOR   | LAST NAME<br>Jones                                          | FIRST NAME<br>Steven   | MIDDLE NAME<br>Tarran        |
|     | RESIDENCE & CITIZENSHIP | CITY OR OTHER LOCATION<br>Radlett, Hertfordshire,           | STATE OR COUNTRY<br>GB | CITIZENSHIP<br>GB            |
|     | POST OFFICE ADDRESS     | POST OFFICE ADDRESS<br>10 The Close, Radlett, Hertfordshire | CITY<br>WD7 8HA, GB    | ZIP CODE                     |
| 205 | FULL NAME OF INVENTOR   | LAST NAME<br>Saldanha                                       | FIRST NAME<br>José     | MIDDLE NAME<br>William       |
|     | RESIDENCE & CITIZENSHIP | CITY OR OTHER LOCATION<br>Enfield, Middlesex,               | STATE OR COUNTRY<br>GB | CITIZENSHIP<br>GB            |
|     | POST OFFICE ADDRESS     | POST OFFICE ADDRESS<br>22 Lincoln Way, Enfield, Middlesex   | CITY<br>EN1 1TE, GB    | ZIP CODE                     |
| 206 | FULL NAME OF INVENTOR   | LAST NAME                                                   | FIRST NAME             | MIDDLE NAME                  |
|     | RESIDENCE & CITIZENSHIP | CITY OR OTHER LOCATION                                      | STATE OR COUNTRY       | CITIZENSHIP                  |
|     | POST OFFICE ADDRESS     | POST OFFICE ADDRESS                                         | CITY                   | STATE OR COUNTRY<br>ZIP CODE |

|     |                         |                        |                  |                              |
|-----|-------------------------|------------------------|------------------|------------------------------|
| 207 | FULL NAME OF INVENTOR   | LAST NAME              | FIRST NAME       | MIDDLE NAME                  |
|     | RESIDENCE & CITIZENSHIP | CITY OR OTHER LOCATION | STATE OR COUNTRY | CITIZENSHIP                  |
|     | POST OFFICE ADDRESS     | POST OFFICE ADDRESS    | CITY             | STATE OR COUNTRY<br>ZIP CODE |
| 208 | FULL NAME OF INVENTOR   | LAST NAME              | FIRST NAME       | MIDDLE NAME                  |
|     | RESIDENCE & CITIZENSHIP | CITY OR OTHER LOCATION | STATE OR COUNTRY | CITIZENSHIP                  |
|     | POST OFFICE ADDRESS     | POST OFFICE ADDRESS    | CITY             | STATE OR COUNTRY<br>ZIP CODE |
| 209 | FULL NAME OF INVENTOR   | LAST NAME              | FIRST NAME       | MIDDLE NAME                  |
|     | RESIDENCE & CITIZENSHIP | CITY OR OTHER LOCATION | STATE OR COUNTRY | CITIZENSHIP                  |
|     | POST OFFICE ADDRESS     | POST OFFICE ADDRESS    | CITY             | STATE OR COUNTRY<br>ZIP CODE |

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

|                                                 |                                                 |                           |
|-------------------------------------------------|-------------------------------------------------|---------------------------|
| SIGNATURE OF INVENTOR 204<br><i>J. I. Jones</i> | SIGNATURE OF INVENTOR 205<br><i>J. Saldanha</i> | SIGNATURE OF INVENTOR 206 |
| DATE<br>15/10/93                                | DATE<br>15/10/93                                | DATE                      |
| SIGNATURE OF INVENTOR 207                       | SIGNATURE OF INVENTOR 208                       | SIGNATURE OF INVENTOR 209 |
| DATE                                            | DATE                                            | DATE                      |